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Elucidation of Mechanisms of Fetal Hemoglobin Regulation 
 by CRISPR/Cas9 Mediated Genome Editing 
Abstract 
Despite nearly complete understanding of the genetics of the β-hemoglobinopathies for several 
decades, definitive treatment options have lagged behind. Fetal hemoglobin (HbF) reinduction 
represents a “silver bullet” for therapy of the β-globin disorders. Recent development of the 
clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 nuclease system has 
allowed for facile manipulation of the genome for the study of genes and genetic elements. Here 
we developed CRISPR/Cas9-based methodology to reliably engender targeted genomic 
deletions ranging from 1.3 kilobases to over 1 megabase, which suggested an inverse 
relationship between deletion size and deletion frequency. Targeted deletion methods and 
Cas9-mediated in situ saturating mutagenesis were applied to the enhancer of the HbF 
repressor BCL11A, which revealed discrete vulnerabilities. This finding is consistent with 
emerging evidence in the field that large enhancers are comprised of constituent parts with 
some harboring the majority of the activity. The identified “Achilles heel” of the enhancer 
represents a promising therapeutic target. We further enhanced the resolution of the in situ 
saturating mutagenesis technique by using multiple Cas9 nucleases and variant-aware library 
design to identify functional sequences within the HBS1L-MYB intergenic region, a locus 
associated with elevated HbF levels. These data demonstrate the robustness of CRISPR/Cas9 
mediated in situ saturating mutagenesis and targeted deletion to interrogate functional 
sequence within regulatory DNA. Harnessing the power of genome editing may usher in a 
second generation form of gene therapy for the β-globin disorders.  
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Chapter 1 
Introduction 
 
The β-hemoglobinopathies, namely sickle cell disease (SCD) and β-thalassemia, result from 
genetic mutations in the β-globin gene and are among the most common monogenic diseases 
in the world1. SCD results from a nonsynonymous A to T mutation in codon 6 of the β-globin 
gene leading to a Glu-Val replacement2,3 , whereas β-thalassemias are caused by diverse point 
mutations or deletions4–9. Treatment options are largely supportive. Transfusion and iron 
chelation are mainstays in the thalassemias while pain management, hydration, and 
hydroxyurea are used in SCD10–16.  
 The hemoglobin tetramer is comprised of two α-like globin chains encoded by any of the 
three genes in the α-globin cluster on chromosome 16 and two β-like globin chains encoded 
from any of five genes in the β-globin locus on chromosome 11. The expression of the three 
genes at the α-globin locus (ζ, α1, α2) and the five genes at the β-globin locus (ε, Gγ, Aγ, δ, β) are 
developmentally regulated. It has been appreciated for many years that levels of fetal 
hemoglobin (HbF, α2γ2), subject to developmental silencing in the months after birth, is a 
modifier of disease severity in patients with β-globin disorders16–23. This protective effect of HbF 
has motivated the therapeutic strategy to re-induce its expression in adult life. Hydroxyurea, a 
cytotoxic agent that inhibits ribonucleotide reductase, induces HbF modestly through an 
unknown mechanism. However, it has dose-limiting myelosuppressive effects and some 
patients are non-responders to therapy10–13. While bone marrow transplant represents the sole 
established curative option for patients, its use is limited by donor availability and graft versus 
host disease (GVH). A clinical trial has demonstrated successful gene addition of an anti-
sickling form of β-globin to a transfusion-dependent βEβ0 thalassemia patient that gained 
transfusion independence as a result of gene transfer24. Several additional somatic gene 
therapy trials for β-thalassemias and SCD are on-going25. Despite a deep understanding of 
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molecular defects and gene control mechanisms, treatment options for the majority of patients 
remain limited3. 
 
BREAKTHROUGHS IN GENOME EDITING TECHNOLOGIES 
The emergence of designer nucleases for eukaryotic genome editing has prompted an era of 
unprecedented control over the genome. The development of zinc finger nucleases (ZFNs)26–35, 
TAL effector nucleases (TALENs)36–40, and meganucleases41–44 established genome editing as 
a valuable laboratory technique. The emergence of the clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas9 nuclease system45–49, which utilizes a single guide RNA 
(sgRNA) to direct the Cas9 nuclease for site-specific cleavage, has engendered tremendous 
excitement about potential clinical applications. The breakneck speed at which new variations 
on the general theme are developed is truly remarkable. Other Cas9-like systems include the 
CRISPR/Cpf1 nuclease platform50, dimeric RNA-guided FokI nucleases51,52, and use of Cas9’s 
derived from a variety of prokaryotic species53,54. It is unlikely that the discovery of novel 
CRISPR-based systems and Cas9-like nucleases capable of eukaryotic genome editing will end 
soon55.  
The relative benefits of the newly developed CRISPR-based systems, ZFNs, and 
TALENs are still subject to debate. While CRISPR-based systems are often cited as the most 
efficient56, ZFNs are the only editing technology that has been brought thus far to a clinical trial. 
The CCR5 gene has been targeted by ZFNs in autologous CD4+ T cells from patients with HIV. 
The gene-modified cells were subsequently reinfused, which led to a decrease in the blood level 
of HIV in most patients57. Notably, this study demonstrated that reinfusion of autologous 
genome edited primary human cells could be achieved, well-tolerated and possibly lead to 
clinical benefit.  
Genome editing-based therapies rely on gene correction or disruption. Double strand 
break (DSB) induction by an engineered nuclease is repaired by the endogenous repair 
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pathways of homology-directed repair (HDR) or non-homologous end joining (NHEJ)58. Genetic 
correction strategies exploit the HDR pathway to insert custom sequences into the genome 
through co-delivery of an extrachromosomal repair template in conjunction with an engineered 
nuclease. The creation of a DSB improves HDR frequency59. As such, wild-type (or customized) 
sequences can be provided as an extrachromosomal donor for repair following site-specific 
cleavage by the nuclease. In contrast, genetic disruption strategies rely on the NHEJ pathway 
following nuclease-induced DSB to produce local insertions/deletions (indels)47,48,58. Introduction 
of two engineered nucleases can result in targeted deletion or inversion, duplication, local indels 
at nuclease cleavage sites, or translocations/chromosomal rearrangements60–73.  
 
ELUCIDATION OF MECHANISMS OF FETAL HEMOGLOBIN REGULATION BY CRISPR/CAS9 
MEDIATED GENOME EDITING 
In this dissertation work, I aimed to develop the ability to use CRISPR/Cas9 to engender 
targeted genomic deletions for the study of genes and genetic elements (Chapter 2). I also 
aimed to interrogate a genetic element necessary for HbF suppression through CRISPR-
mediated targeted deletion and the novel approach of Cas9-mediated saturating mutagenesis 
(Chapter 3). I further aimed to develop computational methods to enhance the saturating 
mutagenesis technique through the usage of multiple nucleases and variant-aware library 
design (Chapter 4). Taken together, this dissertation work sought to use CRISPR/Cas9 genome 
editing to develop methodologies to study genes and genetics elements in erythroid cells to 
further understanding of HbF regulation and to identify novel therapeutic targets for HbF 
induction therapy for patients with β-globin disorders. 
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Chapter 2 
Characterization of genomic deletion efficiency mediated by CRISPR/Cas9 in mammalian cells 
 
ABSTRACT 
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 
(Cas) 9 nuclease system has provided a powerful tool for genome engineering. Double-strand 
breaks (DSBs) may trigger non-homologous end joining (NHEJ) repair, leading to frameshift 
mutations, or homology-directed repair (HDR) using an extrachromosomal template. 
Alternatively, genomic deletions may be produced by a pair of DSBs. The efficiency of 
CRISPR/Cas9-mediated genomic deletions has not been systematically explored. Here we 
present a methodology for the production of deletions in mammalian cells, ranging from 1.3 
kilobases to greater than one megabase. We observed a high frequency of intended genomic 
deletions. Non-deleted alleles are nonetheless often edited with inversions or small indels 
produced at CRISPR recognition sites. Deleted alleles also typically include small indels at 
predicted deletion junctions. We retrieved cells with biallelic deletion at a frequency exceeding 
that of probabilistic expectation. We demonstrate an inverse relationship between deletion 
frequency and deletion size. This work suggests that CRISPR/Cas9 is a robust system to 
produce a spectrum of genomic deletions to allow investigation of genes and genetic elements. 
 
INTRODUCTION 
Recent studies have revealed a prokaryotic adaptive immune system which may be repurposed 
to allow for genomic engineering of eukaryotic genomes45,46,48,74. The Streptococcus pyogenes 
type II CRISPR/Cas9 adaptive immune system relies on three genes: two noncoding CRISPR 
RNAs (crRNAs) including a trans-activating crRNA (tracrRNA) and a precursor crRNA (pre-
crRNA), as well as the CRISPR-associated Cas9 nuclease. The pre-crRNA is transcribed from 
an array that contains repetitive elements with interspersed unique sequences (spacers) derived 
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from exogenous DNA. Once processed and after interaction with the tracrRNA, the mature 
crRNA guides Cas9 to direct cleavage of foreign DNA45,48,74,75. This system has been 
repurposed for mammalian genome engineering using SpCas9 along with a fusion of the 
tracrRNA and mature crRNA to create a chimeric single guide RNA (sgRNA)48,69,74. Site-specific 
cleavage is directed by complementarity of the sgRNA to a 20-base pair genomic sequence 
(protospacer) immediately 5’ of a protospacer-adjacent motif (PAM), which is NGG for Cas9. 
This recruits Cas9 to introduce site-specific DSBs repaired by either HDR or by 
insertion/deletion (indel)-forming NHEJ48,74. Heterologous expression of the CRISPR system 
components has been shown to be a facile method of genome engineering as compared to 
previous systems such as zinc finger nucleases (ZFNs) or TAL effector nucleases (TALENs) in 
part because of the ease with which individual sgRNAs may be designed and produced56. 
 The CRISPR/Cas9 system has already demonstrated wide applicability for efficient 
genome editing in a variety of model systems76–81, which has spawned an era of unprecedented 
control over the genome. This includes applications such as genome editing in clonal cell lines 
in a matter of weeks69, CRISPR-interference (CRISPRi)-mediated gene regulation with a 
catalytically inactive Cas982, pooled sgRNA library screening for functional genomics83–85, and 
potential CRISPR-based therapy highlighted by its recent use for gene correction in both murine 
and human stem cells86,87. 
A strategy of using two DSBs to create a deletion of the intervening segment by NHEJ 
has previously been successfully applied using ZFN, TALEN, and CRISPR systems64–69,88. 
However, the efficiency, reliability, and genomic outcomes of using pairs of CRISPRs to 
introduce genomic deletions remain incompletely characterized. Here we sought to test the 
capability and efficiency of creating deletions in mammalian cell lines. Our results indicate that 
the CRISPR/Cas9 system is a powerful tool for the robust and dependable generation of 
genomic deletions.  
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METHODS 
CRISPR design and creation 
sgRNA-specifying oligo sequences were chosen to minimize likelihood of off-target cleavage 
based on publicly available online tools69. Each sgRNA specified sequences exonic, intronic, or 
intergenic (within 3.5 kb of a gene body) with respect to a RefSeq gene (Figure 2.1a, b). 
“CACC” was added to the 5’ end of the sgRNA-specifying oligo sequence and “AAAC” was 
added to the 5’ end of the reverse complement of the sgRNA-specifying oligo for cloning using 
the BbsI restriction enzyme. G was added immediately following CACC if the first nucleotide 
was A, T, or C (in these cases C was added at the 3’ end of the reverse complement oligo). The 
two oligos were phosphorylated and annealed using the following conditions: guide sequence 
oligo (10 μM), guide sequence reverse complement oligo (10 μM), T4 ligation buffer (1X) (New 
England Biolabs [NEB], Ipswich, MA), and T4 polynucleotide kinase (5 U) (NEB, Ipswich, MA) 
with the following temperature conditions: 37°C for 30 minutes; 95°C for 5 minutes and then 
ramp down to 25°C at 5°C/minute. The annealed oligos were cloned into pSpCas9(BB) (pX330; 
Addgene plasmid ID: 42230) using a Golden Gate Assembly strategy with the following 
conditions: 100 ng of circular pX330 vector, annealed oligos (0.2 μM), 2.1 buffer (1X) (NEB, 
Ipswich, MA), BbsI restriction enzyme (20 U) (NEB, Ipswich, MA), ATP (0.2 mM) (NEB, Ipswich, 
MA), BSA (1X) (NEB, Ipswich, MA), and T4 DNA ligase (750 U) (NEB, Ipswich, MA) with the 
cycling conditions of 20 cycles of 37°C for 5 minutes, 20°C for 5 minutes; 80°C for 20 minutes. 
The sgRNAs were not pre-screened for editing efficiency prior to genomic deletion experiments 
presented herein. 
 
Cell culture, transfection, and screening clones 
Murine erythroleukemia (MEL) cells were cultured in Dulbecco’s modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2% penicillin-streptomycin (PS), 
and 1% L-glutamine at 37oC with 5% CO2 (Life Technologies, Green Island, NY). Despite a 
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complex karyotype, MEL cells exhibit karyotypic stability and are disomic for most 
chromosomes by karyotype reconstruction analysis89,90. Analysis of the MEL cells used in these 
experiments revealed a karyotype consistent with these previous reports. Two copies were 
present for each chromosome studied (data not shown). 2 x 106 cells were electroporated with 
0.5 μg pmaxGFP plasmid (Lonza, Allendale, NJ) and 5 μg of each pX330-sgRNA plasmid using 
the ECM 830 Square Wave Electroporation System (Harvard Apparatus, Holliston, MA) for a 
total of 10.5 μg of plasmid69. Preliminary experiments showed this concentration of cells and 
plasmids to be effective for production of genomic deletions. Extensive analysis regarding 
optimal concentrations of cells and plasmids were not performed. Cells were resuspended in 
100 μL BTX solution, and electroporated at 250 V, 5 ms, in 2 mm cuvettes (Harvard Apparatus, 
Holliston, MA). Cells were placed in 1 mL culture media immediately following electroporation. 
To enrich for deletion, the top 3% GFP+ cells were sorted via FACSAria cell sorter (BD 
Biosciences, San Jose, CA) 1-3 days post-electroporation (Figure 2.1c, d). Preliminary 
experiments showed these timepoints to be effective for production of genomic deletions. 
Extensive analysis regarding optimal timepoints for cell sorting were not performed. Cells were 
plated at 30 cells per 96-well plate to isolate single cell derived clones. After 7-10 days for 
expansion, clones were screened for CRISPR-mediated deletion (Figure 2.1c). Genomic DNA 
(gDNA) was extracted by resuspending cells in 50 μL QuickExtract DNA extraction solution per 
well and incubating at the following conditions: 65oC for 6 minutes; 98oC for 2 minutes 
(Epicentre, Madison, WI). Polymerase chain reaction (PCR) was performed using two sets of 
primers (Figure 2.1a, c): one set to amplify a sequence within the segment to be deleted (“non-
deletion band”) and one set that only amplified in the presence of a deletion (“deletion band”) 
using the Qiagen HotStarTaq 2x master mix and the following cycling conditions: 95oC for 15 
minutes; 35 cycles of 95oC for 15 seconds, 60oC for 1 minute, 72oC for 1 minute; 72oC for 10 
minutes.  
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Monoallelic deletion clones were defined as having PCR amplification of both the non-
deletion band and deletion band. Biallelic deletion clones were defined as having PCR  
 
Figure 2.1: Schema for CRISPR/Cas9-mediated genomic deletions. a, Exonic, intronic, and intergenic sgRNA 
deletion strategies. The sgRNA sites are shown in relation to an idealized gene. The PAM sequence (purple) is 
shown on the top strand for simplicity, but PAMs on both the top (Watson) and bottom (Crick) strands were used in 
different combinations. The red line indicates the predicted Cas9 cleavage between positions 17 and 18. The blue 
arrows indicate the position of PCR primers for deletion band amplification and the red arrows indicate the position 
of PCR primers for non-deletion band amplification. b, sgRNA localization (exonic/intronic/intergenic), deletion 
size, chromosome, genomic coordinates (mm10), and sequence for each sgRNA pair. Loci 1-4 used for further 
sequence analysis are indicated. c, CRISPR/Cas9-mediated genomic deletion strategy for MEL cells. 2 x 106 cells 
were electroporated with 5 μg of each sgRNA construct and 0.5 μg of a GFP expression construct. The top 3% 
GFP+ cells were sorted 1-3 days post-electroporation and plated at limiting dilution. 7-10 days after plating, gDNA 
was extracted and clones screened for deletion by PCR. A representative screening agarose gel shows the 
detection of two non-deletion clones, two monoallelic deletion clones, and two biallelic deletion clones. The red 
“ND” refers to the non-deletion amplicon as schematized in A, and the blue “D” refers to the deletion amplicon as 
schematized in A. Upon inversion analysis, clones were further classified as non-deletion/non-inversion, 
compound inversion/scar-complex, compound deletion/scar-complex, and compound deletion/inversion. The 
distinction between scar and complex was established by presence or absence of PCR amplification flanking both 
sgRNA target recognition sites. “Inv” refers to inversion amplicons flanking left and right sgRNA recognition sites 
(“L” and “R”, respectively). d, gDNA was extracted from cells prior to (unsorted) and after sorting the top 3% GFP+ 
cells (sorted). Deletion enrichment was calculated by RT-qPCR and data was normalized to the unsorted cells 
using the 2-ΔCt method. A biallelic deletion clone for each locus was used as a positive control and non-edited 
parental gDNA as a negative control. e, top panel, Primers flanking the sgRNA recognition sites (shown in green 
and purple) were used to amplify 500-700 bp regions around each sgRNA site on non-deletion/non-inversion 
alleles (primers 1/2  and ¾, top panel). Inversion PCR utilized primer pairs (primers 1/3 and 2/4, respectively; 
bottom panel) in which both primers were in the same orientation, one inside and one outside the intended 
deletion. 
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amplification of the deletion band and absence of the non-deletion band. Clones with PCR 
amplification of the non-deletion band and absence of the deletion band were defined as non-
deletion clones (Figure 2.1c).  
Non-deletion/non-inversion alleles were analyzed using PCR primers flanking the 
sgRNA recognition sites to amplify 500-700 bp regions around each sgRNA site with one primer 
inside and one outside the intended deletion (Figure 2.1e, top panel). Monoallelic and biallelic 
inversion clones were defined by amplification of inversion bands at each inversion junction, 
using primer pairs in which both primers were in the same orientation, one inside and one 
outside the intended deletion (Figure 2.1e, bottom panel). Specifically, monoallelic inversion 
clones were defined as having PCR amplification using one or both inversion primer pairs. 
Biallelic inversion clones were defined as having PCR amplification of one or both inversion 
primer pairs in conjunction with neither deletion band PCR amplification nor amplification of 
sequences flanking the sgRNA recognition site.  
Deletion, non-deletion, and inversion amplicons from non-deletion, monoallelic, and 
biallelic deletion clones were subjected to Sanger sequencing; the deletion amplicons from 
biallelic deletion clones were separately amplified by Phusion Hot Start PCR (New England 
Biolabs, Ipswich, MA) with the following conditions: Phusion High Fidelity DNA Polymerase (0.5 
U), dNTPs (2 mM each), GC Buffer (1X), 3% dimethyl sulfoxide (DMSO), forward and reverse 
primers (0.1 μM each) with the cycling conditions of 95oC for 15 minutes; 40 cycles of 95oC for 
15 seconds, 60oC for 30 seconds, 72oC for 30 seconds; 72oC for 5 minutes. Amplicons were 
either gel purified and directly Sanger sequenced or cloned with Zero Blunt PCR Cloning kit 
(Life Technologies, Green Island, NY) where four clones each were subjected to Sanger 
sequencing. Deletion frequency was calculated as  
100% (
(# 𝑀𝑜𝑛𝑜𝑎𝑙𝑙𝑒𝑙𝑖𝑐 𝐷𝑒𝑙𝑒𝑡𝑖𝑜𝑛𝑠)∙(2∙# 𝐵𝑖𝑎𝑙𝑙𝑒𝑙𝑖𝑐 𝐷𝑒𝑙𝑒𝑡𝑖𝑜𝑛𝑠 )
2(# 𝐶𝑙𝑜𝑛𝑒𝑠 𝑆𝑐𝑟𝑒𝑒𝑛𝑒𝑑)
). 
Inversion frequency was calculated using the same equation. 
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RESULTS 
CRISPR/Cas9 is a robust system for the production of genomic deletions 
Seventeen sgRNA pairs at twelve genomic loci were assayed in MEL cells to determine their 
ability to engender genomic deletions and to determine the robustness of the approach. At each 
locus, a pair was comprised of an sgRNA 5’ with respect to the top (Watson) strand, indicated 
as sgRNA-A, and another 3’ with respect to the Watson strand, sgRNA-B (Figure 2.1a, b). The 
ability to create interstitial deletion of the segment AB was tested by conventional PCR. These 
sgRNAs were either exonic, intronic, or intergenic (within 3.5 kb of a gene body) with respect to 
RefSeq genes (Figure 2.1a, b). None of the genes was known to be essential for cell viability. 
The sgRNA pairs were designed to create a spectrum of deletions, ranging in size from 1.3 to 
1,026 kb (Figure 2.1b). 1,974 clones across 17 sgRNA pairs were screened for deletions. 
Clones with deleted alleles were observed for all tested sgRNA pairs (Table 2.1). 
Table 2.1: Observed biallelic deletion frequency exceeds probabilistic expectation. Expected (Exp) number 
of clones in each category (non-deletion clones, monoallelic deletion clones, biallelic deletion clones, and all 
clones) were calculated based on the observed (Obs) deletion frequency using the quadratic equation (analogous 
to Hardy-Weinberg equilibrium). In this case, monoallelic deletion clones consisted of compound deletion/scar, 
compound deletion/complex, and compound deletion/inversion clones. sgRNA pairs were analyzed individually 
and collectively for agreement with expected number of non-deletion, monoallelic, and biallelic deletion clones 
obtained. Chi square statistics (Χ2) and p values were generated by Pearson’s chi square tests. Inversion 
frequency was evaluated for the four pairs studied in detail as well as for pairs 16 and 17. 
 
 
Indels are often formed at the predicted deletion junctions 
The deleted allele was examined in monoallelic and biallelic deletion clones at four loci, referred 
to as loci 1-4, spanning a range of intended deletion sizes (2.0, 8.0, 15.0, and 20.3 kb)  (Figure 
2.1b). One primer from upstream of sgRNA-A and another primer from downstream of sgRNA-B 
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were used to amplify and sequence across the deletion junction (Figures 2.1a, c; 2.2a, 2.3a, 
2.4a, 2.5a). Indel sizes were enumerated as the sum of the number of base pairs inserted 
(positive values) or deleted (negative values) relative to the predicted deletions, assuming 
cleavage between positions 17 and 18 as specified by each sgRNA (Figure 2.1a) 48,69,74. Indels 
ranged from -176 bp to +538 bp in monoallelic deletion clones and from   -286 bp to +449 bp in 
biallelic deletion clones. Both monoallelic and biallelic deletion clones showed the 
preponderance of indels clustering between -10 to 0 bp (Figure 2.6a). Notably, absence of 
indels occurred as the most frequent outcome at each sgRNA predicted cleavage site in both 
monoallelic deletion clones (77/174 sites on 87 alleles from 87 clones, 44.3%) and biallelic 
deletion clones (17/80 sites on 40 alleles from 31 clones, 21.3%) (Figure 2.6a). Furthermore, 
the precise predicted deletion (i.e absence of indels at both sites on a deleted allele) occurred in 
31.0% (27/87) of monoallelic deletion clones and 15.0% (6/40) of alleles from biallelic deletion 
clones. Positive indels (i.e. relative insertions to the predicted deletion) had homology to 
sequences flanking the predicted deletion site except in one case where a 538-bp insertion with 
sequence homology to a portion of the pX330 plasmid was identified. However, this accounting 
is likely an underestimate of the full spectrum of indels since the PCR-based screening method 
would not identify large deletions and insertions. In several instances, we identified large 
insertions and deletions around cleavage sites not detectable by the screening PCR strategy 
(data not shown).  
Sanger sequencing of biallelic deletion clones revealed 9/31 (29.0%) to be compound 
heterozygotes based on differing indels at the predicted deletion sites on each allele. The 
remaining 22/31 (71.0%) had only a single deletion junction identified by both amplicon 
sequencing as well as sequencing of multiple clones of the PCR product. This finding may 
suggest that in these cells both alleles were independently repaired in an identical manner, or 
that one allele served as a template for HDR of the other allele. Other possibilities include 
uniparental disomy, monosomy, or a large insertion/deletion at one allele. Each of the biallelic   
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Figure 2.2: Indels at the non-deleted/non-inversion allele and indels at the predicted deletion/inversion 
junction at locus 1. a, Sequencing of the deletion allele in compound deletion/scar-complex-inversion clones and 
biallelic deletion clones at locus 1 (intended 2.0 kb deletion). Top row indicates sequence of unmodified allele. 
sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown by an equivalent 
number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted cleavage site, 
between positions 17 and 18 of the sgRNA. b, Sequencing of the non-deletion/non-inversion allele in compound 
deletion/scar-complex clones and compound inversion/scar-complex clones. Top row indicates sequence of the 
unmodified allele. sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown 
by an equivalent number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted 
cleavage site, between positions 17 and 18 of the sgRNA. c, Sequencing of the inversion allele in compound 
deletion/inversion clones and compound inversion/scar-complex clones. Top row indicates perfect inversion of 
intervening segment between predicted cleavage sites. sgRNA sequences are shown in green, PAM sequences in 
red, and inverted sequence in purple. Deletion events are shown by an equivalent number of dash marks and 
insertions are highlighted in blue. Vertical lines indicate predicted cleavage site, between positions 17 and 18 of 
the sgRNA. MD indicates monoallelic deletion, MI monoallelic inversion, and BD biallelic deletion. 
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Figure 2.3: Indels at the non-deleted/non-inversion allele and indels at the predicted deletion/inversion 
junction at locus 2. a, Sequencing of the deletion allele in compound deletion/scar-complex-inversion clones and 
biallelic deletion clones at locus 2 (intended 8.0 kb deletion). Top row indicates sequence of unmodified allele. 
sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown by an equivalent 
number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted cleavage site, 
between positions 17 and 18 of the sgRNA. b, Sequencing of the non-deletion/non-inversion allele in compound 
deletion/scar-complex clones and compound inversion/scar-complex clones. Top row indicates sequence of 
unmodified allele. sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown 
by an equivalent number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted 
cleavage site, between positions 17 and 18 of the sgRNA. c, Sequencing of the inversion allele in compound 
deletion/inversion clones and compound inversion/scar-complex clones. Top row indicates perfect inversion of 
intervening segment between predicted cleavage sites. sgRNA sequences are shown in green, PAM sequences in 
red, and inverted sequence in purple. Deletion events are shown by an equivalent number of dash marks and 
insertions are highlighted in blue. Vertical lines indicate predicted cleavage site, between positions 17 and 18 of 
the sgRNA. MD indicates monoallelic deletion, MI monoallelic inversion, and BD biallelic deletion. Clone MD10 
exhibited amplification using PCR primers flanking sgRNA-site-B (see Figure 2.1e, top panel) and amplification 
using inversion PCR primers flanking sgRNA-site-A (see Figure 2.1e, bottom panel) suggesting a complex 
inversion. Clone MD2 exhibited amplification using PCR primers flanking sgRNA-site-A (see Figure 2.1e, top 
panel) and amplification using inversion PCR primers flanking both sgRNA-site-A and sgRNA-site-B (see Figure 
2.1e, bottom panel) suggesting at least three copies at tested locus, which could be consistent with rare 
tetraploidies observed in MEL cells by karyotype (data not shown) or with a mixed clone. This was the only clone 
out of the 278 clones examined in detail across the four loci to exhibit apparent copy number greater than two. 
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Figure 2.4: Indels at the non-deleted/non-inversion allele and indels at the predicted deletion/inversion 
junction at locus 3. a, Sequencing of the deletion allele in compound deletion/scar-complex-inversion clones and 
biallelic deletion clones at locus 3 (intended 15.0 kb deletion). Top row indicates sequence of unmodified allele. 
sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown by an equivalent 
number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted cleavage site, 
between positions 17 and 18 of the sgRNA. b, Sequencing of the non-deletion/non-inversion allele in compound 
deletion/scar-complex clones and compound inversion/scar-complex clones. Top row indicates sequence of 
unmodified allele. sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown 
by an equivalent number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted 
cleavage site, between positions 17 and 18 of the sgRNA. c, Sequencing of the inversion allele in compound 
deletion/inversion clones, compound inversion/scar-complex clones, and biallelic inversion clones. Top row 
indicates perfect inversion of intervening segment between predicted cleavage sites. sgRNA sequences are 
shown in green, PAM sequences in red, and inverted sequence in purple. Deletion events are shown by an 
equivalent number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted cleavage 
site, between positions 17 and 18 of the sgRNA. MD indicates monoallelic deletion, MI monoallelic inversion, BD 
biallelic deletion, and BI biallelic inversion. Biallelic inversion alleles are labeled A through D (rather than merely A 
and B) since phase of inversion junctions within a clone was not resolved. Clone MD16 did not exhibit amplification 
using PCR primers flanking either sgRNA-site-A or sgRNA-site-B (see Figure 2.1e, top panel), but did exhibit 
amplification using inversion PCR primers flanking sgRNA-site-B only (see Figure 2.1e, bottom panel) suggesting 
a complex inversion. 
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Figure 2.5: Indels at the non-deleted/non-inversion allele and indels at the predicted deletion/inversion 
junction at locus 4. a, Sequencing of the deletion allele in compound deletion/scar-complex-inversion clones and 
biallelic deletion clones at locus 4 (intended 20.3 kb deletion). Top row indicates sequence of unmodified allele. 
sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown by an equivalent 
number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted cleavage site, 
between positions 17 and 18 of the sgRNA. b, Sequencing of the non-deletion/non-inversion allele in compound 
deletion/scar-complex clones and compound inversion/scar-complex clones. Top row indicates sequence of 
unmodified allele. sgRNA sequences are shown in green and PAM sequences in red. Deletion events are shown 
by an equivalent number of dash marks and insertions are highlighted in blue. Vertical lines indicate predicted 
cleavage site, between positions 17 and 18 of the sgRNA. c, Sequencing of the inversion allele in compound 
deletion/inversion clones, compound inversion/scar-complex clones, and biallelic inversion. Top row indicates 
perfect inversion of intervening segment between predicted cleavage sites. sgRNA sequences are shown in green, 
PAM sequences in red, and inverted sequence in purple. Deletion events are shown by an equivalent number of 
dash marks and insertions are highlighted in blue. Vertical lines indicate predicted cleavage site, between 
positions 17 and 18 of the sgRNA. MD indicates monoallelic deletion, MI monoallelic inversion, BD biallelic 
deletion, and BI biallelic inversion. Biallelic inversion alleles are labeled A through D (rather than merely A and B) 
since phase of inversion junctions within a clone was not resolved. Clones MD1, MD5, MD8, and MD25 did not 
exhibit amplification using PCR primers flanking either sgRNA-site-A or sgRNA-site-B (see Figure 2.1e, top panel), 
but did exhibit amplification using inversion PCR primers flanking sgRNA-site-A only (see Figure 2.1e, bottom 
panel) suggesting complex inversions. Clone MD17 exhibited amplification using PCR primers flanking sgRNA-
site-B (see Figure 2.1e, top panel) and amplification using inversion PCR primers flanking sgRNA-site-A (see 
Figure 2.1e, bottom panel) suggesting a complex inversion.  
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Figure 2.6: Indels at deleted, scarred, and inverted alleles. a, left panel, Frequency distribution of indel 
formation at the predicted deletion junctions from the deleted alleles of monoallelic and biallelic deletion clones 
across four loci examined in detail. Indels ranged from -176 bp to +538 bp in monoallelic deletion clones and from 
-286 bp to +449 bp in biallelic deletion clones with the majority found at -10 to 0 bp. a, right panel, Distribution of 
negative indels on the deletion allele produced by sgRNA-A and sgRNA-B from both monoallelic and biallelic 
deletion clones. Positive indels could not be reliably mapped to individual sites so were excluded from analysis. b, 
left panel, Frequency distribution of indel formation (scarring) on the non-deleted allele from compound 
deletion/scar-complex clones and on the non-inverted allele from compound inversion/scar-complex clones across 
eight sgRNA sites from four loci examined in detail. Indels ranged from -83 bp to +1 bp for the non-deletion alleles 
and from -134 bp to +2 bp for the non-inversion alleles. b, right panel, Distribution of indels on the non-deleted 
allele in compound deletion/scar clones and the non-inverted allele in compound inversion/scar clones in which 
sequences surrounding both sgRNA-A and sgRNA-B sites were amplified. c, left panel, Frequency distribution of 
indel formation at the predicted inversion junctions from the inversion alleles of compound inversion/scar-complex-
deletion clones across all four loci examined in detail. Indels ranged from -115 bp to +138 bp with the majority 
found at -10 to 0 bp. c, right panel, Distribution of indels on the allele produced by sgRNA-A and sgRNA-B from 
compound inversion/scar-complex-deletion clones.  
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deletion clones was confirmed to result in loss of expression of the deleted gene by RT-qPCR 
(data not shown). 
 
Editing (“scarring”) occurs in the absence of deletion 
Deletion is only one possible outcome following two DSBs at a locus. Another outcome is local 
NHEJ repair of each DSB without deletion of the intervening segment. We examined the non-
deleted allele using Sanger sequencing of the monoallelic deletion clones from the same four 
sgRNA-pairs targeting different loci spanning a range of intended deletion sizes (2.0, 8.0, 15.0, 
and 20.3 kb) (Figures 2.2b, 2.3b, 2.4b, 2.5b). Primers flanking the sgRNA recognition sites were 
used to amplify 500-700 bp regions around each sgRNA site (Figure 2.1e, top panel). Three 
amplification patterns were observed for each sgRNA pair: amplification at both sgRNA-site-A 
and sgRNA-site-B (50/87, 57.5%), amplification at either sgRNA-site-A or sgRNA-site-B (11/87, 
12.6%), or amplification at neither sgRNA-site-A nor sgRNA-site-B (26/87, 29.9%). For each 
locus, both sgRNA sites amplified from parental gDNA. The sites lacking amplification could 
represent large indels, inversions, or structural aberrancy and were excluded from this analysis. 
Clones with both sites amplifying were classified as “compound deletion/scar” clones while 
clones with one site or both sites not amplifying were classified as “compound deletion/complex” 
clones. Sanger sequencing of the amplifying sgRNA sites revealed indels at 99% (92/93) of 
eight sgRNA predicted cleavage sites across the four loci. Only one site exhibited either non-
cleavage or cleavage with perfect repair (Figures 2.2b, 2.3b, 2.4b, 2.5b). No monoallelic 
deletion clones were obtained that exhibited a precise predicted deletion in combination with an 
absence of scarring of the non-deleted allele. The high frequency of indel formation across all 
four loci suggested that the frequency of indel formation was independent of the intended 
deletion size. Indels ranged from -83 bp to +1 bp with most of the indels clustering between -10 
and -1 bp (Figure 2.6b). This high frequency of indel formation at the sgRNA sites on the non-
deleted allele of monoallelic deletion clones indicates that the sgRNA recognition and/or PAM 
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sequence is often obliterated (Figures 2.2b, 2.3b, 2.4b, 2.5b, 2.6b). Therefore, re-targeting the 
non-deleted allele in monoallelic deletion clones would likely require independent sgRNAs. 
From the non-deletion clones, 131/161 were chosen for analysis using the same primers 
flanking the sgRNA recognition sites to amplify 500-700 bp regions around each sgRNA site 
(Figure 2.1e, top panel). The same three amplification patterns were observed for each sgRNA 
pair: amplification at both sgRNA-site-A and sgRNA-site-B (110/131, 84.0%), amplification at 
either sgRNA-site-A or sgRNA-site-B (10/131, 7.6%), or amplification at neither sgRNA-site-A 
nor sgRNA-site-B (11/131, 8.4%). Of the 120 clones with at least one PCR amplification band, 
108 clones were selected and subjected to Sanger sequencing (n=108). 24.1% (26/108) of 
these clones were subsequently determined to be monoallelic or biallelic inversion clones. 
Analysis of the remaining 82 sequenced non-deletion clones, classified as “non-deletion/non-
inversion” clones, revealed indel formation of at least one allele in 75.6% (62/82) of instances 
with no apparent relationship between editing frequency and intended deletion size (data not 
shown). 24.4% (20/82) of the non-deletion/non-inversion clones exhibited wild-type sequencing, 
which could result from insufficient or absent sgRNA/Cas9 expression, perfect repair, or the 
presence of a large indel on one allele and an unmodified (or perfectly repaired) other allele. 
Based on the high frequency of indel formation, it is apparent that a large fraction of non-
deletion clones were exposed to Cas9, sgRNA-A, and sgRNA-B. Therefore the induction of 
deletion is not simply limited by delivery of both CRISPR plasmids. However, the reduced rate 
of indel formation in non-deletion clones as compared to monoallelic deletion clones could 
indicate reduced delivery of one or both CRISPR plasmids to the cells, suggesting that deletion 
may be sensitive to sgRNA/Cas9 dose. 
 
Inversion is a frequent outcome 
The alleles from monoallelic deletion clones exhibiting amplification at neither sgRNA-site-A nor 
sgRNA-site-B (26/87, 29.9%) on the non-deletion allele (Figure 2.1e, top panel) were screened 
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for inversions by PCR (Figure 2.1e, bottom panel). Notably, 100% of these clones (26/26) 
demonstrated inversions. Each of the non-deletion clones previously analyzed (n=131) was 
evaluated for inversions. This analysis revealed 29.8% (39/131) of non-deletion clones to be 
monoallelic inversion clones and 1.5% (2/131) biallelic inversion clones. Notably, for the 8.4% 
(11/131) of non-deletion clones with PCR amplification at neither sgRNA-site-A nor sgRNA-site-
B (11/131, 8.4%) (Figure 2.1e, top panel), 9/11 were determined to be monoallelic inversion 
clones and 2/11 were determined to be biallelic inversion clones by inversion PCR (Figure 2.1e, 
bottom panel). Sanger sequencing of the inversion amplicons revealed indels ranging from -115 
bp to +138 bp for compound inversion/scar-complex-deletion clones at the predicted inversion 
junction (Figures 2.2c, 2.3c, 2.4c, 2.5c, 2.6c). This included a +35 bp insertion with homology to 
Cas9 and a +138 bp insertion with homology to a different chromosomal locus. Monoallelic 
inversion clones showed the preponderance of indels clustering between -10 to 0 bp (Figure 
2.6c). Two biallelic inversion clones were identified and also exhibited small indel formation at 
the inversion junction (Figures 2.4c, 2.5c). 
The non-inversion allele from the monoallelic inversion clones was analyzed for editing 
in the absence of inversion (Figure 2.1e, top panel). Sanger sequencing of the amplifying 
sgRNA sites revealed indels at 100% (45/45) of sgRNA cleavage sites analyzed, which ranged 
from -134 bp to +2 bp (Figures 2.2b, 2.3b, 2.4b, 2.5b, 2.6b). No clones were obtained that 
exhibited the predicted inversion in combination with an absence of scarring on the non-
inversion allele. Of the monoallelic inversion clones, 59.0% (23/39) were “compound 
inversion/scar” clones and 41.0% (16/39) “compound inversion/complex” clones. 
Pairs 16 and 17 each possess greater than 1 megabase between sgRNA-A and sgRNA-
B (Figure 2.1b). Inversions were identified in 1.5% (2/133) and 1.0% (2/210) of clones, 
respectively (Table 2.1).,These data indicate that both large scale deletions and inversions of at 
least one megabase can be produced using two sgRNA. 
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Deletion occurs more frequently than inversion 
The four loci analyzed in detail include a total of 278 clones (558 alleles). Deletion and inversion 
frequencies were calculated on a per allele basis, which revealed a deletion frequency of 26.8% 
(149/558) and an inversion frequency of 12.9% (72/558) (Figure 2.7a). Alleles characterized by 
non-editing, scarring, and complex indels remained the most common outcome (60.3%, 
335/556). Clones were classified into 8 categories based on combination of deletion, inversion, 
scar/non-edited, and complex alleles. The assignment of scarring required PCR amplification of 
both the sgRNA-A and sgRNA-B target sites from the non-deletion or non-inversion allele. If one 
or both sites failed to amplify, alleles were classified as complex. Non-deletion/non-inversion 
clones were the most frequent outcome (42.8%, 119/278). Monoallelic deletion with scarring on 
the non-deletion allele was second most common (14.7%, 41/278) (Figure 2.7b). While biallelic 
inversion was least common (0.7%, 2/278), biallelic deletion was third most common (11.2%, 
31/278). This distribution may reflect the complicated repair processes cells undergo after a pair 
of DSBs initiated by CRISPR/Cas9. 
 
Observed frequency of monoallelic and biallelic deletion clones deviates from 
probabilistic expectation 
A quadratic equation (analogous to Hardy-Weinberg equilibrium) was used to calculate the 
expected number of monoallelic and biallelic deletion clones for each deletion based on the 
observed deletion frequency: 
𝑓𝑁𝑜𝑛−𝐷𝑒𝑙𝑒𝑡𝑖𝑜𝑛
2 + 2𝑓𝑁𝑜𝑛−𝐷𝑒𝑙𝑒𝑡𝑖𝑜𝑛𝑓𝐷𝑒𝑙𝑒𝑡𝑖𝑜𝑛 + 𝑓𝐷𝑒𝑙𝑒𝑡𝑖𝑜𝑛
2
, 
where f represents allele frequency. A Pearson’s chi square test demonstrated that the 
observed frequency of non-deletion, monoallelic and biallelic deletion clones did not match 
expectations (p=2.41x10-24). The deviation from probabilistic expectations occurred due to an 
increased frequency of biallelic deletion clones at the expense of the observed number of 
monoallelic deletion clones (Table 2.1). This suggests that the deletion of one allele may 
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increase the likelihood of deletion of the other allele. This finding could be consistent with the 
hypothesis that high expression of components of the CRISPR/Cas9 system favor production of 
genomic deletions. In any event, this observation is favorable for the creation of biallelic 
deletions for the study of genes or regulatory elements. 
 
Figure 2.7: Deletion/inversion frequency and characterization of outcomes when using two sgRNA. a, 
Deletion and inversion frequency were calculated on a per allele basis for all 278 clones (556 alleles) across the 
four loci examined in detail. b, The 278 clones from across the four loci examined in detail were classified into 
eight categories based on presence of deletion, inversion, scar, and complex alleles. c, Deletion frequency 
inversely related to deletion size. Genomic deletion sizes ranged from 1.3 kb to 1,026 kb, which show a decrease 
in the frequency of deletion events as deletion size increases. The size of the circles corresponds to the number of 
clones screened for the corresponding sgRNA pair. The best fit relationship was determined by a weighted (by 
number of clones screened) non-linear regression of the form function(Deletion Size) = k1 + k2(Deletion Size)-k3, 
where k1, k2, and k3 represent constants (function(Deletion Size) = -2.84+41.41(Deletion Size)-0.36; R2 = 0.62). The 
weighted non-linear regression was computed using the fitnlm function available in MATLAB R2013b software 
(MathWorks, Natick, MA). 
 
Deletion frequency varies inversely to deletion size 
Genomic deletion demonstrated an inverse relationship between genomic deletion size and 
frequency of deletion over the range of 1.3 to 1026 kb (Figure 2.7c). The best fit relationship 
was determined by a weighted (by number of clones screened) non-linear regression of the 
form function(Deletion Size) = k1 + k2(Deletion Size)-k3, where k1, k2, and k3 represent constants 
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(function(Deletion Size) = -2.84+41.41(Deletion Size)-0.36; R2 =0.62). The weighted non-linear 
regression was computed using the fitnlm function available in MATLAB R2013b software 
(MathWorks, Natick, MA). These data appear consistent with a competitive relationship between 
exposed cleaved ends at sgRNA sites-A and -B for local A-A indel repair and long-range A-B 
deletion repair (as well as inversion repair). Practically, these results suggest that more clones 
need to be screened as intended deletion size increases to reliably retrieve biallelic deletion 
clones.  
 
DISCUSSION 
Efficient genomic deletion may be useful for creation of specific and reproducible gene 
knockouts as compared to those produced by a single sgRNA to rely on indel-forming NHEJ to 
produce frameshift mutations. First, only 2/3 indels would result in a frameshift. Second, many 
frameshift mutations escape nonsense-mediated decay91. Third, alternative splicing may result 
in isoforms that may compensate or change gene function.  
Given the high observed frequency of scarring of the non-deleted allele and the inverse 
relationship between deletion size and frequency, we suggest that two exonic sgRNAs designed 
to create a disruptive interstitial deletion of modest size (see Figure 2.1a, left panel) could be an 
efficient strategy to produce gene knockout clones. Rapid screening via PCR would identify 
clones with an appropriate deletion. Even in the event that adequate biallelic deletion clones 
could not be easily obtained, a monoallelic deletion would enrich for compound heterozygous 
loss-of-function alleles, which could be confirmed by measurement of RNA and protein levels.  
Off-target cleavages from CRISPR/Cas9 have been reported, particularly at sites of 
sequence match in the PAM-proximal seed region92–94. The full extent of CRISPR/Cas9-
mediated off-target events such as might be determined by deep whole genome sequencing 
remains incompletely characterized. The introduction of two sgRNAs as described in our 
deletion schema theoretically carries twice the frequency of off-target mutations as compared to 
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a single sgRNA. Off-target effects may be minimized using a double nickase strategy for 
DSBs68,69, truncated sgRNAs95, or dimeric Cas9-FokI fusions51,96 but it remains to be determined 
how these approaches might affect deletion frequency. Complementation of the deletion 
phenotype by reintroduction of the deleted sequence would verify the association of the deletion 
to the phenotype but may be laborious to achieve. Alternatively, we suggest that multiple 
sgRNA pairs with non-overlapping sequences be utilized as a practical measure to control for 
off-target effects. Consistent phenotypes associated with deletions produced by unique 
reagents would seem unlikely due to off-target mutations.  
These results identify an inverse relationship between deletion size and frequency. Of 
course a chromosome is not organized as a purely one-dimensional structure but rather as 
three-dimensional chromatin. The relationship between genome editing and chromatin context 
remains poorly understood and is an important topic for future investigation. The loci analyzed in 
this study mainly represent euchromatin. Although we observed some variation in deletion 
efficiency at different loci, based on a given deletion size a minimal number of clones needed to 
be screened to obtain biallelic deletion clones may be estimated. If biallelic deletion frequency 
was found below probabilistic expectation, it could suggest that full loss-of-function is cell lethal. 
Alternatively, lower than expected apparent biallelic deletion frequency in conjunction with the 
presence of apparent monoallelic deletion clones could indicate gene copy number greater than 
two, particularly in cancer cell lines. 
These data suggest that both genomic deletions and inversions are a common outcome 
of a pair of DSBs initiated by CRISPR/Cas9. Despite relatively high deletion and inversion 
frequency, the paucity of biallelic inversion as compared to biallelic deletion clones may reflect a 
more complicated mechanism of inversion resolution as compared to deletion production. It is 
possible that some of the excess of biallelic deletion clones indicate circumstances in which the 
first deletion allele served as template for HDR of the second allele. For pairs of sgRNAs 
separated by greater than 1 Mb, we observed a similar frequency of deletions and inversions 
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(0.58% or 4/686 for both inversions and deletions; Figure 2.1b, Table 2.1). These results 
suggest that this technique may be suitable for the production of even relatively large 
intrachromosomal inversions and deletions. 
The high scarring frequency observed related to indel production at the sgRNA 
recognition sites on non-deleted/non-inverted alleles provides insight into the efficiency of the 
CRISPR/Cas9 system. Even transient transfection of components of this system, can induce 
extensive on-target editing in the form of deletions, inversions, and scarring (i.e. small indels) in 
selected subpopulations. For example, it would be difficult to retarget monoallelic deletion 
clones with the same sgRNAs since in most cases the recognition sites have been altered by 
indels. Although small indels at deletion and inversion junctions are common, we also observed 
alleles with the precise predicted deletion or inversion without additional indels.  
It has been previously observed that individual sgRNAs in the presence of Cas9 may 
show differences in editing efficiency95. We observed relatively substantial editing efficiencies 
for all tested sgRNA pairs (Table 2.1). This finding could indicate that enrichment via marker-
based sorting can minimize differences in sgRNA efficiency, although the efficiency of these 
same sgRNA pairs to produce deletion without marker-based sorting was not characterized in 
detail. 
The CRISPR-mediated deletion strategy appears particularly suited for the study of non-
coding regulatory DNA where frameshift mutations do not pertain67. The importance of efficient 
strategies for assessment of regulatory DNA function is emphasized by recent reports that have 
suggested the majority of variants associated with human disease reside in non-coding 
regulatory DNA97. Combinatorial deletion of regulatory elements and/or genes may be a 
powerful method for studying pathways, the hierarchy of regulatory elements, and gene-
regulatory element interactions. This study demonstrates that the CRISPR/Cas9 system is a 
robust tool to produce biallelic genomic deletions for prospective functional genetics. 
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Chapter 3 
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis 
 
ABSTRACT 
Enhancers are critical determinants of cellular identity, yet their underlying structure remains 
poorly understood. Enhancers are commonly identified by correlative chromatin marks and gain-
of-function potential, though only loss-of-function studies can demonstrate their requirement for 
gene expression in the native genomic context. Previously we identified an erythroid enhancer 
of BCL11A, subject to common genetic variation associated with fetal hemoglobin (HbF) level, 
whose mouse ortholog is necessary for erythroid BCL11A expression. Here we develop pooled 
CRISPR-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and 
mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of 
these enhancers. Despite conserved function of the composite enhancers, their architecture 
diverges. The crucial human sequences appear primate-specific. Through editing of primary 
human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a 
target for HbF reinduction. This detailed enhancer map will inform therapeutic genome editing. 
 
INTRODUCTION 
Enhancers are classically described as distal genetic elements that positively regulate gene 
expression in an orientation-independent manner in ectopic heterologous gain-of-function 
expression experiments98. These elements coordinate when, where, and how genes are 
expressed. Enhancer sequences bind transcription factors and are correlated with specific 
chromatin features including reduced DNA methylation, characteristic histone modifications, 
heightened chromatin accessibility, long-range promoter interactions, and bidirectional 
transcription. Recent chromatin mapping has demonstrated the abundance of distal regulatory 
elements bearing an enhancer signature99–101.  
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The biological importance of enhancers is underscored by gene expression studies 
showing the predictive power of enhancer profile on lineage-specific programs102–104. Highly 
marked and clustered enhancers (e.g. so-called strong, stretch, or super-enhancers) are 
particularly suggestive of cellular identity and may help to infer lineage-specific regulatory 
factors105–107. Genome-wide association studies reveal enrichment of trait-associated variants in 
sequences bearing lineage-restricted enhancer signatures97,101,105,108. Enhancers display signs 
of evolutionary constraint as well as heightened turnover with evidence of positive selection109–
112
.  
Despite their importance, enhancers are typically defined by criteria unrelated to in situ 
functional requirement. Advances in putative enhancer mapping, as well as large-scale 
oligonucleotide synthesis, facilitate enhancer reporter assays on a massively parallel scale, 
allowing a systematic evaluation of the functional significance of enhancer sequences113,114. 
Nonetheless, ectopic heterologous enhancer assays cannot address the necessity of an 
element in its native chromatin environment. The growing appreciation of the nonrandom 
distribution of distal elements both with respect to the linear genome and within the three-
dimensional nuclear environment emphasizes the importance of studying enhancers by 
perturbing their endogenous condition107,115. 
Insightful observations have been made by mutagenizing enhancers using traditional 
molecular genetic approaches116,117. However the low throughput of these classical methods 
constrains their widespread application. Furthermore the elevated turnover of many enhancer 
sequences between species may limit the ability to derive conclusions from nonhuman 
organisms regarding human gene regulation. Advances in genome editing technology make 
practical the facile modification of the human genome47,48. High-throughput Cas9-mediated 
functional genomics studies have revealed novel genes required for various biologic 
processes83,84,118,119. Genome editing is likewise suitable for the study of non-coding genetic 
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elements such as enhancers, although these experiments have previously been conducted at 
low-throughput67,120,121.  
 
METHODS 
Generation of genomic deletions in HUDEP-2 cells 
HUDEP clone 2 (HUDEP-2), was utilized as previously described122. HUDEP-2 cells were 
expanded in StemSpan SFEM (Stem Cell Technologies) supplemented with 10-6 M 
dexamethasone (Sigma), 100 ng/mL human stem cell factor (SCF) (R&D), 3 IU/mL 
erythropoietin (Amgen), 1% L-glutamine (Life Technologies), and 2% penicillin/streptomycin. 1 
μg/mL doxycycline (Sigma) was included in the culture to induce expression of the human 
papilloma virus type 16 E6/E7 genes122. HUDEP-2 cells were differentiated in Iscove’s Modified 
Dulbecco’s Medium (IMDM) (Life Technologies) supplemented with 330 μg/mL holo-transferrin 
(Sigma), 10 μg/mL recombinant human insulin (Sigma), 2 IU/mL heparin (Sigma), 5% human 
solvent detergent pooled plasma AB (Rhode Island Blood Center), 3 IU/mL erythropoietin, 100 
ng/mL human SCF, 1 μg/mL doxycycline, 1% L-glutamine, and 2% penicillin/streptomycin.  
Tandem sgRNA lentiviruses were transduced into HUDEP-2 with stable Cas9 
expression (Supplemental Table 3.1). Bulk cultures were incubated for 7-10 days with 10 μg/mL 
blasticidin and 1 μg/mL puromycin selection to allow for editing. Then bulk cultures were plated 
clonally at limiting dilution. 96 well plates with greater than 30 clones per plate were excluded to 
avoid mixed clones. After approximately 14 days of clonal expansion, genomic DNA was 
extracted using 50 μL QuickExtract DNA Extraction Solution per well (Epicentre). Clones were 
screened for deletion by conventional PCR with one PCR reaction internal to segment to be 
deleted (‘non-deletion band’) and one gap-PCR reaction across the deletion junction (‘deletion 
band’) that would only amplify in the presence of deletion60. Biallelic deletion clones were 
identified as the absence of the non-deletion PCR band and the presence of the deletion PCR 
band. Inversion clones were identified as previously described by PCR60 (Supplemental Table 
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3.3). Briefly inversion clones had one inverted allele and one deleted allele without the presence 
of nondeletion alleles. In our experience biallelic inversion clones are very rare events60. PCR 
was performed using the Qiagen HotStarTaq 2x master mix and the following cycling conditions: 
95oC for 15 minutes; 35 cycles of 95oC for 15 seconds, 60oC for 1 minute, 72oC for 1 minute; 
72oC for 10 minutes. Alternatively, PCR was also performed using 2x Accuprime Supermix II 
(Life Technologies) with the following cycling conditions: 94oC for 2 minutes; 35 cycles of 94oC 
for 20 seconds, 60oC for 20 seconds, 68oC for 1 min/kb of PCR product; 68oC for 5 minutes. 
RNA was extracted from each positive clone using a kit (Qiagen) and quantitative real-time RT-
qPCR was performed using iQ SYBR Green Supermix (Bio-Rad). Primers used are found in 
Supplemental Table 3.5. Gene expression was normalized to that of GAPDH. We isolated four 
control, one BCL11A null, three composite enhancer deleted, one h+55 deleted, one h+58 
deleted, five h+62 deleted, three h+55 inverted, and two h+58 inverted clones. The BCL11A null 
clone had a 216 bp interstitial deletion of exon 2, preventing binding of the RT-qPCR primers. 
All gene expression data reported from these clones represents the mean of at least three 
technical replicates. 
 
Design and synthesis of human and mouse lentiviral sgRNA libraries 
Every 20-mer sequence upstream of an NGG or NAG PAM sequence on the plus or minus 
strand was identified for both the human and mouse orthologous +55, +58, and +62 DNase I 
hypersensitive site (DHS) as well as BCL11A/Bcl11a exon 2 (Supplemental Data). Relative to 
the human hg19 reference genome, a reference was used with the following substitutions to 
approximate a common low-HbF associated haplotype: rs1427407-G, rs1896293-T, rs6706648-
T, rs6738440-G, rs7606173-C. The mouse orthologous sequences to each of the human DHSs 
were defined by using the liftOver tool of UCSC Genome Browser as previously described67. 
Each of the sgRNA oligos were synthesized as previously described84,123,124 and cloned using a 
Gibson Assembly master mix (New England Biolabs) into lentiGuide-Puro (Addgene plasmid ID 
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52963) which had been BsmBI digested, PCR purified, and dephosphorylated. Gibson 
Assembly products were transformed to electrocompetent cells (E. cloni, Lucigen). Sufficient 
colonies were isolated to ensure ~90X library coverage for both human and mouse libraries. 
Plasmid libraries were deep sequenced to 533X and 813X coverage for human and mouse 
libraries respectively to confirm representation. 
To produce lentivirus, HEK293T cells were cultured with Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Omega 
Scientific) and 2% penicillin-streptomycin (Life Technologies) in 15 cm tissue culture treated 
petri dishes. HEK293T were transfected at 80% confluence in 12 mL of media with 13.3 μg 
psPAX2, 6.7 μg VSV-G, and 20 μg of the lentiviral construct plasmid of interest using 180 μg of 
linear polyethylenimine (Polysciences). Medium was changed 16-24 hours after transfection. 
Lentiviral supernatant was collected at 48 and 72 hours post-transfection and subsequently 
concentrated by ultracentrifugation (24,000 rpm for 2 hours at 4oC with Beckman Coulter SW 32 
Ti rotor). 
 
Tiled pooled CRISPR-Cas9 screen for in situ functional mapping the human BCL11A 
erythroid enhancer 
HUDEP-2 cells with stable Cas9 expression were transduced at low multiplicity with the human 
sgRNA library lentivirus pool while in expansion medium. Control transductions were performed 
to ensure transduction rate did not exceed 50%. Cell numbers were maintained throughout the 
experiment at levels adequate to exceed 1000X representation of the library. 10 μg/mL 
blasticidin (Sigma) and 1 μg/mL puromycin (Sigma) were added 24 hours after transduction to 
select for lentiviral library integrants in cells with Cas9. Cells were cultured in expansion media 
for one week followed by differentiation media for an additional week. 
Intracellular staining was performed by fixing cells with 0.05% glutaraldehyde (grade II) 
(Sigma) for 10 minutes at room temperature. Cells were centrifuged for 5 minutes at 600 g and 
31 
 
then resuspended in 0.1% Triton-X 100 (Life Technologies) for 5 minutes at room temperature 
for permeabilization. Triton X-100 was diluted with phosphate buffered saline (PBS) with 0.1% 
BSA and then centrifuged at 600 g for 15 minutes. Cells were stained with anti-human 
antibodies for HbF (clone HbF-1 with FITC or APC conjugation; Life Technologies) and β-
hemoglobin antibody (clone 37-8 with PerCP-Cy5 or PE conjugation; Santa Cruz) for 20 
minutes in the dark. Cells were washed to remove unbound antibody prior to FACS analysis. 0.2 
μg HbF and 2 μg of HbA (β-hemoglobin) antibodies were used per 5 million cells. Control cells 
exposed to a nontargeting sgRNA sample and BCL11A exon 2 were used as negative and 
positive controls respectively to establish flow cytometry conditions. Populations of cells with the 
top and bottom 10% of expression of HbF were sorted by FACS. 
After sorting the HbF-high and HbF-low pools, library preparation and deep sequencing 
was performed as previously described84. Briefly, genomic DNA was extracted using the Qiagen 
Blood and Tissue kit. Herculase PCR reaction (Agilent) using lentiGuide-Puro specific primers 
(5’-AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG-3’ and 5’- 
CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCCC-3’) including a handle 
sequence was performed as follows: Herculase II reaction buffer (1x), forward and reverse 
primers (0.5 μM each), dimethyl sulfoxide (DMSO) (8%), deoxynucleotide triphosphates 
(dNTPs) (0.25 mM each), Herculase II Fusion DNA Polymerase (0.5 reactions) using the 
following cycling conditions: 95oC for 2 minutes; 20 cycles of 95oC for 15 seconds, 60oC for 20 
seconds, 72oC for 30 seconds; 72oC for 5 minutes. Multiple reactions of no more than 200 ng 
each were used to amplify from 6.6 ug gDNA (~1e6 cell genomes) per pool. Samples were 
subjected to a second PCR using handle-specific primers84 to add adaptors and indexes to each 
sample using the following conditions: Herculase II reaction buffer (1x), forward and reverse 
primers (0.5 μM each), dNTPs (0.25 mM each), Herculase II Fusion DNA Polymerase (0.5 
reactions) with the following cycling conditions: 95oC for 2 minutes; 25 cycles of 95oC for 15 
seconds, 60oC for 20 seconds, 72oC for 30 seconds; 72oC for 5 minutes. PCR products were 
32 
 
run on an agarose gel and the band of expected size was gel purified. Illumina MiSeq 150 bp 
paired end sequencing was performed.  
sgRNA sequences present in the plasmid pool as well as in the HbF-high and HbF-low 
pools were enumerated. Guide sequences were mapped to the guides comprising the sgRNA 
library without allowing mismatches. Total reads were normalized to library sequencing depth. 
Cellular dropout score was determined by calculating (1) the ratio of normalized reads in the 
cells at end of experiment (average of reads in the HbF-high and HbF-low pools) to reads in the 
plasmid pool; (2) log2 transformation; and (3) median of biological replicates. HbF enrichment 
score was determined by calculating (1) the ratio of normalized reads in the HbF-high compared 
to reads in the HbF-low pools; (2) log2 transformation; and (3) median of biological replicates. 
After exclusion of sgRNAs with dropout scores < 2-3 and NAG PAM sgRNAs, a Q-Q plot was 
made with a line fitted through the first and third quantiles using R software. HbF enrichment 
scores and cellular dropout scores were compared by Spearman rank correlation. sgRNA 
sequences were mapped to the human genome (hg19) with cleavage positions set to between 
positions 17 and 18 given PAM positions 21-23. For visual comparisons to targeting sgRNAs, 
nontargeting sgRNAs were pseudomapped each separated by 5 bp.  
 
Validation in primary human CD34+ hematopoietic stem and progenitor cells (HSPCs) 
Primary human CD34+ HSPCs from G-CSF mobilized healthy adult donors were obtained from 
the Center of Excellence in Molecular Hematology at the Fred Hutchinson Cancer Research 
Center, Seattle, Washington. CD34+ HSPCs were subject to erythroid differentiation liquid 
culture as previously described125. Briefly, HSPCs were thawed on day 0 into erythroid 
differentiation medium (EDM) consisting of IMDM supplemented with 330 μg/mL holo-human 
transferrin, 10 μg/mL recombinant human insulin, 2 IU/mL heparin, 5% human solvent detergent 
pooled plasma AB, 3 IU/mL erythropoietin, 1% L-glutamine, and 2% penicillin/streptomycin. 
During days 0-7 of culture, EDM was further supplemented with 10-6 M hydrocortisone (Sigma), 
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100 ng/mL human SCF, and human IL-3 (R&D). During days 7-11 of culture, EDM was 
supplemented with 100 ng/mL human SCF only. During days 11-18 of culture, EDM had no 
additional supplements.  
 HSPCs were transduced with lentiCas9-Blast (Addgene plasmid ID 52962) 24 hours 
after thawing in the presence of 10 μM 16,16-dimethylprostaglandin E2 (PGE2; Cayman 
Chemical). At 48 hours after thawing, medium was changed and cells were transduced with 
lentiGuide-Puro or lentiGuide-Crimson cloned with relevant sgRNA sequence in the presence of 
10 μM PGE2. Three independent transductions were performed per sgRNA. At 72 hours after 
thawing, medium was changed and HSPCs were selected with 10 μg/mL blasticidin and 1 
μg/mL puromycin or 10 μg/mL blasticidin followed by sorting for lentiGuide-Crimson+ cells on 
day 16 of culture. Blasticidin and/or puromycin selection occurred from days 3 to 8 of culture. 
Differentiation was assessed on day 18 of culture using anti-human antibodies against 
the transferrin receptor (CD71) [Clone OKT9 with FITC conjugation; eBioscience] and 
glycophorin A (CD235a) [Clone HIR2 with PE conjugation; eBioscience]. Enucleation was 
assessed using 2 μg/mL of the cell-permeable DNA dye Hoescht 33342 (Life Technologies). 
CD235a+Hoescht 33342- cells were determined to be enucleated erythroid cells. Cells were 
intracellularly stained for HbF and HbA on day 18 of culture as described above. 50,000-
100,000 cells were centrifuged onto microscope slides at 350rpm for 4 minutes. Slides were 
stained with Harleco May-Grünwald stain (Millipore) for two minutes, Giemsa stain (Sigma) for 
12 minutes, and two water washes for 30 seconds each. Slides were air dried and then cover-
slipped using Fisher Chemical Permount Mounting Medium (Fisher). RNA isolation and RT-
qPCR was performed as above. Gene expression was normalized to that of GAPDH. All gene 
expression data represents the mean of at least three technical replicates. 
PCR primers were designed to amplify the genomic cleavage site for a given sgRNA. 
Resulting PCR products were subjected to Sanger sequencing. Sequencing traces were used 
for editing quantification using a previously described publically available tool126. 
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Computational analysis 
Human erythroid H3K27ac ChIP-seq was obtained from Xu et al104 and mouse erythroid 
H3K27ac ChIP-seq was obtained from Kowalczyk et al127 and Dogan et al128. We uniformly 
processed all the datasets using the same pipeline with the same criteria to call super-
enhancers. Specifically, we started from raw reads and realigned each dataset with Bowtie2 
with the default parameters. We then removed duplicate reads with the Picard Suite. To call the 
peaks we used MACS2 in the narrow mode. Finally to call the super-enhancers we used the 
ROSE algorithm with the default parameters107. Using these settings, peaks closer than 12.5 kb 
are stitched together and then ranked based on the H3K27ac intensity. To assign super-
enhancers to genes we used again ROSE with default settings. In particular, the tool reports 
three categories of genes for each super-enhancer: 1) overlapping genes - genes for which the 
gene body region overlaps a super-enhancer; 2) proximal genes - genes close to a SE 
considering a window of 50kb; 3) closest gene - closest gene considering its TSS and the center 
of the super-enhancer. To generate a Venn diagram of genes for super-enhancer datasets, we 
used the union of these three gene categories. 
Hidden Markov Model (HMM) segmentation was performed to automatically segment the 
enrichment score signals into enhancer regions with Active, Repressive and Neutral effect. We 
designed a HMM with 3 states using the GHMM package (http://ghmm.sourceforge.net/). To 
learn the HMM parameters we used the Baum-Welch algorithm. To find the best segmentation 
for each region we used the Viterbi algorithm. The emission probability for each state was 
modeled as a Gaussian distribution and all the possible transitions between states were allowed 
as shown in Supplemental Figure 3.3a. Since the signal was not obtained with a constant 
genomic resolution, we interpolated and smoothed the signal using a Gaussian kernel over 12 
bp and applied the HMM to the smoothed signal. To set the initial parameters, we used the 1%, 
50% and 99% percentile of the smoothed signal for the prior of the means of the Repressive, 
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Neutral and Active states respectively, while the prior for the standard deviation was set to 
0.001 for all the three states. 
Motif analysis was performed to evaluate the human and mouse enhancer regions for 
potential binding sites for known transcription factors (TFs). We used the FIMO software129 with 
a P-value threshold of < 10-4. For each region we extracted sequences using the hg19 and mm9 
assemblies respectively for human and mouse. The motif database was the latest version of the 
JASPAR database130. 
Deep sequencing paired-end reads of genomic amplicons from genome editing target 
sites were first filtered for reads with PHRED quality score <30, merged with the FLASH (Fast 
Length Adjustment of SHort reads) software, and subsequently aligned to a reference amplicon 
using the needle aligner from the EMBOSS suite (http://emboss.sourceforge.net/) to quantify 
insertions and deletions. Per nucleotide frequency of deletion of a position, insertion directly 
adjacent to the position, or no mutation at the position was quantitated using CRISPResso 
(https://github.com/lucapinello/CRISPResso).  
 
Pooled CRISPR-Cas9 screen for high resolution functional mapping of mouse Bcl11a 
enhancer 
Murine erythroleukemia (MEL) cells were cultured in DMEM supplemented with 10% FBS, 1% 
L-glutamine, and 2% penicillin-streptomycin as previously described67. Cell lines tested negative 
for mycoplasma contamination. εy:mCherry reporter MEL cells with stable Cas9 expression 
were transduced at low multiplicity with the mouse sgRNA library lentivirus pool (Supplemental 
Data). Control transductions were performed to ensure transduction rate did not exceed 50%. 
Cell numbers were maintained throughout the experiment at levels adequate to exceed 1000X 
representation of the library. 10 μg/mL blasticidin and 1 μg/mL puromycin were added 24 hours 
after transduction to select for lentiviral library integrants in cells with Cas9. Subsequently cells 
were cultured for two weeks. The top and bottom 5% of εy-mCherry-expressing cells exposed to 
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the library were sorted by FACS. A nontargeting sgRNA sample was used as a negative control 
and Bcl11a exon 2 as a positive control to establish flow cytometry conditions. After sorting, 
library preparation and deep sequencing were performed as described for the human library84.  
sgRNA sequences present in the Hbb-εy:mCherry-high and Hbb-εy:mCherry-low pools 
were enumerated. Cellular dropout and εy enrichment scores were calculated analogously to 
the human screen. sgRNA sequences were then mapped to the mouse genome (mm9). 
 
Generation of genomic deletions in MEL cells 
Deletions in MEL cells were generated using two sgRNA as previously described60. Briefly, 
sgRNA sequences were cloned into pX330 (Addgene plasmid ID 42230) using a Golden Gate 
assembly cloning strategy (Supplemental Data Table 3.1 and 3.4). MEL cells were 
electroporated with 5 μg of each pX330-sgRNA plasmid and 0.5 μg pmax-GFP (Lonza) in BTX 
electroporation buffer using a BTX electroporator (Harvard Apparatus). Approximately 48 hours 
post-electroporation, the top 1-3% of GFP+ cells were sorted and plated clonally at limiting 
dilution. Clones were allowed to grow for 7-10 days. Clones were screened for deletion by 
conventional PCR using the same strategy as with the HUDEP-2 cells (Supplemental Table 
3.2). Inversion clones were identified by PCR as previously described60 (Supplemental Table 
3.3).  
 
Generation of genomic deletions in mouse embryonic stem cells (mESCs) 
mESCs were maintained on irradiated mouse embryonic fibroblasts (GlobalStem) and cultured 
in high glucose DMEM supplemented with 20% FBS, L-glutamine, penicillin/streptomycin (Life 
Technologies), non-essential amino acids (Life Technologies), nucleosides, β-mercaptoethanol 
(Sigma), and leukemia inhibitory factor (Millipore). Cells were passaged using 0.25% trypsin 
(Life Technologies).  
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The Bcl11a +62 deletion mice were derived from CRISPR-Cas9 modified CJ9 ES cells. 
Using Amaxa ES Cell transfection reagent (Lonza), two million mESCs cells were 
electroporated with 2 μg of each pX330 plasmid vector containing individual target sequences 
flanking the +62 site along with 0.5 μg of a GFP plasmid. After 48 hours, the top 5% of GFP 
expressing cells were sorted, plated on irradiated fibroblasts and maintained. Individual ES cell 
colonies were then picked and screened for biallelic deletion using the same strategy as 
HUDEP-2 and MEL cells60. DNA for screening CRISPR-Cas9 modified clones was obtained 
from gelatin adapted ES cell clones to avoid genomic contamination from the fibroblasts. 
Correctly targeted clones with greater than 80% normal karyotype were used to generate mice. 
Clones were injected into embryonic day 3.5 (E3.5) C57Bl6 blastocysts and implanted into 
pseudo-pregnant females.  
The β-YAC mouse line (A20), previously described as containing a transgene 
encompassing ~150 kb of the human β-globin locus131, was used to analyze human globin 
expression. The mouse line was maintained in a hemizygous state and bred with Bcl11a +62 
deletion mice. Sufficient matings were established to ensure adequate homozygotes for 
analysis. 
 
Mouse cell and tissue analysis 
For developmental hematopoiesis, fetal liver cells were taken at E12.5, E14.5, E16.5, and E18.5 
and mechanically dissociated to form single cell suspensions from which RNA was extracted 
using the RNeasy Plus Mini Kit (Qiagen) and analyzed. At E16.5, fetal liver were also stained 
with CD19-PerCP-Cy5.5 (Clone 1D3; eBioscience), B220-APC (RA3-6B2; Biolegend), CD71-PE 
(Clone C2; BD Biosciences), and Ter119-FITC (Clone Ter119; BD Biosciences) to isolate B 
cells (B220+CD19+) and erythroid cells (Ter119+CD71+) by FACS for RNA extraction and 
BCL11A quantification. Additionally, flow cytometry was used to analyze fetal liver from E18.5 
embryos. Single cell suspensions were stained with IgM-FITC (Clone Il-41; eBioscience), CD19-
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PerCP-Cy5.5, (Clone 1D3; eBioscience), CD43-PE (Clone S7; eBioscience), AA4.1-PE-Cy7 
(Clone AA4.1; BD Biosciences), B220-APC, (RA3-6B2; Biolegend), and DAPI (Invitrogen). For 
adult hematopoietic assays, peripheral blood was obtained from the tail vein of four week old 
mice. Blood was collected in EDTA-coated tubes, red cells removed by 2% dextran (Sigma), 
residual red cells lysed with ammonium chloride solution (Stem Cell Technologies) and stained 
with the following anti-mouse antibodies: CD3e-FITC (Clone 145-2C11; Biolegend), CD19-
PerCP-Cy5.5 (Clone 1D3; eBioscience), CD71-PE (Clone C2; BD Biosciences), NK1.1-PE-Cy5 
(Clone PK136; Biolegend), Ter119-APC (Clone TER-119; Biolegend), Gr-1-eF450 (Clone RB6-
8C5; eBioscience), B220-BV605 (RA3-6B2; Biolegend), Mac-1-BV510 (Clone M1/70; 
Biolegend), and 7-AAD (BD Biosciences). Fetal brain analysis was conducted on whole brains 
from E16.5 mouse embryos on ice cold PBS. Tissue was directly lysed into the RLT plus buffer 
(Qiagen) and total RNA extracted according to manufacturer’s instructions provided in the 
RNeasy Plus Mini Kit. RT-qPCR performed as above, with gene expression normalized to 
Gapdh. All gene expression data represents the mean of at least three technical replicates. All 
animal experiments were conducted under the approval of the local Institutional Animal Care 
and Use Committee.  
 
Cloning lentiCas9-Venus 
Venus template132 was PCR amplified to add BamHI-HF (5’) and EcoRI-HF (3’) restriction sites 
for cloning purposes using the following conditions: KOD buffer (1x), MgSO4 (1.5 mM), dNTPs 
(0.2 mM each), forward primer (0.3 μM; 
GGCCGGCCggatccGGCGCAACAAACTTCTCTCTGCTGAAACAAGCCGGAGATGTCGAAGA
GAATCCTGGACCGATGGTGAGCAAGGGCGAGGA), reverse primer (0.3 μM; 
GGCCGGCCgaattcTTACTTGTACAGCTCGTCCA), and KOD Hot Start DNA Polymerase (0.02 
U/μL) (Millipore). KOD PCR reaction used the following cycling conditions: 95oC for 2 minutes; 
50 cycles of 95oC for 20 seconds, 60oC for 20 seconds, and 70oC for 30 seconds; 60oC for 5 
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minutes. PCR products were purified (QIAquick PCR Purification Kit, Qiagen) and blunt end 
cloned with Zero Blunt PCR cloning kit (Invitrogen). PCR-blunt cloned products and lentiCas9-
Blast (Addgene plasmid ID 52962) were separately digested with BamHI-HF (New England 
Biolabs) and EcoRI-HF (New England Biolabs) in 1x Buffer CutSmart at 37oC (New England 
Biolabs). Digest of lentiCas9-Blast was performed to remove the blasticidin cassette. Then 
digested PCR product was ligated into the lentiCas9 backbone. 
 
Cloning lentiGuide-Crimson 
E2-Crimson template (Clontech) was PCR amplified to add BsiWI (5’) and MluI (3’) restriction 
sites for cloning purposes using the following conditions: KOD buffer (1x), MgSO4 (1.5 mM), 
dNTPs (0.2 mM each), forward primer (0.3 μM; 
GGCCGGCCCGTACGcgtacgGCCACCATGGATAGCACTGAGAACGTCATCAAGCCCTT), 
reverse primer (0.3 μM; GGCCGGCCacgcgtCTACTGGAACAGGTGGTGGCGGGCCT), and 
KOD Hot Start DNA Polymerase (0.02 U/μL). KOD PCR reaction used the following cycling 
conditions: 95oC for 2 minutes; 50 cycles of 95oC for 20 seconds, 60oC for 20 seconds, and 
70oC for 30 seconds; 60oC for 5 minutes. PCR products were purified (QIAquick PCR 
Purification Kit) and cloned with Zero Blunt PCR cloning kit. Cloned products and lentiGuide-
puro were separately digested with BsiWI (New England Biolabs) and MluI (New England 
Biolabs) in 1x Buffer 3.1 at 37oC (New England Biolabs). Digest of lentiGuide-Puro (Addgene 
plasmid ID 52963) was performed to remove the puromycin cassette. Then digested PCR 
product was ligated into the lentiGuide backbone. 
 
Cloning sgRNAs 
lentiGuide-Puro (Addgene plasmid ID 52963) was digested with BsmBI in 1X Buffer 3.1 at 37oC 
(New England Biolabs) for linearization. One unit of TSAP thermosensitive Alkaline 
Phosphatase (Promega) was added for 1 hour at 37oC to dephosphorylate the linearized 
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lentiGuide and then TSAP was heat inactivated at 74oC for 15 minutes. Linearized and 
dephosphorylated lentiGuide was run on an agarose gel and gel purified. sgRNA-specifying 
oligos were phosphorylated and annealed using the following conditions: sgRNA sequence oligo 
(10 μM); sgRNA sequence reverse complement oligo (10 μM); T4 ligation buffer (1x) (New 
England Biolabs); and T4 polynucleotide kinase (5 units) (New England Biolabs) with the 
following temperature conditions: 37 °C for 30 min; 95 °C for 5 min; and then ramp down to 25 
°C at 5 °C/min. Annealed oligos were ligated into lentiGuide in a 1:3 ratio (vector:insert) using 
T4 ligation buffer (1X) and T4 DNA Ligase (750 Units) (New England Biolabs. Plasmids were 
verified by sequencing using a U6F promoter forward primer 
CGTAACTTGAAAGTATTTCGATTTCTTGGC.  
 sgRNA-specifying oligos using sgRNA sequences from the screen library (Supplemental 
Data) were obtained and cloned as described into either lentiGuide-Puro or lentiGuide-Crimson. 
sgRNA constructs were used to produce lentivirus and transduce HUDEP-2 with stable Cas9 
expression. Bulk cultures were incubated for 7-10 days with 10 μg/mL blasticidin and 1 μg/mL 
puromycin selection to allow for editing. Then bulk cultures were plated clonally at limiting 
dilution. Clones were allowed to grow for approximately 14 days and then genomic DNA was 
extracted using 50 μL QuickExtract DNA Extraction Solution per well.  
 
lentiTandemGuide cloning 
lentiGuide-sgRNA1 was digested with PspXI and XmaI at 37oC for four hours (New England 
Biolabs). Digests were run on an agarose gel and gel purified. lentiGuide-sgRNA2 was 
linearized using NotI (New England Biolabs). The hU6 promoter and sgRNA chimeric backbone 
for lentiGuide-sgRNA2 was PCR amplified using the following conditions: KOD buffer (1x), 
MgSO4 (1.5 mM), dNTPs (0.2 mM each), forward primer (0.3 μM; 
GGCCGGCCgctcgaggGAGGGCCTATTTCC), reverse primer (0.3 μM; 
CCGGCCGGcccgggTTGTGGATGAATACTGCCATTT), and KOD Hot Start DNA Polymerase 
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(0.02 U/μL) (Millipore). KOD PCR reaction used the following cycling conditions: 95oC for 2 
minutes; 50 cycles of 95oC for 20 seconds, 60oC for 20 seconds, and 70oC for 30 seconds; 60oC 
for 5 minutes. PCR products were purified (QIAquick PCR Purification Kit), blunt ended cloned 
with Zero Blunt PCR cloning kit, transformed, and plated. Colonies were screened by digesting 
minipreps with EcoRI. Mini-preps were then digested with PspXI and XmaI as described above 
followed by PCR purification. Following PCR purification, sgRNA2 was ligated into digested 
lentiGuide-sgRNA1. Sequence verified with following primers: 
GGAGGCTTGGTAGGTTTAAGAA and CCAATTCCCACTCCTTTCAA.  
 
Generation of HUDEP-2 with stable Cas9 
lentiCas9-Blast (Addgene plasmid ID 52962) or lentiCas9-Venus were produced as described 
above and used to transduce HUDEP-2 cells. Transduced cells were selected with 10 μg/mL 
blasticidin or Venus+ cells were sorted. Functional Cas9 was confirmed using the pXPR-011 
(Addgene plasmid ID 59702) GFP reporter assay as previously described133.  
 
Generation of εy:mCherry reporter MEL cells 
A reporter MEL line in which mCherry was been knocked into the Hbb-y locus was created 
(Supplemental Figure 3.5a). Briefly, a TALEN-induced DSB was created adjacent to the Hbb-y 
transcriptional start site. A targeting vector with mCherry and a neomycin cassette were 
introduced through homology directed repair. Homology arms included mm9 sequences from 
chr7:111,001,667-111,002,675 and chr7:111,000,661-111,001,666. Cre-mediated 
recombination was utilized to remove the neomycin cassette. Long-range PCR spanning each 
homology arm was utilized to ensure appropriate targeted integration. Cells were tested upon 
Bcl11a disruption by RT-qPCR and flow cytometry to confirm expected effects on εy:mCherry 
derepression. Subsequently CRISPR-Cas9 was used as described above to produce cells with 
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monoallelic composite enhancer deletion to maximize screening sensitivity for enhancer 
disruption. 
 
Generation of MEL cells with stable Cas9 expression 
lentiCas9-Blast (Addgene plasmid ID 52962) lentivirus were produced as described above and 
used to transduce MEL cells. Transduced cells were selected with 10 μg/mL blasticidin. 
Functional Cas9 was confirmed using the pXPR-011 (Addgene plasmid ID 59702) GFP reporter 
assay as previously described133.  
 
RESULTS 
Human composite enhancer 
Recently we observed that common genetic variants associated with HbF (α2γ2) level and β-
hemoglobin disorder clinical severity mark an adult developmental stage- and erythroid-lineage 
specific intronic enhancer of BCL11A67, a validated repressor of HbF and therapeutic target for 
β-hemoglobin disorders67,134–136. This composite human enhancer is composed of three DNase I 
hypersensitive sites (DHSs), termed h+55, h+58, and h+62, based on distance in kilobases from 
the transcriptional start site (TSS)67. The most highly trait-associated haplotype is defined by 
two SNPs, rs1427407 within h+62 and rs7606173 within h+55 (Supplemental Figure 3.1a). 
Previously we showed that this enhancer possessed ectopic erythroid-restricted, adult-stage-
specific enhancer activity67. Moreover, the mouse ortholog of the composite enhancer, defined 
by primary sequence homology, shared erythroid enhancer chromatin signature, and syntenic 
position relative to coding sequences, was shown to be required for BCL11A expression and 
embryonic globin gene repression in a mouse erythroid cell line but dispensable in a mouse B-
lymphoid cell line67. 
To evaluate the requirement for human BCL11A enhancer sequences, we utilized 
HUDEP-2 cells, an immortalized human CD34+ hematopoietic stem and progenitor cell (HSPC)-
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derived erythroid precursor cell line that expresses BCL11A and predominantly β- rather than γ-
globin122. We used the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 
nuclease system to generate clones of HUDEP-2 cells with deletion of the 12-kb BCL11A 
composite enhancer by introduction of a pair of chimeric single guide RNAs (sgRNAs). 
Enhancer deletion resulted in near complete loss of BCL11A expression and induction of γ-
globin and HbF protein to similar levels as cells with BCL11A knockout (Figure 3.1a-c), 
consistent with the possibility that these sequences could serve as targets for therapeutic 
genome editing for HbF reinduction for the β-hemoglobinopathies137. Although targeted 
deletions by paired double strand breaks (DSBs) may be achieved by genome editing, 
competing genomic outcomes include local insertion/deletion (indel) production at each 
cleavage site as well as inversion of the intervening segment47,48,60,68,138. 
 
Tiled pooled enhancer editing in situ 
We hypothesized that composite enhancers may be composed of a functional hierarchy with 
essential and dispensable constituent components. A functional hierarchy might enable 
enhancer disruption by a single DSB at a critical region followed by nonhomologous end joining 
(NHEJ) repair with indels. In fact, the hypothesis that a prevalent mechanism of trait 
associations is enhancer variation rests on the premise that single nucleotide changes 
themselves may substantively modulate enhancer function. Therefore we reasoned that a tiling 
set of sgRNAs could uncover critical enhancer regions by disruption of nearly all sequences 
within an enhancer based on the typical outcome of Cas9 cleavage and NHEJ repair, an indel 
spectrum with frequent deletions of up to 10 bp from the cleavage position47,48,60,68,93. 
We designed all possible sgRNAs within the human BCL11A composite enhancer DHSs 
(Figure 3.1d, e) as restricted only by the presence of the SpCas9 NGG protospacer adjacent 
motif (PAM), which restricts cleavage at an average 1/8 frequency at each genomic position47,93. 
The NGG PAM restricted sgRNAs had a median gap between adjacent genomic cleavages of 4  
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bp and 90th percentile of 18 bp (Figure 
3.1f), which suggested that this strategy 
could approach saturation mutagenesis 
in situ. We included nontargeting 
sgRNAs as negative controls as well as 
sgRNAs tiling exon-2 of BCL11A as 
positive controls (Figure 3.1e). The 
library was successfully cloned to a 
lentiviral vector. The basic experimental 
schema was to transduce HUDEP-2 
cells with the lentiviral library at low 
multiplicity such that nearly all selected 
cells contained a single integrant 
(Figure 3.1d). Following expansion, 
differentiation, sorting by HbF level, 
genomic DNA isolation, and deep 
sequencing of integrated sgRNAs, an 
HbF enrichment score was calculated 
for each sgRNA by comparing its representation in HbF-high and HbF-low pools (see 
Supplementary Information and Supplemental Figure 3.2 for additional technical details). 
We mapped the HbF enrichment score of each sgRNA to its predicted position of 
genomic cleavage (Figure 3.2a). The majority of enhancer targeting sgRNAs showed no 
significant enrichment or depletion from the HbF-high pool. The enriching sgRNAs colocalized 
to discrete genomic positions. For example, we observed a cluster of sgRNAs at h+62 with 
modest enrichment, a cluster at h+55 with moderate enrichment (as well as adjacent clusters 
with depletion), and a cluster at h+58 with marked enrichment. Of note, we observed 10  
 
Figure 3.1: Tiled pooled in situ CRISPR-Cas9 BCL11A 
enhancer screen. a-c, Deletion of the human composite 
BCL11A enhancer in HUDEP-2 cells demonstrates its 
necessity for BCL11A expression (normalized to GAPDH), 
repression of γ-globin mRNA, and repression of HbF. Error 
bars show s.e.m. d, Workflow of CRISPR-Cas9 enhancer 
screen showing library synthesis, delivery, and analysis. e, 
Human NGG PAM sgRNA library distribution. f, Gaps between 
adjacent genomic cleavages for NGG PAM sgRNAs targeting 
BCL11A exon-2, h+55, h+58, and h+62.   
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sgRNAs at h+58 with cleavage 
positions within 42 bp each with HbF 
enrichment scores exceeding 0.99, the 
median enrichment score of BCL11A 
exon-2 targeting sgRNAs.  
Exon-2 targeted sgRNAs 
showed a linear correlation between 
HbF enrichment and cellular dropout, 
suggesting sgRNAs that result in 
complete knockout of BCL11A lead to 
a reduced rate of cell accumulation 
inseparable from HbF derepression 
(Figure 3.2b). In contrast, the sgRNAs 
at h+58 associated with marked HbF 
enrichment showed blunted impact on 
dropout (Figure 3.2b). This finding 
could be consistent with a low residual 
level of BCL11A adequate to promote 
cellular accumulation but inadequate to 
suppress HbF. 
To corroborate these findings, 
we introduced two sgRNAs to the HUDEP-2/Cas9 cells to produce targeted deletion or inversion 
clones60. Deletion of h+58 phenocopied deletion of the composite enhancer and deletion of 
h+55 had a moderate effect (while deletion of h+62 showed a nonsignificant trend towards a 
modest effect), consistent with the magnitude of top-scoring and colocalizing sgRNAs from the 
screen (Figure 3.2a, c-e). Inversion of the h+58 or h+55 sites had no significant effect on gene 
 
Figure 3.2: Functional mapping of the BCL11A enhancer. a, 
Mapping sgRNA HbF enrichment scores relative to genomic 
cleavage positions. Nontargeting sgRNAs pseudo-mapped with 
5 bp spacing. b, Correlation between cellular dropout and HbF 
enrichment scores. c-e, BCL11A expression normalized to 
GAPDH, β-like globin expression, and HbF+ fraction in HUDEP-
2 cells with deletion or inversion of individual DHSs. f-h, 
BCL11A expression normalized to GAPDH, β-like globin 
expression, and HbF+ fraction in primary human erythroid 
precursors transduced with Cas9 and individual sgRNAs. Error 
bars represent s.e.m. (c, d, f, g) or s.d. (e, h). 
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expression, demonstrating that the BCL11A enhancer functions in an orientation-independent 
manner in situ, consistent with the classic enhancer definition98 (Figure 3.2c-e).  
To validate the findings from the HUDEP-2 cells, the top-scoring enhancer targeting 
sgRNA from the screen (#1621 at h+58) was tested in primary human erythroblasts by lentiviral 
transduction of human CD34+ HSPCs exposed to ex vivo erythroid culture conditions. 
Consistent with the screen results, sgRNA-1621 resulted in downregulation of BCL11A 
expression and corresponding upregulation of γ-globin expression and increase in HbF+ cells 
(Figure 3.2f-h). Notably, sgRNA-1621 did not alter surface marker profile, enucleation 
frequency, or cellular morphology (Supplemental Figure 3.3c). Together these results suggest 
proof-of-principle of an individual sgRNA targeting a noncoding element for therapeutic genome 
editing of β-hemoglobin disorders.  
 
Primate-specific enhancer sequences 
We applied a hidden Markov model (HMM) to the sgRNA enrichment score data to infer 
functionally important sequences within each DHS (Supplemental Figure 3.4a). This model 
defined three functional states, Active, Repressive, and Neutral, based on likelihood to 
encompass sequences that positively, negatively, and neutrally regulate target gene expression, 
respectively. The model identified functional states within each DHS (Figure 3.3a-c). At each of 
the three DHSs, the Active states were precisely located at regions with the highest degree of 
DNase I sensitivity. 
The overall sequence conservation at the h+58 Active region appears both less intense 
and less distinct from flanking sequences as compared to those of h+62 and h+55 (Figure 3.3a-
c). The top-scoring sgRNAs in the screen colocalize to 42 bp within h+58 (Figure 3.4, 
Supplemental Figure 3.5b). The third-highest scoring enhancer-targeted sgRNA (sgRNA-1617) 
mapped directly onto an apparent GATA1 motif, though below a genome-scale significance 
threshold (P = 3.74 x 10-4). The mouse orthologous sequence has a GATA1 motif P-value only  
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modestly higher than the human (p 
= 4.33 x 10-4). This GATA1 motif 
appears to have relatively high 
vertebrate conservation, with exact 
human sequence identity in rabbits, 
pigs, dogs, and elephants. The top-
scoring sgRNA (sgRNA-1621) 
mapped to a position 15 bp from this 
GATA1 motif (Figure 3.4). An 
additional four sgRNAs mapping 
between sgRNA-1621 and 1617 
each had substantially elevated HbF 
enrichment scores. Underlying these 
sgRNAs were additional predicted 
motifs (i.e. RXRA, EHF, ELF1, and 
STAT1). Although these sequences 
showed a high level of conservation 
among primates, they showed high 
degeneracy among nonprimate 
vertebrates (Figure 3.4).  
We tested the pattern of mutations observed upon treatment of cells with either sgRNA-
1621 or sgRNA-1617 by deep sequencing. Each of these sgRNAs is sufficient to substantially 
induce HbF in human erythroid cells (Figure 3.2h; Supplemental Figure 3.3a, b). We sorted cells 
exposed to Cas9 and these sgRNAs into HbF-high and HbF-low pools. We determined the indel 
spectrum in each population by deep sequencing (Supplemental Figure 3.4b). As expected we 
observed indels clustering around the predicted cleavage positions. By comparing the per  
 
Figure 3.3: Inferred functional enhancer states relative to 
genomic features. a-c, Hidden Markov model segmentation of 
functional enhancer states. HbF enrichment scores shown 
throughout DHSs h+55, h+58, h+62 by gray lines and circles with 
blue line representing smoothed enrichment score. DNase I 
sequencing from primary human erythroblasts67. PhyloP (scale 
from -4.5 to 4.88) and PhastCons (from 0 to 1) estimates of 
evolutionary conservation among 100 vertebrates. Positions of 
SNPs rs7606173 and rs1427407 denoted which together define 
the haplotype most highly associated to HbF level67. 
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Figure 3.4: Primate-specific BCL11A enhancer functional core. DHS h+58 functional core defined by maximal 
HbF enrichment score and Active HMM state. HbF enrichment scores shown by gray lines and circles. HbF indel 
enrichment per nucleotide based on amplicon genomic sequencing of sorted cells exposed to either sgRNA-1617 
or -1621. No common SNPs (MAF>1%) present at this region. JASPAR motifs (P < 10-4) depicted in black with 
selected motifs annotated by TF based on known erythroid-specific function or genomic position. Gata1 motif 
LOGO at sgRNA-1617 cleavage position as described in text. Orthologous sequences listed from representative 
primates and nonprimates of distributed phylogeny. PhyloP (scale from -4.5 to 4.88) and PhastCons (from 0 to 1) 
estimates of evolutionary conservation among 100 vertebrates. 
 
nucleotide indel ratio between cells from the HbF-high and HbF-low pools, we calculated a 
relative indel enrichment across the sequencing amplicon. Notably both sgRNAs yielded 
maximal HbF indel enrichment not precisely at the expected cleavage position but offset at 
shared intervening sequences (Figure 3.4). These sites of maximal HbF mutation enrichment 
mapped to 7 bp directly overlapping predicted motifs (Figure 3.4). Taken together, these data 
suggest that a conserved GATA1 motif scoring below the prediction threshold adjacent to 
primate-specific sequences form the core of an enhancer essential for human erythroid BCL11A 
expression and HbF repression.  
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Mouse enhancer dissection 
To test functional conservation of the BCL11A enhancer, we examined the orthologous mouse 
Bcl11a enhancer in greater detail. Erythroid DNase I sensitivity is only observed at those 
sequences homologous to h+55 and h+62 and not h+58 (Supplemental Figure 3.6a), consistent 
with the reduced sequence homology within the h+58 Active region (Figure 3.3a-c). We 
performed a pooled CRISPR enhancer saturating mutagenesis screen in MEL εy:mCherry 
reporter cells, similar to the human screen described above (Supplemental Figure 3.6, 3.7; 
Supplementary Information).  
 
Figure 3.5: Functional sequence requirement at the mouse Bcl11a erythroid enhancer for in vivo 
hemoglobin switching. a, Mapping sgRNA εy enrichment scores to genomic cleavage positions. Nontargeting 
sgRNAs pseudo-mapped with 5 bp spacing. b, BCL11A expression in mouse erythroid clones with deletion or 
inversion of individual DHSs relative to nondeleted controls. c, Transgenic human β-like globin (each symbol 
represents the mean of at least 3 embryos) expression in β-YAC / +62 deletion mice. Error bars represent s.e.m. 
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Upon mapping the sgRNA cleavage positions to the genome, we again observed that 
the majority of enhancer targeting sgRNAs demonstrated no significant εy enrichment or 
depletion. We observed colocalization of sets of sgRNAs with εy enrichment (Figure 3.5a). 
There was a similar complex pattern at the m+55 ortholog as at h+55, with adjacent regions with 
enriching and depleting sgRNAs from the high-εy:mCherry pool at the DHS core. At the m+58 
ortholog we did not observe any evidence of εy enriching or depleting sgRNAs. At the m+62 
ortholog there was a marked peak, with five sgRNAs with εy enrichment scores exceeding 1.30, 
the median enrichment score of Bcl11a exon-2 targeting sgRNAs (Figure 3.5a). This potent 
impact of the m+62 ortholog was in contrast to the modest impact of individual sgRNAs or DHS 
deletion at h+62.  
We used pairs of sgRNAs in the presence of Cas9 to produce MEL clones with deletions 
of various substituent elements at the Bcl11a enhancer (Figure 3.5b). Deletion of the DNase-
insensitive m+58 ortholog had no apparent effect on BCL11A expression consistent with the 
pooled screen result. Deletion of the m+55 ortholog led to an approximately two-fold reduction 
in BCL11A expression (mean residual level 49%, p<0.0001), whereas deletion of the m+62 
ortholog approached deletion of the entire composite enhancer in terms of reduction in BCL11A 
expression (mean residual levels of 8% (p<0.0001) and 6% (p<0.0001) respectively, Figure 
3.5b; also see Supplementary Information and Supplemental Figure 3.8, 3.9). In addition, clones 
in which the m+62 ortholog was inverted showed no change in BCL11A expression, suggesting 
that the mouse, like the human, enhancer functions independent of orientation in situ (Figure 
3.2c-e; 3.5b). 
 
Erythroid-restricted function in vivo 
To substantiate the importance of the m+62 ortholog for BCL11A expression as well as to 
validate BCL11A enhancer disruption as a therapeutic strategy, we generated mice deficient for 
the Bcl11a m+62 ortholog. We used the same Cas9 and paired sgRNA deletion strategy in 
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mouse embryonic stem cells (mESCs), from which we derived mice with germline transmission 
of the enhancer deletion. Previous studies have demonstrated essential roles for Bcl11a in 
structural development of the central nervous system and B-lymphopoiesis139–141. Strikingly, 
unlike conventional Bcl11a knockouts, which die hours after birth, m+62 ortholog deletion mice 
were born healthy at expected Mendelian ratios (Supplemental Figure 3.10a). The m+62 
ortholog deletion mice also showed normal frequencies of B-cell progenitors in the fetal liver and 
mature B-lymphocytes in the adult peripheral blood (Supplemental Figure 3.10b, c). Other 
hematopoietic lineages were also observed at wild-type frequencies (Supplemental Figure 
3.10c). BCL11A expression was unperturbed in the brain or sorted B cell precursors from E16.5 
embryos (Supplemental Figure 3.10d). In contrast, there was substantial reduction in BCL11A 
levels in sorted E16.5 erythroid precursors (26% residual, P<0.05; Supplemental Figure 3.10d).  
The m+62 ortholog deletion mice were bred to mice transgenic for the human β-globin 
cluster (β-YAC) to model the role of BCL11A in hemoglobin switching131. Unlike its fetal-stage 
expression in humans, in the mouse fetal liver transgenic human γ-globin is subject to intense 
repression (like an embryonic globin). Bcl11a is required for this early murine silencing of 
transgenic γ-globin at E14.5, although even in the absence of Bcl11a, γ-globin is ultimately 
repressed135,136. Fetal livers were evaluated between days E12.5 and E18.5 to monitor 
hemoglobin switching. Repression of human γ-globin and activation of human β-globin was 
markedly delayed in the m+62 ortholog deleted mice (Figure 3.5c). Heterozygous mice showed 
an intermediate γ-globin derepression phenotype, underscoring the dose-dependent inverse 
relationship between BCL11A and HbF level. These results indicate that targeting the erythroid 
enhancer of BCL11A in vivo results in erythroid-specific disruption of BCL11A expression and 
relaxed repression of γ-globin, unaccompanied by the obvious neurologic and immunologic 
toxicities seen in the BCL11A conventional knockout context.  
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DISCUSSION 
We employed a novel application of CRISPR-Cas9 genome editing, saturating mutagenesis of 
noncoding elements in situ, to provide important insight into the organization and function of the 
BCL11A erythroid enhancer. Traditional tests of enhancer function rely on ectopic heterologous 
reporter assays and/or correlative biochemical features. Genome editing allows facile evaluation 
of the requirement of enhancer sequences within their endogenous chromatin context for 
appropriate gene regulation. As shown here, high-resolution high-throughput pooled tiling 
sgRNA screening reveals underlying enhancer sequence requirements approaching nucleotide 
resolution. A limitation to the resolution of this approach is the availability of NGG PAM 
sequences in a given region. We did not observe efficient editing by SpCas9 with NAG 
restricted sgRNAs (Supplemental Figure 3.2h , 3.6j). Recent studies have identified Cas9 
orthologs and variants restricted by alternate PAM sequences, each capable of efficient genome 
editing53,54,142. This increased targeting range of Cas9 could allow increased resolution for in situ 
mutagenesis, particularly at sequences with paucity of NGG motifs. Alternatively, approaches 
reliant on homology-directed repair143 could offer nucleotide resolution functional mutagenesis of 
noncoding sequences, though issues of efficiency, fidelity, and quantitative sensitivity would 
need to be considered. We suggest that our tiled pooled CRISPR screening approach could be 
readily adapted to the functional interrogation of numerous noncoding genomic elements. 
In addition, these data demonstrate that apparent sequence conservation at the BCL11A 
enhancer masks underlying functional divergence. The mouse and human BCL11A erythroid 
composite enhancers share primary sequence homology, an erythroid enhancer chromatin 
signature, and syntenic intronic position relative to coding sequences. Moreover, both are 
required for erythroid expression of BCL11A and repression of embryonic/fetal globin genes. 
However, our high-resolution CRISPR mutagenesis analysis reveals divergence in the 
architecture of these enhancers. Of note, human BCL11A enforces the γ- to β-globin 
developmental switch around the time of birth. The timing and nature of these switches and the 
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globin genes themselves are distinct in primates as compared to nonprimate vertebrates that 
only exhibit a mid-gestation embryonic to adult switch144. Therefore it would seem plausible that 
critical regulatory mechanisms at BCL11A might differ between species (also see 
Supplementary Information).  
The hemoglobin disorders represent one of the most common Mendelian inherited 
human conditions. The level of HbF is a key modifier of clinical severity of these diseases and 
BCL11A is the chief regulator of HbF level144. Naturally occurring genetic variation at the 
BCL11A enhancer is well-tolerated and associated with HbF level and β-hemoglobin disorder 
clinical severity. The work presented here offers a framework for therapeutic genome editing of 
the BCL11A enhancer for β-hemoglobin disorders. Enhancer disruption by individual sgRNAs in 
primary erythroid precursors results in substantial HbF induction. This approach may mitigate 
erythroid-specific growth disadvantages of complete BCL11A loss (Figure 3.2b). Furthermore 
erythroid enhancer disruption may spare BCL11A expression and function in nonerythroid 
contexts, such as B-lymphopoiesis (Supplemental Figure 3.10b-d). A challenge for the field is 
that it is not yet possible to accurately model HbF repression experimentally. However, 
individuals haploinsufficient for BCL11A due to microdeletions exhibit marked neurologic 
deficits, and elevated HbF beyond that seen in homozygotes for high-HbF common enhancer 
haplotypes145,146. Taken together, these data suggest that perturbation of critical sequences 
within the BCL11A enhancer defined here may result in HbF levels exceeding a clinical 
threshold required to ameliorate the β-hemoglobin disorders. 
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Chapter 4 
Variant-aware saturating mutagenesis using multiple nucleases identifies regulatory elements 
underlying trait-associations of the HBS1L-MYB intergenic region 
 
ABSTRACT 
High-throughput, saturating in situ mutagenesis permits fine-mapping of function across DNA 
regions. Disease- and trait-associated variants from genome-wide association studies largely 
cluster in regulatory DNA. Here we demonstrate the use of multiple designer nucleases and 
variant-aware library design to interrogate trait-associated regulatory DNA at high resolution. 
DNA Striker offers a computational tool for the creation of saturating mutagenesis libraries with 
single or combinatorial nucleases with incorporation of variants from haplotype structure, whole-
genome sequencing, or a custom list of variants. We applied this methodology to the HBS1L-
MYB intergenic region, a locus associated with fetal hemoglobin levels and red blood cell traits. 
This approach identified four regulatory elements, including two that were previously identified 
and two novel elements. These data establish a high-throughput and high-resolution 
methodology to identify minimal functional sequences within large regions of disease- and trait-
associated DNA.  
 
INTRODUCTION 
Genome-wide association studies (GWAS) are a powerful approach for identification of disease- 
and trait-associated variants. Greater than 90% of GWAS variants lie within regulatory DNA97. 
However, linkage disequilibrium often obscures the causal variant. Reliable methods to identify 
the causal variant and underlying functional sequence remain elusive. The clustered regularly 
interspaced short palindromic repeats (CRISPR)-based genome editing systems have emerged 
as highly efficient tools to study regulatory DNA. Targeted deletion provides a valuable tool to 
illuminate the function of regulatory DNA function through loss of function67,147. However, 
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targeted deletion is low throughput and has limited resolution60. Alternatively, the homology-
directed repair (HDR) pathway can be exploited following cleavage by a designer nuclease to 
insert putative causal variants into endogenous DNA sequence using a customized 
extrachromosomal template. However, HDR to insert variants is also low-throughput and limited 
by its low efficiency. Furthermore, trait-associated variants may underestimate the effect of the 
underlying genetic element67,147.  
Saturating a region with insertions/deletions (indels) constitutes a powerful strategy to 
identify minimal functional sequences within regulatory DNA147. Saturating mutagenesis relies 
on pooled screening with every available single guide RNA (sgRNA) in a region to take 
advantage of the typical indel spectrum following non-homologous end joining (NHEJ) repair of 
1-10 bp48,60,68,74,93,147. The ability to saturate a region with indels is a function of protospacer 
adjacent motif (PAM) availability. Moreover, genomic variants that attenuate sgRNA activity can 
reduce resolution through false negatives. We hypothesized that combining multiple nucleases 
with unique PAM sequences and incorporating variants into sgRNA library design would offer a 
high-throughput and high-resolution tool to interrogate trait-associated regulatory DNA.  
 
METHODS 
 
HUDEP-2 Karyotype 
HUDEP clone 2 (HUDEP-2) was obtained from Nakamura and colleagues122. Karyotype 
analysis was performed at the Cytogenetics Laboratory at Tufts Medical Center.  
 
HUDEP-2 Cell Culture 
HUDEP-2 cells were expanded in SFEM (Stem Cell Technologies) supplemented with 100 
ng/mL stem cell factor (R&D), 3 UI/mL erythropoietin (Amgen), 10-6 M dexamethasone (Sigma), 
1 μ/mL of doxycycline (Sigma), and 2% penicillin-streptomycin (Thermo Fisher). HUDEP-2 cells 
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were differentiated in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 330 
μg/mL holo-human transferrin (Sigma), 10 μg/mL recombinant human insulin (Sigma), 2 IU/mL 
heparin (Sigma), 5% human solvent detergent pooled plasma AB (Rhode Island Blood Center), 
3 IU/mL erythropoietin (Amgen), 100 ng/mL human stem cell factor (SCF) (R&D), 1 μg/mL 
doxycycline (Sigma), 1% L-glutamine (Life Technologies), and 2% penicillin/streptomycin (Life 
Technologies). 
 
HUDEP-2 NGG Cas9 and HUDEP-2 NGA Cas9 Cells 
NGG Cas9 lentivirus was prepared as described below using LentiCas9-Blast (Addgene 
plasmid ID 52962). Cells were transduced with LentiCas9-Blast lentivirus and maintained with 
10 μg/mL blasticidin (Sigma). The LentiCas9-Blast (Addgene plasmid ID 52962) plasmid was 
modified to include the VQR mutations as described in Kleinstiver et al148. NGA Cas9 lentivirus 
was prepared as described below using VQR-modified LentiCas9-Blast lentivirus. Cells were 
transduced with VQR-modified LentiCas9-Blast and maintained with 10 μg/mL blasticidin 
(Sigma). 
 
NGG and NGA Cas9 Activity Reporters 
To assess Cas9 activity, lentiviral reporters were used that included green florescent protein 
(GFP) and either an NGG-restricted or NGA-restricted sgRNA targeting GFP sequence. The 
NGG Cas9 activity reporter has been previously described133. In order to construct an NGA 
Cas9 activity reporter, pLentiGuide-Puro (Addgene plasmid ID 52963) was modified to express 
GFP and the NGA-restricted sgRNA sequence GTTCGAGGGCGACACCCTGG targeting GFP 
sequence. After transduction with the lentiviral reporters, successful transductants were 
selected with 1 μg/mL puromycin and incubated for 14 days to allow editing to occur.  
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Lentivirus Production 
HEK293T cells were cultured with Dulbecco’s Modified Eagle’s Medium (DMEM) (Life 
Technologies) supplemented with 10% fetal bovine serum (FBS) (Omega Scientific) and 2% 
penicillin-streptomycin (Life Technologies). HEK29T were transfected at 80% confluence in 15 
cm tissue culture treated petri dishes with 16.25 μg psPAX2, 8.75 μg VSV-G, and 25 μg of the 
lentiviral construct plasmid of interest using 150 μg of branched polyethylenimine (Sigma). 
Medium was refreshed 16-24 hours after transfection. Lentiviral supernatant was collected at 48 
and 72 hours post-transfection. Viral supernatant was concentrated by ultracentrifugation 
(24,000 rpm for 2 hours at 4oC; Beckman Coulter SW 32 Ti rotor). 
 
Non-targeting sgRNA design 
In order to design sgRNAs that do not target the human (hg19) and mouse (mm9) genomes, we 
first extracted all possible 20 bp sequences immediately preceding NG PAM motifs in both 
genomes. We created 5,000 random 20 bases sgRNA sequences that we compared to all 20 bp 
reference sequences. We calculated a targeting score dependent on the number and position of 
mismatches between both sequences using the methodology of Hsu et al93. The score ranges 
from 0 (non-targeting) to 1 (perfect match). We assigned a score of 0 to sequences with more 
than 4 mismatches. Reference sequences with score > 0 were considered potential off-targets. 
For each random guide, we derived an aggregated score from all possible off-targets, as per 
Hsu et al93:  
𝑆𝑔𝑢𝑖𝑑𝑒 =
100
100 + ∑ 𝑆ℎ𝑖𝑡(ℎ𝑖)
𝑛
𝑖=0
 
 
Where n is the number of potential off-target “hits”, and  Shit(hi) is the targeting score of the 
possible off-target sequence hi. In this situation, an aggregated score of 100 corresponds to no 
possible targets in the genome. Multiple off-targets or the presence of hi-scoring off targets will 
60 
 
lower the score towards 0. We defined guides with an aggregated score > 90 as non-targeting 
(n=128). 
 
Pooled CRISPR/Cas9 library design for high resolution, variant-informed functional 
mapping of the HBS1L-MYB intergenic region 
The summit of every DNase hypersensitive site (DHS) within the HBS1L-MYB region (n = 98) 
was identified from fetal- and adult-derived CD34+ subject to erythroid differentiation67. The 
regions of DHS summit +/- 200 bp were chosen for saturating mutagenesis based on previous 
work that suggested functional sequence was located at the peak of DNase hypersensitivity147. 
Using the DNA Striker tool, every 20-mer sequence upstream of an NGG or NGA PAM 
sequence on the sense or anti-sense strand was identified for each HBS1L-MYB region DHS as 
well as BCL11A exon 2, the core of the +58 DHS within the BCL11A enhancer147, HBS1L exon 
4, MYB exon 5 (Figure 4.1d-e). Phased variants within these region were taken from the 1,000 
Genomes Project database in VCF file format (http://www.1000genomes.org/) using all 
individuals available by August 2015 (2,504 individuals; 5,008 alleles). Using the 1,000 
Genomes variants, the variants feature within DNA Striker was used to identify sgRNAs altered 
by variants or new sgRNA resulting from PAM sequences created by variants. Variant-
associated sgRNA were included in the library if variants were present at a frequency of ≥ 1% 
(Supplemental Fig. 4.10a,b). After filtering non-unique sgRNA, the NGG library was composed 
of 2,166 sgRNAs targeting HBS1L-MYB DHS, 176 variant-associated sgRNAs, 13 sgRNAs 
targeting HBS1L exon 4, 28 sgRNAs targeting MYB exon 5, 21 sgRNAs targeting the BCL11A 
enhancer +58 DHS core, 53 sgRNAs targeting BCL11A exon 2, and 128 non-targeting sgRNAs 
for a total of 2,585 sgRNAs. After filtering non-unique sgRNA, the NGA library was composed of 
2,524 sgRNAs targeting HBS1L-MYB DHS, 186 variant-associated sgRNAs, 32 sgRNAs 
targeting HBS1L exon 4, 28 sgRNAs targeting MYB exon 5, 12 sgRNAs targeting the BCL11A 
enhancer +58 DHS core, 47 sgRNAs targeting BCL11A exon 2, and 128 non-targeting sgRNAs 
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for a total of 3,018 sgRNAs. Each of these 20-mer oligos were synthesized as previously 
described123,124,147,149 and cloned using a Gibson Assembly master mix (New England Biolabs) 
into pLentiGuide-Puro (Addgene plasmid ID 52963). Plasmid libraries were deep sequenced to 
confirm representation (Supplemental Figure 4.10c). 
 
Pooled CRISPR/Cas9 screen for high resolution, variant-informed functional mapping of 
the HBS1L-MYB intergenic region 
HUDEP-2 cells with stable NGG or NGA Cas9 expression were transduced at low multiplicity 
with the corresponding NGG or NGA sgRNA library lentivirus pool while in expansion medium 
(NGG and NGA screens were performed independently). 10 μg/mL blasticidin (Sigma) and 1 
μg/mL puromycin (Sigma) were added 24 hours after transduction to select for lentiviral library 
integrants in cells with Cas9. The screens for fetal hemoglobin expression in HUDEP-2 cells 
were performed as previously described147. Briefly, HUDEP-2 cells were differentiated and 
intracelllularly stained for HbF (clone HbF-1 with APC conjugation; Life Technologies). 0.2 μg 
HbF antibody was used per 500,000-5 million cells. An HbF-stained non-targeting sgRNA 
sample was used as a negative control to set a sorting gate for the HbF-high population 
(approximately top 5% of HbF-expressing cells). A corresponding percentage of cells from the 
HbF-low population were also sorted. After sorting the HbF-high and HbF-low pools, library 
preparation and deep sequencing was performed as previously described84,147. 6.6 μg of DNA 
per sample were submitted for Illumina MiSeq paired end sequencing with Nextera sequencing 
primers. Guide sequences present in the HbF-high and HbF-low pools were enumerated. HbF 
enrichment was determined by the log2 transformation of the median number of occurrences of 
a particular sgRNA in the HbF-high pool divided by the median number of occurrences of the 
same sgRNA in the HbF-low pool across the 3 biological screen replicates for each PAM-
restricted library. Dropout scores were calculated by the ratio of normalized reads in the cells at 
end of experiment (average of reads in the HbF-high and HbF-low pools) to reads in the plasmid 
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pool for the median of the 3 biological screen replicates for each PAM-restricted library followed 
by log2 transformation. sgRNA sequences were mapped to the human genome (hg19). The 
plasmid library was deep sequenced to confirm representation using the same methodology. A 
quantile-quantile (Q-Q) plot was made with a line fitted through the first and third quantiles using 
MATLAB software. 
 
Determination of PAM Distributions 
Repeat-masked regions of the human genome (hg19) were removed. Non-repeat-masked 
repeats were parsed out separately to avoid creating false genomic junctions. PAMs were 
identified and the associated double strand break site for each potential sgRNA was 
determined. sgRNA with double strand break positions outside of these regions were excluded 
from analysis. Double strand break positions were compiled from sgRNA on both the plus and 
minus strands. The difference between adjacent genomic double strand break sites was 
calculated. Promoters (transcriptional start site +/- 2 kilobases), exons, and introns were 
determined from RefSeq annotations. Enhancer and DNase hypersensitive regions for 
GM12878, H1 hESC, HepG2, HMEC, HSMM, HUVEC, K562, NHEK, and NHLF cell lines were 
taken from publically available databases150. Repressed regions were used from previously 
published data151. 
 
Super Enhancer Analysis 
Human H3K27ac ChIP-seq was obtained from a previously published dataset104. The ROSE 
algorithm was used to perform super enhancer analysis107. 
 
Variant Datasets 
Representative DNA Striker output plots were generated for chr6:135282411-135282852 (hg19) 
using haplotype data generated as described above, publically available whole genome 
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sequencing in VCF format from NA12878, and a custom list of variants of SNPs. The custom list 
of SNPs included variants with a minor allele frequency of ≥1% in this region. A VCF of this 
custom list of variants was obtained from the dbSNP database. 
 
RESULTS 
Distribution of PAM sequences in the genome and outline of the DNA Striker algorithm 
A variety of CRISPR-associated nucleases with unique PAM recognition sequences have been 
used for genome editing48,50,53,54,74,148,152,153. The degree of saturation of each nuclease is 
dependent on minimizing genomic distance between potential adjacent cleavages. The levels of 
saturation for each PAM in the genome vary (Figure 4.1a; Supplemental Figures 4.1-4.2). Given 
the sequence-dependence of PAM availability, regional-based variation in degree of saturation 
for each nuclease is observed in DNase I hypersensitivity sites (DHS), enhancers, and 
repressed regions as well as genes (promoters, exons, introns) (Supplemental Figures 4.3-4.7). 
We hypothesized that the usage of multiple nucleases in combination with variant-aware 
saturating mutagenesis library design can optimize resolution and reliability to identify trait-
associated regulatory elements (Figure 4.1b). We created DNA Striker as a MATLAB-based 
computational tool to design saturating mutagenesis libraries using single or combinatorial 
designer nucleases as well as provide alternative sgRNA based on haplotype structure, whole-
genome sequencing, or a custom list of variants. The algorithm for DNA Striker is summarized 
in Figure 4.1b. Briefly, uploaded DNA sequence(s) (fasta format) are analyzed for all PAM(s) 
sequences requested by the user using a sliding window approach. Users must provide 
genomic coordinates for each sequence (bed format) and must choose the sgRNA length for 
each PAM sequence in the library given that optimal sgRNA vary for different CRISPR-
associated nucleases48,50,53,54,74. Variant-aware sgRNA library design involves identifying sgRNA 
altered by variants and novel sgRNA resulting from PAM sequences created by the presence of 
variants (Figure 4.1b).  
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Figure 4.1: Degree of saturation is a function of the availability of PAM sequences. a, Distances between 
adjacent genomic cleavages to assess genome-wide PAM availability and distribution. For each box-and-whisker 
plot, the three lines of box represent the 25th, 50th and 75th percentile. The upper and lower whiskers represent the 
99th and 1st percentile, respectively. Outliers, defined as above the 99th percentile or below the 1st percentile are 
plotted as individual points. Lower whiskers are omitted if the 1st percentile is 0. b, Description of the DNA Striker 
algorithm. c, Ranked enhancers by H3K27ac signal intensity from primary human adult erythroid precursors. 
Super-enhancers occur in the region above the horizontal dotted line and to the right of the vertical dotted line. 
Two super enhancers within the HBS1L-MYB intergenic region are indicated. d, Library composition for NGG-
restricted sgRNA-only, NGA-restricted sgRNA-only, as well as NGG- and NGA-restricted sgRNA together. e, For 
the HBS1L-MYB intergenic region DHS, the degree of saturation of using NGG-only (left panel), NGA-only (middle 
panel), and NGG and NGA combined (right panel).   
 
Variant analysis for whole genome sequencing or custom list of variants (both in VCF 
format) occurs by creating multiple versions of the sliding window: the non-variant version, 
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versions with each variant in the window inserted in isolation, and all combinations of up to three 
variants in each window. Variant analysis for haplotype data (VCF format) occurs by creating 
each individual allele present in the haplotype data provided. Analysis completes by outputting 
the full library design and two output figures assessing the degree of saturation of the uploaded 
sequence(s) (Supplemental Figure 4.8).  
 
Saturating mutagenesis library design 
GWAS, quantitative trait loci (QTL), and other human genetic studies of fetal hemoglobin (HbF) 
level (or the related trait F-cell number) have implicated three loci, including the HBS1L-MYB 
interval154–161. In addition to HbF, MYB has also been associated with various erythroid traits162–
167
. These associations have been suggested to reflect changes in the expression of MYB due 
to distant variants localizing kilobases away and approximately equidistant to the HBS1L gene. 
The density of trait-associated single nucleotide polymorphisms (SNPs) reside in an 83 kilobase 
super enhancer (Figure 4.1c, 4.2a, b). Recent studies have utilized lineage-restricted 
expression patterns, clustering of erythroid transcription factor binding sites affecting MYB 
expression, and chromatin capture to suggest that HbF-associated variants modulate MYB 
expression by altering two regulatory elements -71 and -84 kb upstream of the MYB 
transcriptional start site (TSS)159.  
The HBS1L-MYB region is comprised of 98 DNase hypersensitive sites (DHSs) as 
identified from fetal- and adult-derived CD34+ subject to erythroid differentiation67. In order to 
interrogate this intergenic region in a comprehensive fashion, the regions of each DHS summit 
(peak of DNase sensitivity) +/- 200 bp were chosen for saturating mutagenesis based on 
previous work that suggested functional sequence localizes to the peak of DNase 
hypersensitivity147. Using DNA Striker, we designed a high resolution saturating mutagenesis 
library consisting of all NGG- and NGA-PAM restricted sgRNA given their high degree of 
saturation in DHS (Figure 4.1d; Supplemental Figures 4.3, 4.7). The median and 90th percentile 
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gap distance between adjacent genomic cleavages using NGG Cas9 was 5 bp and 22.5 bp, 
respectively while it was 6 bp and 18 bp for NGA Cas9 (Figure 4.1e). The combination of using 
both NGG and NGA Cas9 nucleases led to a reduction in the median and 90th percentile gap 
between adjacent genomic cleavages to 3 bp and 11bp, respectively. Furthermore, use of both 
nucleases reduced the maximum gap size from 115 bp for NGG and 82 bp for NGA Cas9 to a 
maximum of 41 bp for the combined setting. Therefore, the usage of two nucleases resulted in 
higher resolution by reducing the 50th and 90th percentile of distances between adjacent 
genomic cleavages as well as reducing the maximum gap between adjacent cleavages 
(Supplemental Figure 4.9).  
The library was comprised of every 20-mer sequence upstream of an NGG or NGA PAM 
sequence on the sense or anti-sense strand within the HBS1L-MYB region DHS as well as 
BCL11A exon 2, the core of the +58 DHS within the BCL11A enhancer147, HBS1L exon 4, and 
MYB exon 5 (Figure 4.1d, e). To construct a variant-informed library, phased variants within 
these regions were taken from the 1,000 Genomes Project database and incorporated into the 
sgRNA design by DNA Striker to identify potential altered sgRNA and novel sgRNA resulting 
from variant-induced PAM creation (Figure 4.1b). Variants present within the database with a 
frequency ≥1% were chosen for inclusion in each library (Figure 4.1b, d; Supplemental Figure 
4.10a, b). Both NGG- and NGA-restricted sgRNA libraries were batch cloned into lentiviral 
constructs for screening (Supplemental Figure 4.10c). 
 
Functional saturating mutagenesis screens using NGG and NGA Cas9s 
To demonstrate specificity and efficiency of S. pyogenes NGG Cas9 and S. pyogenes variant 
NGA Cas9148, we used Cas9 reporter constructs that delivered GFP as well as either an NGG-
restricted or NGA-restricted sgRNA targeting GFP. Cells stably expressing NGG Cas9, NGA 
Cas9, or no Cas9 were transduced with the reporter construct at low multiplicity and selected for 
14 days. The analysis demonstrated that the NGG and NGA Cas9 proteins were both specific 
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and efficient nucleases as NGG Cas9 only led to significant GFP reduction with an NGG-
restricted sgRNA, and vice versa (Figure 4.2a). The HUDEP-2 erythroid cell line was used to  
 
Figure 4.2: Pooled saturating mutagenesis screening of the HBS1L-MYB region using NGG- and NGA 
Cas9s. a, Cells stably expressing NGG (red), NGA (purple), or without Cas9 (blue) were transduced with a Cas9 
activity reporter, which contained GFP and either an NGG- or NGA-restricted sgRNA. A non-transduced sample 
(black) was included as a negative control. b,  Mapping enrichment and dropout scores to associated genomic 
loci. Non-targeting sgRNA are pseudo-mapped with 5-bp spacing. c, Quantile-quantile plots of NGG and NGA 
dropout scores.  
 
examine HbF expression as previously described122,147. Briefly, HUDEP-2 cells stably 
expressing NGG or NGA Cas9 were transduced at low multiplicity with the associated NGG-
restricted or NGA-restricted library. Cells were expanded, differentiated, sorted for high and low 
HbF-expression, and deep sequenced to enumerate sgRNA present within the HbF-high and 
HbF-low pools. Three biological replicates were performed for both libraries. Surprisingly, there 
was a lack of enrichment of both HBS1L exon 4- and MYB exon 5-targeted sgRNA (Figure 4.2b) 
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while both positive controls, BCL11A exon 2 targeted and +58 DHS within the BCL11A 
enhancer targeted sgRNA, enriched in the HbF-high pool. However, sgRNA targeting MYB 
showed a preponderance to dropout of the screen consistent with MYB’s known essential role in 
erythropoiesis. HBS1L and BCL11A +58 DHS targeted sgRNA were not underrepresented, 
whereas BCL11A exon 2 sgRNA showed modest dropout consistent with previous findings147 
(Figure 4.2b). Upon dropout analysis of the NGG and NGA libraries, we determined that the 
majority of sgRNA in the library did not dropout, suggesting a neutral effect on erythropoiesis 
(Figure 4.2c). Notably, both libraries identified specific sgRNAs with significant dropout (Figure 
4.2c). The presence of multiple colocalizing sgRNA in an in situ saturating mutagenesis screens 
has been previously shown to identify minimal functional sequences147. Upon mapping these 
sgRNAs to their associated genomic loci, the significant dropout sgRNAs colocalized to four 
discrete loci termed -126, -83, -71, and -7 as their distance in kilobases from the MYB TSS for 
both the NGG- and NGA-restricted libraries (Figure 4.3a-c). Of note, the -83 and -71 DHS fall 
within an annotated super enhancer region. These four identified sites strongly suggest 
regulatory potential and likely suggest control of MYB expression levels.  
 
DISCUSSION 
The functional sequences responsible for the association of the HBS1L-MYB intergenic region 
to HbF and other erythroid traits have been unknown due to a lack of methods to interrogate the 
function of trait-associated non-coding sequences in a high-throughput manner. We propose 
that high-resolution, variant-informed CRISPR-based saturating mutagenesis can provide a 
powerful tool with which to identify functional regions within variant-decorated regulatory DNA. 
Notably, previous studies had focused on two functional regions, -84  and -71159. Our approach 
identified these two known DHS within one kilobase and also implicated two additional loci (-126 
and -7). Of interest, these data suggest that the -83 DHS contains functional sequences as 
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opposed to the -84 DHS, which highlights the enhanced resolution of this technique as opposed 
to methods such as chromosomal conformational capture and motif analysis. Moreover, the  
 
Figure 4.3: Mapped NGG- and NGA-restricted sgRNA to associated genomic loci identifies four functional 
elements. a, Mapping NGG dropout scores to associated genomic loci identifies four identified functional 
elements, -126, -83, -71, and -7 are indicated. b, Mapping NGA dropout scores to associated genomic loci 
identifies four identified functional elements, -126, -83, -71, and -7 are indicated. c, NGG- and NGA-restricted 
sgRNA for each of the identified loci. The -84 DHS has been previously associated with altering MYB expression20. 
 
HBS1L-MYB intergenic region on chromosome 6 is trisomic in HUDEP-2 cells (Supplemental 
Fig. 4.11). The ability to obtain interpretable data in a trisomic context underscores the 
robustness of this approach to interrogate sequence function even in the setting of aneuploidy. 
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These data establish high-resolution, variant-informed saturating mutagenesis as a powerful 
and high-throughput approach for identification of functional sequences in disease- and trait-
associated regulatory DNA. 
 
ACKNOWLEDGMENTS 
This text has been reproduced from the following manuscript in preparation: Canver, MC., 
Pinello, L., Lessard, S., Stern, E., Needleman, A., Chen, DD., Vinjamur, DS., Kurita, R., 
Nakamura, Y., Lettre, G., Yuan, GC., Bauer, DE. & Orkin, SH. (2016). Variant-aware saturating 
mutagenesis using multiple nucleases identifies regulatory elements underlying trait-
associations of the HBS1L-MYB intergenic region. 
 
We thank Z. Herbert, M. Berkeley, and M. Vangala at the Dana-Farber Cancer Institute 
Molecular Biology Core Facility for sequencing and members at the Hematologic Neoplasia 
Flow Cytometry and the Flow Cytometry Core facilities at the Dana-Farber Cancer Institute for 
cell sorting. M.C.C. is supported by a National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) Award (F30DK103359-01A1). L.P. is supported by a National Human 
Genome Research Institute (NHGRI) Career Development Award (K99HG008399). S.L. is 
funded by a Canadian Institutes of Health research Banting doctoral scholarship. E.N.S. is 
supported by a Hematology Opportunities for the Next Generation of Research Scientists 
(HONORS) award from the American Society of Hematology. G.L. is funded by the Canada 
Research Program, the Montreal Heart Institute Foundation, and the Canadian Institute of 
Health Research (MOP136979 and MOP123382). G.C.Y. is supported by awards from the 
National Heart, Lung, and Blood Institute (NHLBI) (R01HL119099 and R01HG005085). D.E.B. 
is supported by an NIDDK Career Development Award (K08DK093705), Doris Duke Charitable 
Foundation Innovations in Clinical Research Award (2013137), and Charles H. Hood 
Foundation Child Health Research Award. S.H.O. is supported by an award from the NHLBI 
71 
 
award (P01HL032262) and an award from the NIDDK (P30DK049216, Center of Excellence in 
Molecular Hematology). 
 
AUTHOR CONTRIBUTIONS 
M.C.C., D.E.B., and S.H.O. conceived this study. M.C.C. developed the DNA Striker 
computational tool. M.C.C., E.S., A.N., D.D.C., D.S.V. performed the experiments. R.K. and 
Y.N. provided the HUDEP-2 cell line. M.C.C., L.P., S.L., G.L., G.C.Y. performed computational 
data and statistical analysis. D.E.B. and S.H.O. supervised this work. M.C.C., D.E.B., and 
S.H.O. wrote the manuscript.  
 
 
 
  
72 
 
Chapter 5 
Conclusion 
 
GENERAL STRATEGIES FOR SCD AND β-THALASSEMIA THERAPEUTIC GENOME 
EDITING 
Correction of underlying genetic defects 
The most appealing and theoretically straightforward application of genome editing for 
monogenic disorders is correction of a mutant DNA sequence and in that manner preserving all 
intrinsic regulatory mechanisms acting on the gene of interest. Precise gene correction relies on 
HDR from an extrachromosomal template containing a wild-type gene sequence. Typically, the 
frequency of HDR is relatively low, and particularly low in CD34+ hematopoietic stem and 
progenitor cells (HSPCs) as discussed below. However, gene correction strategies may benefit 
from mixed chimerism allogeneic transplant studies suggesting that low levels of chimerism can 
produce clinical benefit168. Clinical development of such strategies requires optimizing efficiency 
and safety of correcting the sickle mutation, whereas the diverse spectrum of β-thalassemia 
point mutations and deletions necessitates optimization for each unique genetic target, a 
significant challenge for clinical translation. 
 
Gene editing for reactivation of HbF in SCD and β-thalassemia 
Elevated HbF is beneficial in SCD and β-thalassemia. Targets for manipulation include 
sequences lying within the β-globin cluster or within the genes encoding transcriptional 
regulators of globin gene expression (Figure 5.1 and Table 5.1). Depending on the target, 
editing would rely on HDR or NHEJ. Suitability of each target relates to the ease with which the 
desired gene modifications can be generated and the extent to which the modifications 
reactivate HbF expression. In SCD the goal is to induce sufficient HbF to prevent HbS 
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polymerization. In β-thalassemia, the aim is to replace deficient β-globin and thereby reduce 
globin chain imbalance. 
 
Figure 5.1: Network of potential targets for genome-editing based therapy of the β-globin disorders. 
Therapeutic genome editing strategies rely on genetic correction through the HDR pathway or genetic disruption 
through the NHEJ pathway. Genetic correction/repair strategies involve direct modification of the β-globin gene 
cluster through (1) correction of the sickle mutation in the β-globin gene or (2) insertion of the HPFH-associated 
SNPs into the Gγ or Aγ promoters. Genetic disruption strategies involve targeted disruption of (1) BCL11A coding 
sequence, (2) the minimal critical sequences in the +58 DHS within the erythroid-specific BCL11A enhancer, (3) 
the HbF-associated sequences within the Aγ-δ intergenic region, or (4) other genes with a known role in γ-globin 
regulation such as MYB, KLF1, LRF/ZBTB7A, or EHMT1/EHMT2.  
 
POSSIBLE TARGETS FOR SCD AND β-THALASSEMIA THERAPEUTIC GENOME EDITING 
Genetic correction of the SCD and β-thalassemia mutations 
Classical gene targeting approaches have been used to repair the SCD mutation in embryonic 
stem cells169, but this approach cannot be applied to CD34+ HSPCs due to low efficiency and 
the necessity to isolate and propagate faithful recombinants. Correction of genetic defects in 
cultured cells with an engineered nuclease and a donor repair template has been achieved for 
multiple disorders, including cystic fibrosis86,87,170,171, Duchenne’s muscular dystrophy172,173, and 
other diseases71,174–177. Gene correction for SCD and β-thalassemia has also been 
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accomplished in a laboratory setting169,178–181. Of note, a recent study reported correction of an 
SCD allele at nearly 20% gene in CD34+ HSPCs upon delivery of a repair template via  
Table 5.1: Potential targets for therapeutic genome editing for the β-globin disorders. 
Target Repair Strategy Efficiency Advantages/Disadvantages 
Repair of SCD allele HDR Low-moderate 
Single target allele; inadvertent 
generation of β-thalassemia 
alleles 
Repair of β-thalassemia allele HDR Low-moderate Heterogeneous target alleles 
Recreation of non-deletional 
HPFH HDR Low-moderate 
Inadvertent generation of γ-null 
alleles; identified HPFH patients 
support mutation 
tolerance/clinical benefit 
Recreation of deletional HPFH NHEJ Low-moderate 
Insufficient efficiency of targeted 
deletion; identified HPFH 
patients support mutation 
tolerance/clinical benefit 
Other targets in β-globin cluster NHEJ - Targets unknown 
BCL11A NHEJ High 
HSC/B-cell dysfunction due to 
BCL11A requirement; 
haploinsufficient patients have 
significant HbF induction 
BCL11A enhancer NHEJ High 
Erythroid-specific BCL11A loss; 
haploinsufficient patients have 
significant HbF induction 
α-globin NHEJ Moderate-high 
Balance α-β chains; inadvertent 
generation of α-thalassemia 
cells 
KLF1 NHEJ High Broad role in cell proliferation 
and cellular development 
MYB NHEJ High Broad role in cell proliferation 
and cellular development 
LRF/ZBTB7A NHEJ High Broad role in cell proliferation 
and cellular development 
EHMT1/EHMT2 NHEJ High Role in hematopoiesis unknown 
LIN28B pathway NHEJ High Role in hematopoiesis unknown 
 
integration-deficient lentivirus or by DNA oligonucleotide electroporation in the presence of a β-
globin targeted ZFN. Similar levels of correction were observed in bone marrow cells isolated 
from SCD patients178. Despite successful HDR in bulk cells in vitro, the levels of HDR were 
reduced in the spleen and bone marrow of transplanted immunodeficient mice, suggesting that 
HDR within long-term engrafting hematopoietic stem cells (HSCs) was far less efficient than in 
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downstream progenitors. Another study reported improved rates of HDR in repopulating cells 
via electroporation of ZFN mRNA in conjunction with an adeno-associated virus (AAV) donor 
repair template182. Studies using AAV in conjunction with megaTALs183, transcription activator-
like effectors coupled to a sequence specific homing endonuclease, demonstrated ~14% rates 
of HDR in CD34+ HSPCs184. While megaTALs may enhance HDR through generation of 3’ DNA 
overhangs in HSPCs, the rate of HDR in repopulating HSCs has not been examined.  
The relative efficiency of HDR versus NHEJ is critical to potential use of gene editing for 
gene correction. High rates of NHEJ-mediated indel formation are suboptimal for clinical 
translation of β-globin gene correction as the process creates the possibility of disruption of β-
globin production and inadvertent generation of β-thalassemia alleles. Another consideration is 
that mutagenesis has also been observed in the highly homologous δ-globin gene in β-globin 
gene correction experiments, which may result in deletions and rearrangements affecting β-
globin that may be difficult to detect by standard PCR-based genotyping approaches178.   
It is possible that small molecules that enhance HDR and/or inhibit NHEJ may improve 
the efficiency of gene correction within CD34+ HSPCs, so long as they do not impair cell 
engraftment capability185,186. NHEJ is the dominant pathway in G1, S, and G2 phases of the cell 
cycle, whereas HDR preferentially occurs during late S-phase and G2 phase when sister 
chromatid templates become available187. Since HSCs, the rare long-term repopulating cells 
within CD34+ HSPC preparations, are largely quiescent, HDR is not favored. These 
observations are supported by the roles of BRCA1, PALB2, and BRCA2 in DSB repair. BRCA1 
creates single strand DNA through end resection and interacts with PALB2 to recruit BRCA2 
and RAD51 to mediate HDR at sites of DSB. Identification of the cell cycle’s role in suppressing 
BRCA1 in the G1 phase supports the dominance of NHEJ repair in quiescent cells188. However, 
restoration of the BRCA1-PALB2 interaction during the G1 phase can support HDR. Therefore, 
it may be possible to enhance HDR in quiescent HSCs through modulation of the BRCA1-
PALB2-BRCA2 pathway188. Moreover, one study demonstrated enhanced rates of HDR in 
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HEK293T and non-hematopoietic primary cells through cell cycle synchronization to achieve 
nuclease-mediated cleavage during the optimal portions of the cell cycle for HDR187. However, 
triggering proliferation in HSCs tends to impair their ultimate repopulating potential. Whether 
expansion of HSPC populations with small molecules such as SR1189,190 or UM171191 will allow 
for improved HDR efficiencies with concomitant retention of stem cell activity in vivo is as yet 
unknown. 
 
Modification of the β-globin locus to recreate hereditary persistence of fetal hemoglobin 
As would be anticipated from the existence of rare hereditary persistence of fetal hemoglobin 
(HPFH) alleles, genome wide association studies (GWAS) have linked the β-globin cluster itself 
to HbF levels154,155,192–195. This corroborated previous human genetic studies that identified 
HPFH patients with elevated HbF levels resulting from large deletions within the β-globin 
cluster144,196,197. Re-creating the larger deletional HPFH alleles is impractical given their large 
size60. However, opportunities may exist for targeting discrete regions of the β-globin gene 
cluster by NHEJ. Comparison of large deletions in the cluster that generate either HPFH or δβ-
thalassemia phenotypes has implicated sequences in the Aγ-δ intergenic region as harboring 
silencers of γ-gene expression. Notably, study of three families with overlapping deletions in the 
β-globin cluster identified a 3.5 kilobase region between the Aγ and δ genes that may be 
essential for γ-globin repression. Additional, indirect support was derived from chromatin 
immunoprecipitation-PCR experiments that suggest BCL11A binding within this region134,196,198–
200
. At present, the optimal sequences in the cluster amenable for targeted deletion by editing 
and NHEJ have not been identified. 
Several point mutations or small deletions in the Aγ or Gγ-globin gene promoters lead to 
persistence of HbF into adult life. HbF levels in heterozygotes with these nondeletional HPFH 
mutations may be as high as 30%199,201–203. One of the strongest HPFH alleles (-175 T>C in the 
Aγ promoter) was recently created in cultured K562 cells with TALENs. Increased γ-globin 
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production resulted, most likely through de novo generation of a TAL1 binding site that 
facilitated increased chromatin looping between the Aγ promoter and the locus control region204. 
An HPFH allele with a small deletion in the Aγ promoter was re-created in CD34+ HSPCs with a 
sgRNA and Cas9 expression, presumably due to microdeletion of a repeated sequence205. 
Therapeutic genome editing to generate HPFH mutations is an attractive strategy as the effects 
of these mutations are known through study of families with these rare beneficial alleles. The 
approach, however, faces many of the same challenges as precise gene correction, given the 
apparent dominance of the NHEJ pathway at the expense of HDR efficiency in HSCs.  
 
BCL11A targeting 
 
BCL11A gene disruption   
The GWAS-implicated transcription factor BCL11A is a validated repressor of 
HbF134,135,154,155,192–195. Erythroid-lineage Bcl11a knockout in a mouse model of SCD led to 
pancellular HbF induction and phenotypic correction of a mouse model of sickle cell disease136. 
Haploinsufficient patients with microdeletions within the BCL11A locus have significant 
neurocognitive phenotypes as well as elevated HbF at levels near or above therapeutic 
thresholds206,207. In principle, the genetic knockout of BCL11A by targeting BCL11A coding 
sequence in order to create frameshift null alleles represents a potential therapeutic strategy. 
Roles of BCL11A in non-hematopoietic lineages including the neural lineage140,208, pancreatic 
progenitors209, and the breast epithelium210 would not be problematic upon modification of 
BCL11A in autologous CD34+ HSPCs. However, this strategy is limited by extra-erythroid roles 
of BCL11A in the hematopoietic system, including its requirement for B-cell 
development139,140,211,212 and HSC function213,214. These roadblocks might be circumvented by 
use of erythroid restricted expression of genome editing components. A variation of this 
approach involves erythroid-specific, shRNA-mediated knockdown of BCL11A expression, 
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which is under development as a gene therapy strategy215.  Delivery of genome editing tools 
stably to CD34+ HSPCs would be inadvisable due to potential insertional mutagenesis216 as well 
as elevated risk of off target mutagenesis over time. Furthermore, the effects of long-term 
expression of ZFNs, TALENs, or CRISPR/Cas9 on CD34+ HSPCs are unknown.  
 
BCL11A gene enhancer   
Recent fine mapping of HbF-associated GWAS variants led to the identification of a 
developmental stage-specific, erythroid-restricted 12-kb region bearing a characteristic 
enhancer chromatin signature. This enhancer region is composed of three DNaseI 
hypersensitive sites (DHS), termed +55, +58, and +62 as their distance in kilobases from the 
BCL11A transcriptional start site. Deletion of the orthologous element in a murine erythroid cell 
line resulted in a complete loss of BCL11A at both the RNA and protein levels while expression 
was spared in a B cell line with the same deletion67. Subsequent deletion studies demonstrated 
a similar requirement for this element for BCL11A expression in human erythroid cells147,217.  
BCL11A enhancer targeting has several distinct advantages over coding sequence 
disruption: (1) GWAS studies have demonstrated that variation in the BCL11A enhancer is 
associated with elevated HbF levels and is both common and well-tolerated67. (2) Targeted 
deletion of this element in a human cell line leads to loss of BCL11A expression and 
subsequent HbF induction nearly comparable to BCL11A null clones147. (3) Targeted deletion of 
the murine +62 DHS within the Bcl11a erythroid enhancer results in delayed hemoglobin 
switching sparing expression in the brain and non-erythroid hematopoietic lineages147. The +62 
DHS knockout mice were viable and born in normal Mendelian ratios as compared to Bcl11a-/- 
knockout mice that are perinatal lethal likely to do neural defects135,147. These results further 
highlight the erythroid specificity of this element in vivo147. (4) Targeting the BCL11A  enhancer 
has been shown to be better tolerated even within the erythroid lineage as compared to 
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targeting BCL11A coding sequence, suggesting a residual low level of BCL11A present after 
enhancer targeting is insufficient to repress γ-globin, but promotes cellular fitness147,217. 
Therefore, an alternative approach to targeting BCL11A coding sequence might be 
targeted deletion of the 12 kilobase BCL11A erythroid enhancer67. However, while targeted 
deletions from ~1 kb to 1 Mb have been demonstrated to occur at an appreciable frequency, 
these are unlikely to occur at a sufficient frequency at clinical scale with current genome editing 
technologies due to competing outcomes to deletion when employing a dual nuclease strategy 
including scarring (multifocal indels), inversions, and duplications47,48,60,68,138. Furthermore, the 
heterogeneous population of cells resulting from a dual nuclease strategy would be suboptimal 
for clinical translation.  
Functional footprinting-informed targeting by ZFNs/TALENs within the BCL11A enhancer 
and comprehensive functional mapping of the BCL11A enhancer by CRISPR/Cas9-mediated 
saturating mutagenesis has revealed an “Achilles heel” to the BCL11A enhancer within the +58 
DHS147,217. Disruption of this minimal functional sequence at the core of the DHS +58 by 
CRISPR/Cas9 or ZFNs/TALENs resulted in γ-globin induction comparable to targeting coding 
sequence in CD34+ HSPCs subject to erythroid differentiation conditions147,217. The core region 
has been fine-mapped to an approximately 20 bp region including a GATA1 binding motif which 
appears to be essential for BCL11A expression and subsequent HbF repression147,217. As 
previously discussed, the erythroid specificity of the regulatory element would not require 
erythroid specific expression of the genome editing components, as would be necessary with a 
BCL11A coding sequence targeting approach. Taken together, targeting of the BCL11A 
enhancer disruption at the functional core of +58 DHS in autologous CD34+ HSPCs followed by 
bone marrow transplantation represents a promising therapeutic strategy to induce HbF 
expression in patients with the β-globin disorders (Figure 5.2).  
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Figure 5.2: Reversal of hemoglobin switching to induce therapeutic levels of HbF. Reversal of hemoglobin 
switching can be accomplished through autologous bone marrow transplantation of genome edited CD34+ HSPCs. 
The gray region indicates the hypothesized levels of HbF required for clinical benefit.  
 
LRF/ZBTB7A gene disruption 
Another transcription factor LRF/ZBTB7A (also referred to as Pokemon) has more recently been 
recognized as a major repressor of γ-globin218. LRF-knockout mice exhibit elevated levels of the 
embryonic globin Hbb-βh1 with normal levels of Hbb-y. This contrasts from Bcl11a-null mice 
that exhibit elevation of both embryonic globins, Hbb-y > Hbb-βh1135,136. Zbtb7a-/- mice are 
embryonic lethal due to anemia, whereas conditional knockout of Zbtb7a in adult mice leads to 
inefficient terminal erythropoiesis resulting in a mild macrocytic anemia219. CRISPR/Cas9-
mediated knockout of LRF in an erythroid cell line resulted in dramatic upregulation of γ-globin. 
LRF/BCL11A double knockout in this system was near additive and resulted in HbF of >90%, 
suggesting LRF's role in γ-globin regulation is partially independent of BCL11A. Subsequent 
analysis demonstrated a mild delay in erythroid differentiation upon knockdown of LRF in 
primary human CD34+ HSPCs differentiated down the erythroid lineage with a corresponding 
induction of γ-globin218. While the effect of LRF loss on γ-globin is striking, the role of LRF in cell 
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fate decisions in multiple hematopoietic lineages and its requirement for terminal erythropoiesis 
may limit its therapeutic potential220. 
 
Reducing chain imbalance for β-thalassemias 
The physiologic hallmark of β-thalassemia is globin chain imbalance, such that deficiency of β 
chains leads to precipitation of unstable, free α chains, membrane damage, hemolysis and 
ineffective erythropoiesis20,221–223. α-thalassemia serves as a genetic modifier of β-thalassemia, 
as chain imbalance is reduced223. This is supported by a milder disease course in patients with 
the co-inheritance of α-thalassemia and β-thalassemia223–225. In principle, therefore, α-globin 
genes or their regulatory elements constitute potential targets for genome editing. Targeting an 
α-globin gene itself could result in a heterogeneous population of cells including those null for α-
globin which might not support erythropoiesis. This approach could become a viable option if 
technological advancements allow for the precise control of the number of α-globin null alleles 
generated. However, with present editing tools, the inability to control the number of α-globin 
null alleles created through targeting α-globin coding sequences makes targeting known 
regulatory elements of α-globin or RNAi-mediated knockdown of α-globin more attractive 
alternatives in this context.  
 
Other potential therapeutic targets 
Transcription factors KLF1 and MYB have previously been considered potential targets for HbF 
reactivation, but are not attractive due to their broad roles in cell proliferation and cellular 
development144,197. Other genes such as EHMT1/EHMT2 and the LIN28B pathway have been 
implicated in the regulation of γ-globin; however, the selectivity of these targets and roles in 
hematopoiesis need further investigation226–228. 
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THE PLATFORM: AUTOLOGOUS BONE MARROW TRANSPLANTATION OF GENOME 
EDITED CELLS 
Significant obstacles to wider use of bone marrow transplantation for cure of patients with β-
globin disorders are the availability of compatible donors and risk of GVH disease. Donor 
availability is particularly severe for SCD patients. The most persuasive rationale for therapeutic 
genome editing of β-globin disorders rests with the use of autologous CD34+ HSPCs as the 
cellular target. Through use of the patient’s own cells for therapy, donor availability and GVH 
disease are avoided. As with more “conventional” somatic gene therapy with modified viruses, 
delivery of the requisite editing components to the target cells is the principal hurdle to be 
overcome in achieving clinical success229. Delivery of therapeutic genes to CD34+ HSPCs has 
been accomplished with integrating and non-integrating viral vectors (such as lentiviral, 
adenovirus, and AAV vectors), as well as physical methods (e.g. electroporation)178,230–232. The 
optimal method for gene editing is currently unknown but likely related to the specific technology 
employed. High efficiency delivery at clinical scale, roughly > 108 CD34+ HSPCs cells, presents 
a practical challenge. However, recent studies have taken promising steps forward with 
electroporation of mRNA to CD34+ HSPCs at clinical scale (>1 x 108 cells)217,233. Robust cellular 
delivery is required for clinical translation of any envisioned therapeutic genome editing 
approaches.   
 Genome editing is generally more difficult in primary cells as compared to immortal cell 
lines for reasons that are not entirely well understood, but may reflect inefficient delivery, 
diminished promoter activity of constructs, interferon responses, exonuclease activity, and host 
mechanisms of DNA repair229. Electroporation of ZFNs, TALENs, and CRISPRs as DNA, RNA, 
and/or protein is an efficient delivery strategy to CD34+ HSPCs in a laboratory 
setting178,182,229,234,235. For the CRISPR/Cas9 system, mRNA or ribonucleoprotein (RNP) 
electroporation may obviate toxicity associated with DNA delivery, as well as yield higher rates 
of editing in cell lines and CD34+ HSPCs187,229. The identification of novel Cas9 proteins isolated 
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from diverse prokaryotes or other Cas9-like nucleases that are smaller than the widely used 
Streptococcus pyogenes-derived Cas9 may facilitate delivery efficiency particularly for viral 
vectors53. In addition, chemical modification of sgRNA’s enhances editing efficiency in primary 
hematopoietic cells and CD34+ HSPCs229. 
 
STEPS TO CLINICAL TRANSLATION 
While clinical translation of therapeutic genome editing for the β-hemoglobinopathies is 
appealing, several steps must be taken before the vision can become a reality. (1) Target 
selection, (2) delivery of editing reagents to HSCs, and (3) empirical testing of off-target 
potential must all be addressed and optimized. Targets that may be chosen for clinical 
development are summarized in Figure 5.1 and Table 5.1. (1) Strategies that rely on NHEJ are 
likely to be the first attempted using current technologies due to the dominance of NHEJ in 
quiescent HSCs and overall high efficiency of NHEJ as compared to HDR. At present, 
modification of the core BCL11A enhancer sequences of the +58 DHS of the BCL11A gene by 
NHEJ appears quite favorable in terms of potency of an effect on HbF expression and sparing 
of consequences for non-erythroid lineages. (2) Transient delivery (electroporation or non-
integrating viral vectors) represents a safer alternative to stable integration of genome editing 
components due to reduced risk of insertional mutagenesis and risk of off-target cleavage, as 
well as freedom from the uncertainty of long-term expression of genome editing tools in CD34+ 
HSPCs. Transient delivery also necessitates high levels of on-target editing within a shorter 
window of time prior to loss of the genome editing components through cell division. One 
possibility would be to enrich for edited cells prior to bone marrow transplantation of autologous 
cells60, which could be further enhanced by strategies to expand HSCs ex vivo189–191. (3) Off 
target cleavages represent a legitimate concern for therapeutic genome editing. Newly 
developed techniques allow for unbiased genome-wide identification of off target 
mutagenesis236,237. Various methods have been reported that aim to enhance on-target versus 
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off-target specificity. These include use of Cas9 nickase, truncated guides, dimeric RNA-guided 
FokI nucleases, and rationally engineered enhanced specificity Cas951,52,68,95,238,239. In addition, 
alternative RNA-directed nucleases (Cpf1) or modified Cas9-derivatives with reduced off-target 
cleavage potential appear to be steps toward "clean" editing reagents. It will be necessary to 
empirically test the optimized editing reagents for off-target cleavage potential and assess the 
associated risk of inappropriate DSBs within the genome. As methods to predict and detect off-
target cleavages continue to improve, it may become possible to screen autologous genome 
edited cells prior to bone marrow transplantation for possible pathogenic off-target mutations. 
“CD34+ humanized” mice, NOD-SCID-Gamma mice with bone marrow engrafted human CD34+ 
HSPCs, can be used to evaluate safety of genome editing tools as these models can 
demonstrate multilineage reconstitution, self-renewal, and the ability to monitor 
leukemogenesis. However, due to the inability to model all human hematopoietic lineages, 
notably the erythroid lineage, and general limitations of chimera mouse models, humanized 
mice have limitations in assessing safety of genome editing treatments in vivo.  
One additional challenge for clinical development is harvesting CD34+ HSPCs for 
autologous stem cell transplantation from patients with β-globin disorders. Sufficient numbers of 
CD34+ HSPCs for bone marrow transplant can be harvested from two sources, peripheral blood 
or bone marrow. Harvest of CD34+ HSPCs from peripheral blood is preferred due its minimal 
invasiveness and higher yield of CD34+ HSPCs following mobilization by granulocyte colony-
stimulating factor (G-CSF)240. Use of G-CSF as a mobilizing agent is generally well-tolerated for 
healthy adults and cancer patients. However, there are significant risks of G-CSF administration 
for patients with β-globin disorders. SCD patients have significant risk of vaso-occlusive events, 
acute chest syndrome, multi-organ system failure, and death241 whereas β-thalassemia patients 
are susceptible to splenic rupture, hyperleukocytosis, and thrombosis240. Plerixafor is an 
alternative mobilizing agent that may provide a safer option to G-CSF240,242,243. While the effect 
of plerixafor in SCD patients requires investigation, it has been shown to be safe and effective in 
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both splenectomized and non-splenectomized β-thalassemia patients. In contrast, while G-CSF 
was well-tolerated in non-splenectomized patients, it resulted in hyperleukocytosis and lower 
yield of CD34+ HSPCs as compared to plerixafor in splenectomized β-thalassemia patients242. 
Combination of plerixafor with a reduced dose of G-CSF to avoid adverse effects has been 
shown to be superior to either agent alone240,243. Therefore, plerixafor or combination G-
CSF/plerixafor mobilization may provide a safe avenue for peripheral blood CD34+ HSPC 
harvests for β-thalassemia patients. Until acceptable protocols for mobilization of CD34+ HSPCs 
are established for SCD patients, traditional bone marrow harvesting may be required. It may be 
advisable as well to test ex vivo editing efficiencies and maintenance of modified cells upon 
transfer into suitable immunodeficient mice for CD34+ HSPCs obtained by different methods to 
ensure optimization for clinical use. 
 
CONCLUSIONS 
The technological advances in genome manipulation are breathtaking in terms of the speed with 
which they have been reported in the past several years. The potential of genome editing 
approaches for clinical benefit in the β-globin disorders is immense. Besides the choice of the 
editing platform and its delivery to repopulating cells within CD34+ HSPC harvests, a major 
factor in considering application to these conditions is the target sequences to be modified. If 
the goal is precise gene correction, the desired sequence alteration is clear. This strategy relies 
on HDR, and at the moment must await improved protocols for HDR in bona fide repopulating 
cells for clinical experimentation.  
Reactivation of HbF is an attractive approach, as it might be "one size fits all" in 
principle, suitable for both SCD and the β-thalassemias. The precise levels of pancellular HbF 
necessary for clinical benefit remain elusive, but is hypothesized to be ≥20% for SCD and likely 
somewhat higher in β-thalassemia (Figure 5.2). Due to the inability to accurately model HbF 
experimentally, it may be difficult to assess the minimal threshold for clinical benefit in a 
86 
 
laboratory setting. Further, it is unlikely that HSCs undergoing therapeutic genome editing 
based on the strategies outlined above will have a selective advantage in vivo. However, results 
from mixed chimerism allogeneic transplant demonstrate that low levels of chimerism can 
produce clinical benefit due to the survival advantage of normal RBCs168.   
Given the current state of genome editing technologies, HbF induction mediated by NHEJ repair 
may provide a long-sought “silver bullet” for therapy. As such, harnessing the power of genome 
editing tools may finally allow for therapeutic exploitation of the deep understanding of the 
genetics of hemoglobin and lead to a genome editing-based therapeutic option for the β-
hemoglobinopathies in the near future. 
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Appendix: Supplemental Material 
 
CHAPTER 3 SUPPLEMENTAL MATERIAL 
 
CHAPTER 3 SUPPLEMENTAL TEXT 
Evaluation of human BCL11A enhancer in immortalized human erythroid precursors 
We utilized HUDEP-2 cells, an immortalized human CD34+ hematopoietic stem and progenitor 
cell (HSPC)-derived erythroid precursor cell line that expresses BCL11A and predominantly β- 
rather than γ-globin122. We used the CRISPR-Cas9 nuclease system to generate a clone of 
HUDEP-2 cells null for BCL11A by deleting coding sequences (Figure 3.1a). These cells 
demonstrated elevated levels of γ-globin mRNA and HbF protein, consistent with the functional 
requirement of BCL11A for HbF repression (Figure 3.1b, c). Deletion of the 12-kb BCL11A 
composite enhancer with a pair of sgRNAs resulted in near complete loss of BCL11A 
expression and induction of γ-globin and HbF protein to similar levels as cells with BCL11A 
knockout (Figure 3.1a-c), analogous to the requirement of the orthologous mouse composite 
enhancer for erythroid BCL11A expression67. Introduction of Cas9 and an individual sgRNA 
targeting BCL11A exon-2 to HUDEP-2 cells as well as to primary human erythroid precursors 
produced cells with elevated HbF expression, indicating loss of BCL11A function and resultant 
derepression of BCL11A’s target γ-globin (Figure 3.2g, h; Supplemental Figure 3.2e). The level 
of BCL11A transcript was unaffected in these cells (Figure 3.2f), suggesting that BCL11A 
transcripts with protein truncating variants (due to frameshift or nonsense mutations) escape 
nonsense-mediated decay. 
 
Pooled CRISPR enhancer saturating mutagenesis screen in the HUDEP-2 cells 
We designed all possible sgRNAs within the human BCL11A composite enhancer DHSs (Figure 
3.1d-f) as restricted only by the presence of the SpCas9 NGG protospacer adjacent motif 
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(PAM)47,93. The NGG PAM restricted sgRNAs had a median adjacent genomic cleavage 
distance of 4 bp and 90th percentile of 18 bp (Figure 3.1f), which suggested that this strategy 
could approach saturation mutagenesis in situ given the expected indel spectrum produced by 
each sgRNA to include frequent deletions up to 10 bp from the cleavage position47,48,60. The 
production of indels within an enhancer sequence could alter gene regulation by a variety of 
non-mutually exclusive mechanisms including: (1) disruption of transcription factor (TF) binding 
motifs, (2) creation of TF binding motifs, (3) changes in spacing of TF binding motifs without 
direct disruption of the binding sequences themselves, and (4) effects independent of TF 
binding motifs. 
NAG may act as an alternate PAM for SpCas9, albeit with lower efficiency93. We also 
designed sgRNAs restricted by the NAG PAM (Supplemental Figure 3.2a, b). The NAG PAM 
restricted sgRNAs had a median adjacent genomic cleavage distance of 5 bp and 90th 
percentile of 15 bp (Supplemental Figure 3.2b).  
We included 120 nontargeting sgRNAs as negative controls as well as 88 sgRNAs tiling 
exon-2 of BCL11A as positive controls. The total library included 1,338 sgRNAs (Supplemental 
Figure 3.2c). We synthesized oligonucleotides for the NGG and NAG restricted and 
nontargeting sgRNAs on a microarray and cloned the sgRNAs as a pool to a lentiviral vector84. 
Deep sequencing of the lentiviral plasmid library (including both NGG and NAG sgRNAs) 
demonstrated that 1,337 of 1,338 sgRNAs (99.9%) were successfully cloned. The 
representation of sgRNAs within the library showed a relatively narrow distribution, with a 
median of 718 and the 10% and 90% percentile ranging from 337 to 1,205 normalized reads 
(Supplemental Figure 3.2d). Since the number of viral integrants per cell follows a Poisson 
distribution, maximizing single integrants can be achieved by decreasing multiplicity of 
infection244–246. Therefore, the basic experimental schema was to transduce cells with the 
lentiviral library at low multiplicity such that nearly all selected cells contained a single integrant 
(Figure 3.1d). We transduced HUDEP-2 cells stably expressing SpCas9 with the pooled library 
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of BCL11A enhancer targeting sgRNAs. We initially expanded the cells for one week, and 
subsequently transferred them to erythroid differentiation conditions, for a total of two weeks of 
culture. Then we performed intracellular staining for HbF. Fluorescence activated cell sorting 
(FACS) was employed to isolate HbF-high and HbF-low pools (consistent with low and high 
BCL11A activity respectively; Figure 3.1d; Supplemental Figure 3.2e, g). We enumerated the 
representation of the library in each pool by deep sequencing. The HbF enrichment score of 
each sgRNA was calculated as the log2-ratio of normalized reads in the HbF-high compared to 
HbF-low pools. We compared the HbF enrichment of the 120 nontargeting negative control 
sgRNAs and 88 coding sequence targeted positive controls for both NGG and NAG PAM 
restricted sgRNAs. We observed equivalent representation of the nontargeting sgRNAs in the 
HbF-high and HbF-low pools but highly significant enrichment of the NGG sgRNAs targeting 
exon-2 of BCL11A in the HbF-high pool, consistent with a reduction of BCL11A activity 
(Supplemental Figure 3.2h). One nontargeting sgRNA (#0548) had an HbF enrichment score of 
0.803, while the remaining 119/120 nontargeting sgRNAs (99.2%) showed enrichment scores 
below 0.259. In contrast 40/48 sgRNAs targeting BCL11A exon 2 (83.3%) showed enrichment 
scores above 0.259. These results suggest that the large majority of sgRNAs in the library were 
competent to produce indels. However, exon-2 targeting sgRNAs with NAG PAM restriction did 
not show significant HbF enrichment suggesting inefficient indel production (Supplemental 
Figure 3.2h). Therefore the NAG restricted sgRNAs were excluded from further analyses.  
We compared the representation of sgRNAs in the initial plasmid pool to the 
representation of sgRNAs in the cells at the end of in vitro culture. While the majority of the 
library maintained neutral representation throughout the experiment, we observed a fraction of 
sgRNAs that were depleted, mainly among the h+62 sgRNAs (Supplemental Figure 3.2i). We 
observed that these dropout sgRNAs overlapped with repetitive elements within the genome, in 
particular to a SINE AluSq element that appears in the genome nearly 100,000 times247 
(Supplemental Figure 3.2k). Initial design of sgRNAs did not include prediction of off-target 
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cleavage to maximize the resolution of target mutagenesis. We removed from subsequent 
analysis the 35 of 582 (6.0%) NGG PAM sgRNAs with cellular dropout from the plasmid pool 
greater than 8-fold, since these dropouts indicated apparent BCL11A-independent effects of 
genomic disruption (Supplemental Figure 3.2i, k).  
The majority of enhancer targeting sgRNAs showed no significant enrichment or 
depletion from the HbF-high pool (Supplemental Figure 3.2j). We observed a number of 
sgRNAs with HbF enrichment at each of the DHSs as well as some with HbF depletion at h+55 
(Supplemental Figure 3.2j). We observed discrete sets of colocalizing sgRNAs with elevated 
HbF enrichment, with a particularly robust cluster at h+58 (Figure 3.2a). Our screen data appear 
consistent with the effects of indels as produced by individual sgRNAs rather than combinations 
of sgRNAs for several reasons: (1) negative control sgRNAs did not show evidence of impact on 
BCL11A expression, arguing against the occurrence of prevalent passenger effects (Figure 
3.2a); (2) positive control sgRNAs targeting BCL11A coding sequences (in which the expected 
outcome of individual sgRNAs would be frameshifted null alleles) show that the great majority 
produce the expected effect of HbF derepression (Figure 3.2a); (3) the enhancer targeting 
sgRNAs largely follow a null distribution of effect sizes with the exception of a few outliers 
suggesting most of the enhancer targeting sgRNAs had no impact on BCL11A expression again 
arguing against prevalent passenger effects (Supplemental Figure 3.2j, 3.7b); and (4) the 
enhancer targeting outliers with positive enrichment map to colocalizing discrete genomic 
sequences (Figure 3.2a, 3.3, 3.5a) which would appear unlikely if the impact on BCL11A 
expression were due to multifocal indels, large deletions, inversions, rearrangements, or 
translocations (the expected outcomes of more than one genomic cleavage) but likely if the 
impact were due to individual indels (the expected outcomes of single genomic cleavages).  
A limitation of our primary pooled screen approach is that the measurements of the 
enrichment of sgRNAs come from a pooled population of cells that were transduced by the 
entire library. Therefore we endeavored to prospectively validate the results of individual 
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sgRNAs as identified by the screen. We observed a strong correlation between the HbF 
enrichment score from the screen and the fraction of HbF+ cells in arrayed format, testing 24 
sgRNAs with enrichment scores ranging from the highest to the lowest in the screen, and 
representing sgRNAs from all 5 mapping categories (r = 0.816, p < 0.0001; Supplemental 
Figure 3.3a, b). These results demonstrate that a single enhancer-targeting sgRNA may 
mediate robust HbF induction. 
 
Common genetic variation in functional enhancer cores 
The h+62 Active region contains only one common SNP (MAF>1%), the variant rs1427407, 
which was previously identified by fine-mapping as the most highly trait-associated SNP67 
(Figure 3.3c; Supplemental Figure 3.5c). The high-HbF T-allele is disruptive of an apparent half 
E-box/GATA composite motif (P = 9.74 x 10-4 for T-allele, P = 1.69 x 10-4 for G-allele, though 
neither met our predefined threshold for significance of P < 10-4) and associated with reduced 
GATA1 and TAL1 occupancy in primary human erythroid chromatin as previously described67. 
Multiple sgRNAs with cleavages mapping directly to the motif demonstrated positive enrichment 
scores (Supplemental Figure 3.5c). Of note, there was a gap of 88 nucleotides between sgRNA 
cleavages at the core of the Active region due to lack of NGG PAM motifs. Despite this 
uncommon limitation of functional resolution by SpCas9 and NGG PAM restricted sgRNAs 
(Figure 3.1f), the HMM model was still able to identify the region. Substantial interspecies 
conservation as evaluated by both PhyloP and PhastCons (which model individual nucleotide 
and multibase element conservation, respectively) was observed at this h+62 Active state 
region as compared to flanking regions (Figure 3.3c, Supplemental Figure 3.5c). 
DHS h+55 encompasses the SNP rs7606173, which along with rs1427407 defines the 
most highly trait-associated haplotype (Figure 3.3a; Supplemental Figure 3.5a). Previous fine-
mapping was unable to find additional SNPs at BCL11A with predictive power for the trait 
association beyond the rs1427407–rs7606173 haplotype based on conditional or rare-variant 
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analyses. No common SNPs were found directly within the Active or Repressive state regions of 
h+55, however rs7606173 resides merely 3 bp from the Repressive region and 34 bp from the 
Active region (Supplemental Figure 3.5a). The next closest common SNP to an Active or 
Repressive state within h+55 is rs62142646, which is 739 bp from an Active state. The major, 
ancestral G allele at rs7606173 is associated with high-HbF. The HUDEP-2 cells used in this 
screen are homozygous for this G variant. Given a model in which high-HbF trait is due to 
disruption of TF binding sequences at the BCL11A enhancer, sgRNA-mediated disruption of the 
high-HbF rs7606173-G allele might not be expected to lead to further functional impact. We did 
observe six motifs predicted (P < 10-4) to be differentially impacted by the rs7606173 genotype 
(Supplemental Figure 3.5a). The top-scoring sgRNAs in h+55 cluster 56-58 bp from rs7606173, 
at a site with a predicted TAL1::GATA1 motif (P < 10-4). This sequence element possesses high 
vertebrate conservation (Supplemental Figure 3.5a). The entire region encompassing the 
Active/Repressive h+55 states appears to have elevated sequence conservation as compared 
to flanking sequences (Figure 3.3a).  
The only common SNP within the h+58 Active region is rs6738440 just at the edge of 
the Active state region (chr2:60722241), 118 to 160 bp from the cluster of top-scoring sgRNAs 
(chr2:60722359-60722401; Figure 3.4; Extended Figure 3.5b); the next closest common SNP 
was rs62142615 (chr2:60722120), 119 bp away. Neither sgRNAs with significant adjacent 
enrichment nor overlying genome-scale significant motifs with either the major A- or minor G-
allele were observed at rs6738440. Previous conditional analysis of the rs1427407-rs7606173 
haplotype was unable to demonstrate residual significant trait association for this variant67. 
Enhancers paradoxically may demonstrate both evolutionary conservation and 
heightened turnover. Common trait-associated enhancer variation suggests the frequent 
occurrence of intraspecies polymorphic sequences sufficient to modulate enhancer function and 
thereby produce novel phenotypes. Per above, we previously described that the trait-associated 
enhancer haplotype at BCL11A is defined by two SNPs67. Our pooled CRISPR screening 
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revealed that each of these SNPs reside near functional enhancer states consistent with their 
roles as causal variants. The most potent enhancer region, within h+58, has no trait-associated 
variants near its functional core. This example demonstrates how fine-mapping GWAS 
associations to individual SNPs can substantially underestimate the biologic importance of the 
underlying elements to the associated trait.  
 
Pooled CRISPR enhancer saturating mutagenesis screen in mouse erythroid εy:mCherry 
reporter cells 
We generated a MEL cell reporter line with the mCherry fluorescent reporter knocked-in to the 
embryonic globin Hbb-y locus (Supplemental Figure 3.6c). Introduction of Cas9 and sgRNA 
targeting Bcl11a exon-2 resulted in the appearance of cells with elevated εy:mCherry 
expression, indicating derepression of the BCL11A target εy-globin (Supplemental Figure 3.6h). 
The mouse sgRNA library was comprised of both NGG and NAG PAM restricted 
sgRNAs. The library included sgRNA sets tiling the DHS m+55, m+58, and m+62 orthologs, as 
well as 120 nontargeting negative controls and 91 Bcl11a exon-2 targeting positive controls 
(Supplemental Figure 3.6d, g). Similar to the human enhancer screen, the sgRNAs were 
distributed throughout the target sites, with a median distance to adjacent cleavage site of 4 bp 
and 90% of adjacent cleavage sites falling within 18 bp for NGG PAM restricted sgRNAs 
(Supplemental Figure 3.6e). We successfully cloned into lentiviral plasmids all 1271 members of 
the library with a relatively narrow distribution of representation (median 735, 10%ile 393, 
90%ile 1240 normalized reads; Supplemental Figure 3.6f).  
Following transduction at low multiplicity by the lentiviral library, and in vitro culture for 
two weeks, cells were sorted into high- and low-εy:mCherry pools (Supplemental Figure 3.6i). 
Deep sequencing was performed of the genomic DNA to evaluate the representation of sgRNA 
libraries in the pools. The nontargeting negative control sgRNAs were evenly represented in the 
high- as compared to low-εy:mCherry pools whereas the positive control Bcl11a exon-2 
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targeting sgRNAs with NGG PAM were significantly overrepresented in the εy:mCherry-high 
pool (Supplemental Figure 3.6j). Although there was slight enrichment that reached statistical 
significance, the NAG PAM restricted sgRNAs showed substantially reduced overrepresentation 
relative to the potent NGG restricted sgRNAs, so further analysis was restricted to the NGG 
PAM restricted sgRNAs (Supplemental Figure 3.6j).  
We analyzed the representation of the library in cells that had completed two weeks of in 
vitro culture (sum of the high- and low-εy:mCherry pools) as compared to the initial lentiviral 
plasmid pool. The large majority of sgRNAs showed equivalent representation in the initial 
plasmid pool and as integrants in cells at the completion of the experiment (Supplemental 
Figure 3.7a). A small number of sgRNAs (n=8) showed substantial cellular dropout >2-3 and 
were removed from subsequent enrichment analysis. Similar to the human screen, these 
mapped to repetitive elements (Supplemental Figure 3.7c). 
We determined εy enrichment score as the log2-ratio between representation in the 
εy:mCherry-high as compared to εy:mCherry-low pools (Figure 3.5a; Supplemental Figure 
3.7a). We noted almost all exon-2 targeting sgRNAs demonstrated both positive εy enrichment 
scores and negative cellular dropout scores with high correlation (Figure 3.5a; Supplemental 
Figure 3.7a, c, d). 
The majority of enhancer targeting sgRNAs showed no significant εy enrichment 
(Supplemental Figure 3.7b). We detected sgRNAs with both modest enrichment and depletion 
from the εy:mCherry-high pool at the m+55 ortholog, similar to h+55. We detected a set of 
sgRNAs with marked εy enrichment at the m+62 ortholog, exceeding the potency of those 
enriching at h+62. At the m+58 ortholog we did not observe any evidence of εy enriching or 
depleting sgRNAs (Supplemental Figure 3.7b). 
We applied the same HMM model to infer Active, Repressive, and Neutral states at the 
mouse BCL11A enhancer orthologs (Supplemental Figure 3.4a, 3.8a-c). We identified an Active 
state at the m+62 ortholog and Active and Repressive states at the m+55 ortholog. Only the 
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Neutral state was identified at the m+58 ortholog. The regions of the m+55 and m+62 DHSs 
with peak DNase I sensitivity were inferred as possessing Active states (Supplemental Figure 
3.8a-c). We analyzed 108 clones in which the entire composite enhancer was first 
monoallelically deleted and subsequent hemizygous mutations were produced by sgRNAs 
targeting the m+62 ortholog on the remaining allele. We measured BCL11A expression by RT-
qPCR in each of these 108 clones normalized to 25 control clones not exposed to m+62 
targeting sgRNAs. This clonal analysis identified a core region of the m+62 ortholog containing 
functional sequences required for BCL11A expression and embryonic εy-globin repression 
(Supplemental Figure 3.8d, 9). The region is rich with TF-binding motifs, particularly those of 
key factors involved in erythropoiesis and globin gene regulation, including Gata1, Klf1, and 
Myb (Supplemental Figure 3.9). Of note, despite the presence of relatively high vertebrate 
conservation throughout the m+62 and h+62 Active state regions (Figure 3.4c, Supplemental 
Figure 3.5c, 3.8c, 3.9b), the impact of the m+62 ortholog on BCL11A and globin gene regulation 
greatly exceeded that of h+62 (Figure 3.2a, c-e, 3.5a-c; Supplemental Figure 3.8c, d, 3.9).  
 
Human and mouse sequence and functional conservation 
Sequence homology is detectable at an approximately similar distal intron-2 position with 
respect to the TSS for each of the mouse sequences homologous to the three human DHSs: 
h+55 (length 1283 bp) has 402 positions of nucleotide identity (31.3%) compared to the m+55 
ortholog (length 1046 bp), h+58 (1264 bp) has 367 positions of nucleotide identity (28.6%) 
compared to the m+58 ortholog (length 1341 bp), and h+62 (length 1369 bp) has 281 positions 
of nucleotide identity (20.5%) compared to the m+62 ortholog (length 1216 bp). By comparison, 
of the 2508 bp in human BCL11A coding sequence (XL isoform), 2424 nucleotides demonstrate 
identity (96.7%) compared to mouse Bcl11a coding sequence (XL isoform). 
Although enhancers are composed of TF binding motifs, the presence of motifs alone is 
inadequate to predict enhancers. Motif predictions can be overly sensitive, in that only a small 
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fraction of predicted motifs tend to be corroborated by ChIP-seq occupancy studies. On the 
other hand, motif prediction can also be insensitive; for example, a recent report highlights the 
importance of low-affinity motifs for achieving specificity of enhancer function248. Previously we 
showed that GATA1 occupies h+58 in primary human erythroid precursors67. However the 
orthologous m+58 region possesses neither DNase sensitivity nor functional requirement in 
mouse erythroid cells. Despite this divergence, the human core GATA1 motif has a similar P-
value in the nonfunctional mouse ortholog. These results are consistent with a model in which 
the motif context is critically important in enhancer activity. The sequences immediately adjacent 
to the GATA1 motif, where both HbF-associated sgRNAs and mutations enrich, are candidates 
to fulfill this contextual requirement.  
Recent appreciation for the wide variation in intensity of biochemical features associated 
with enhancer elements has led to a renewed interest in clustered enhancer elements and so-
called super-enhancers. Based on H3K27ac ChIP-seq in primary human adult erythroid 
precursors, the composite BCL11A enhancer scores as a human erythroid super-enhancer 
(Supplemental Figure 3.1a, b). We used published H3K27ac ChIP-seq data from mouse 
erythroid cells and found variable results, in one dataset128 Bcl11a scores as a mouse erythroid 
super-enhancer whereas in another dataset127 it ranks below the super-enhancer threshold 
(Supplemental Figure 3.6a, b). Here we provide an example of a super-enhancer organized as 
a hierarchy of constituent DHSs, with some critical and others minimally required for gene 
expression. Even within a critical substituent DHS such as BCL11A h+58, there are many 
dispensable and only a few critical sequences. These experiments show how a super-enhancer 
may be vulnerable to indels produced by single DSBs. 
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CHAPTER 3 SUPPLEMENTAL FIGURES AND TABLES 
 
 
Supplemental Figure 3.1: Human BCL11A locus. a, Schematic of the human BCL11A locus (hg19, transcription 
from right to left) with erythroid chromatin marks and trait-associated haplotype denoted, and composite enhancer 
as previously defined67. b, Ranked enhancers in primary human adult erythroid precursors by H3K27ac signal 
intensity, with super-enhancers shaded, and super-enhancer associated genes indicated. 
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Supplemental Figure 3.2: Tiled pooled in situ CRISPR-Cas9 BCL11A enhancer screen. a, Distribution of 
NGG and NAG PAM sgRNAs mapped to genomic cleavage position. The vertical lines represent cleavage sites 
for sgRNAs mapped to plus and minus strands. b, Gap distance between adjacent genomic cleavage position for 
NAG PAM sgRNAs. c, Library composition by target sequence and PAM restriction. d. Representation of both 
NGG and NAG sgRNA (1,338 sgRNAs in total) within the plasmid pool by deep-sequencing. The median was 718 
normalized reads and the 10th and 90th percentiles (indicated by the vertical dotted lines) ranged from 337 to 
1,205 normalized reads. e, HbF distribution in HUDEP-2 cells transduced with Cas9 and individual sgRNAs, either 
nontargeting or targeting BCL11A exon 2. f, HbF enrichment scores of NGG sgRNAs in six biological replicates. g, 
Sort of library-transduced cells into HbF-high and HbF-low pools. h, Control sgRNA enrichment. Boxes 
demonstrate 25th, median, and 75th percentiles and whiskers minimum and maximum values. **** P < 0.0001, ns 
non-significant. i, NGG sgRNA representation in plasmid pool and cells at conclusion of experiment (left), and in 
HbF-high and HbF-low pools (right), with dotted lines at x=y and x=8y. j, Quantile-quantile plots of NGG sgRNA 
enrichment scores. k, Cellular dropout scores of NGG sgRNAs relative to genomic cleavage position and repetitive 
elements. Nontargeting sgRNAs pseudo-mapped with 5 bp spacing. 
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Supplemental Figure 3.3: Validation of enhancer screen. a, HbF+ fraction in HUDEP-2 cells transduced in 
arrayed format with 24 sgRNAs from all 5 mapping categories with enrichment scores ranging from the highest to 
the lowest in the screen. b, Correlation between HbF enrichment score from pooled sgRNA screen and HbF+ 
fraction by arrayed validation of individual sgRNAs in HUDEP-2 cells.  c, Erythroid differentiation of primary human 
erythroid precursors evaluated by CD71 and CD235a surface markers, enucleation frequency (CD235a+ 
Hoescht33342-), and morphology by May-Grünwald-Giemsa staining. 
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Supplemental Figure 3.4: Functional assessment of enhancer sequences. a, Topology of the Hidden Markov 
model (HMM) used to infer the three functional enhancer states (Active, Repressive, and Neutral). The emission 
probabilities of HbF enrichment scores from each state were modeled as Gaussian distributions (the values 
of μ and σ2 are shown). The transition probabilities (arrows) are displayed. b, Frequency distribution of indels from 
HUDEP-2 cells exposed to Cas9 and individual sgRNAs, sorted into HbF-high and -low pools, and subjected to 
deep sequencing of the target site. Indels calculated on a per nucleotide basis throughout an amplicon 
surrounding the sgRNA-1617 and -1621 cleavage sites (dotted lines). An indel enrichment ratio was calculated by 
dividing normalized indel frequencies in the HbF-high pool by those in the HbF-low pool. 
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Supplemental Figure 3.5: Functional cores of the BCL11A enhancer. a-c, 200 bps at the functional cores of 
DHSs h+55, h+58, and h+62 defined by HMM states (Active red, Repressive green). HbF enrichment scores 
shown by gray lines and circles. HbF indel enrichment per nucleotide based on amplicon genomic sequencing of 
sorted cells exposed to either sgRNA-1617 (top) or -1621 (bottom). Common SNPs (MAF>1%) shown with dotted 
lines with HbF-low allele in blue and HbF-high allele in red; no common SNPs present at h+58 region. JASPAR 
motifs (P < 10-4) depicted in black except for those with allele-specific significance depicted by allelic color. 
Selected motifs annotated by TF based on known erythroid-specific function or genomic position. Motif LOGOs at 
key positions with motif scores P < 10-3 as described in text. Dotted boxes show regions of highest HbF 
enrichment score at each core with underlying predicted motifs. Orthologous sequences listed from representative 
primates and nonprimates of distributed phylogeny. PhyloP (scale from -4.5 to 4.88) and PhastCons (from 0 to 1) 
estimates of evolutionary conservation among 100 vertebrates. An arrow indicates a 144 bp insertion in the mouse 
genome relative to the human reference adjacent to the orthologous GATA1 motif at h+58. 
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Supplemental Figure 3.6: Tiled pooled in situ CRISPR-Cas9 Bcl11a enhancer screen. a, Schematic of the 
mouse Bcl11a locus (mm9, transcription from left to right) with erythroid chromatin marks (top, dark blue H3K27ac 
from Kowalczyk et al127, middle, light blue H3K27ac from Dogan et al128, and bottom, black DNase I from Bauer et 
al67) and regions of primary sequence homology to the human DHSs displayed. Y-axes for H3K27ac tracks are 
both scaled to maximum 3.5 reads per million. Composite enhancer as previously defined67. b, Ranked enhancers 
in mouse erythroid precursors by H3K27ac signal intensity127,128, with super-enhancers shaded. Super-enhancer 
associated genes indicated by Venn diagram. c, Strategy to knock-in by homology-directed repair the fluorescent 
protein mCherry into the mouse embryonic globin Hbb-y locus (encoding the εy embryonic globin chain). d, 
Distribution of NGG and NAG PAM sgRNAs mapped to genomic cleavage position with vertical lines representing 
cleavage sites for sgRNAs mapped to plus and minus strands. e, Distance to adjacent genomic cleavage position 
for NGG (left) and NAG (right) PAM sgRNAs. f, Representation of the 1,271 NGG and NAG sgRNAs within the 
plasmid pool by deep-sequencing. The median was 735 normalized reads and the 10th and 90th percentiles 
(indicated by the vertical dotted lines) ranged from 393 to 1,240 normalized reads. g, Library composition by target 
sequence and PAM restriction. h, mCherry expression upon exposure to Cas9 and an individual NGG sgRNA 
targeting Bcl11a exon 2 in MEL εy:mCherry reporter cells. i, εy:mCherry sort of library transduced cells. j, Control 
sgRNA enrichment. Boxes demonstrate 25th, median, and 75th percentiles and whiskers minimum and maximum 
values. **** P < 0.0001. k, Enrichment scores of NGG sgRNAs between four biological replicates. 
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Supplemental Figure 3.7: Bcl11a enhancer screen analyses. a, NGG sgRNA representation in plasmid pool 
and cells at conclusion of experiment (left), and in εy:mCherry-high and εy:mCherry-low pools (right), with dotted 
lines at x=y and x=8y. b, Quantile-quantile plots of NGG sgRNA εy enrichment scores. c, Cellular dropout scores 
of NGG sgRNAs relative to genomic cleavage position and repetitive elements. Nontargeting sgRNAs pseudo-
mapped with 5 bp spacing. d, Correlation between cellular dropout and εy enrichment scores. 
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Supplemental Figure 3.8: Functional sequences at the Bcl11a erythroid enhancer. a-c, HMM segmentation 
of active functional states at m+55, m+58, and m+62 orthologs. HbF enrichment scores shown as gray lines and 
circles with blue line representing smoothed enrichment score. DNase I sequencing from mouse fetal liver 
erythroid precursors67. PhyloP (scale from -3.3 to 2.1) and PhastCons (from 0 to 1) estimates of evolutionary 
conservation among 30 vertebrates. d, Top, BCL11A expression determined by RT-qPCR displayed as a heatmap 
in 108 hemizygous m+62 ortholog deletion clones ordered by genomic position of deletion midpoint. Each bar 
demonstrates the genomic position of the deletion breakpoints and the associated color demonstrates the level of 
BCL11A expression. Bottom, BCL11A expression determined by RT-qPCR in 108 hemizygous m+62 ortholog 
deletion clones. Per nucleotide mean effect size was calculated as the mean fold change in BCL11A expression 
from all clones in which that nucleotide was deleted. Gray shading represents one s.d. The BCL11A expression 
data are shown with same x-axis as in Supplemental Figure 3.8c immediately above. 
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Supplemental Figure 3.9: Evaluation of the m+62 functional core. 200 bp at the functional core of the m+62 
ortholog defined by HMM state. Enrichment scores shown as gray lines and circles with blue line representing 
smoothed enrichment score. JASPAR motifs (P < 10-4) depicted with selected motifs annotated by TF name based 
on known erythroid-specific function or genomic position. Orthologous human sequences listed. PhyloP (scale 
from -3.3 to 2.1) and PhastCons (from 0 to 1) estimates of evolutionary conservation among 30 vertebrates. 
Individual numbered hemizygous deletion clones with indicated breakpoints were evaluated by BCL11A 
immunoblot (C, control). Clones 9 and 10 encompass the entire m+62 ortholog. 
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Supplemental Figure 3.10: Requirement of Bcl11a erythroid enhancer during murine ontogeny. a, Progeny 
of heterozygous Bcl11a m+62 ortholog deletion intercrosses as compared to expected Mendelian ratio. b, Fraction 
of fetal liver comprised of B cell progenitors at E16.5 from various genotypes. c, Peripheral blood analysis from 4 
week old mice to examine the frequency of various circulating hematopoietic lineages in Bcl11a m+62 ortholog 
deletion wild-type, heterozygous, and homozygous mice. d, BCL11A expression in β-YAC / +62 deletion mice 
(each symbol represents the mean expression from technical replicates from an individual mouse). * P < 0.05, 
error bars represent s.e.m. 
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Supplemental Table 3.1: sgRNA Sequences 
sgRNA Target Gene or Region Species Sequence 
Composite Enhancer 5’ Target 1 Human TGGAAAGGAGAACGGCCCGG 
Composite Enhancer 5’ Target 2 Human TGAACACCCTCGTTAAAGGC 
Composite Enhancer 5’ Target 3 Human AACACTAGCCCACATGCCAA 
Composite Enhancer 3’ Target 1 Human GCCCACAGAGGCACGGTTAA 
Composite Enhancer 3’ Target 2 Human AGGCACGGTTAATGGTGGCG 
Composite Enhancer 3’ Target 3 Human CACAGGAAGCCATGGTCCTT 
+55 5’ Target 1 Human GCACTGACGTAGGTAGTGAC 
+55 5’ Target 2 Human ATAGGATATGGCACTGACGT 
+55 3’ Target 1 Human CATTATCTTCTCTGGTCTCG 
+55 3’ Target 2 Human ATACTGGGGAACACATTGTA 
+58 5’ Target 1 Human TGAGCACATTCTTACGCCTA 
+58 5’ Target 2 Human CTAGGCGTAAGAATGTGCTC 
+58 3’ Target 1 Human GAACCCCCTATAAACTAGTC 
+58 3’ Target 2 Human GGCAAACCAGACTAGTTTAT 
+62 5’ Target 1 Human CAGGGGAGAACTCGGCATGA 
+62 5’ Target 2 Human GATGGAGTTGGTTGACCGTA 
+62 3’ Target 1 Human GGTAGGACCCAACACTACGC 
+62 3’ Target 2 Human ATGCCTAGGGTGTTTTGACG 
BCL11A Exon 2 Target 2 Human TGAACCAGACCACGGCCCGT 
BCL11A Exon 2 Target 3 Human GCATCCAATCCCGTGGAGGT 
+55 5’ Target Mouse CACTGGCTTCCTGTTCTTGT 
+55 3’ Target Mouse AAGGTTTTCAAGGCAAATAA 
+58 5’ Target Mouse GTAATGGAGCCCGCATGCTG 
+58 3’ Target Mouse GCCAGTGTACAGGCAAGTAC 
+62 5’ Target Mouse TCGCTGCCTTCAGTTCTGCT 
+62 3’ Target Mouse TTATGGAACTCAGGAACTGC 
Bcl11a Exon 2 Target Mouse GATGCCTTTTTCATCTCGAT 
+62 Target 1 Mouse ATTCCTTGAGTGTCATATAT 
+62 Target 2 Mouse TCTGGAATCACTATGTATAT 
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Supplemental Table 3.2: Oligonucleotides for deletion clone screening 
Gene or 
Region Species 
Non-Deletion 
(ND) or 
Deletion (D) 
CRISPR Pair Orientation Sequence 
Composite 
Enhancer Human ND 
5’ Target 3 Forward TGCTCCGAGCTTGTGAACTA 
3’ Target 1 Reverse TATCACAGGCTCCAGGAAGG 
Composite 
Enhancer Human D 
5’ Target 3 Forward TAGTTTGCTTCCCCCAATGA 
3’ Target 1 Reverse GCCAGGAAATTGGTGGTAGA 
Composite 
Enhancer Human ND 
5’ Target 2 Forward TGCTCCGAGCTTGTGAACTA 
3’ Target 2 Reverse TATCACAGGCTCCAGGAAGG 
Composite 
Enhancer Human D 
5’ Target 2 Forward GTGGGCAGTTACGTTTTCGT 
3’ Target 2 Reverse GCCAGGAAATTGGTGGTAGA 
+55 Human ND 
5’ Target 1 or 2 Forward GGTCAGGGTGTTGCAGAGAT 
3’ Target 1 or 2 Reverse CACACCCTGTGATCTTGTGG 
+55 Human D 
5’ Target 1 or 2 Forward GACTTAAACTGCCGCTCCTG 
3’ Target 1 or 2 Reverse GGGCCTCAGGCTCTTTATCT 
+58 Human ND 
5’ Target 1 or 2 Forward CCCAGAGCTCAGTGAGATGA 
3’ Target 1 or 2 Reverse GGGAAAGGGCCTGATAACTT 
+58 Human D 
5’ Target 1 or 2 Forward GAACAGAGACCACTACTGGCAAT 
3’ Target 1 or 2 Reverse CTCAGAAAAATGACAGCACCA 
+62 Human ND 
5’ Target 1 or 2 Forward TTTGAAAGTACCAGCACAGCA 
3’ Target 1 or 2 Reverse CCCTCTGGCATCAAAATGAG 
+62 Human D 
5’ Target 1 or 2 Forward AACAGACCCATGTGCTAGGC 
3’ Target 1 or 2 Reverse TGCTGAATTCCTGTAAAGTGAGG 
+55 Mouse ND 
5’ Target Forward GAGGTGACCAGGGTGTGAGT 
3’ Target Reverse AAGAAGAGGCCCTGGACATT 
+55 Mouse D 
5’ Target Forward CATCTTAAGGCAAGAATCACT 
3’ Target Reverse CCAGTCAATCCAAACCCTGT 
+58 Mouse ND 
5’ Target Forward TATTAATGCCCAGCCAGCTC 
3’ Target Reverse GTGGTCCAGACCTAGCCAAG 
+58 Mouse D 
5’ Target Forward TTTGAGCAGGAGGGAATTTG 
3’ Target Reverse ATAGGTGGTTGGGCTTCTCC 
+62 Mouse ND 
5’ Target Forward GGAGTGGCTGTTGAAAGAGG 
3’ Target Reverse CACTCAAGGAATGCAAGCAA 
+62 Mouse D 
5’ Target Forward TACTTGGTGGCTTTCCCAAC 
3’ Target Reverse AGATGGTCCTCTGCATCCAC 
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Supplemental Table 3.3: Oligonucleotides for inversion clone screening 
Inverted 
Region Species CRISPR Pair Orientation Sequence 
+55 Human 
5’ Target 1 or 2 Forward GACTTAAACTGCCGCTCCTG 
3’ Target 1 or 2 Forward AGGCATCCAAAGGGAAGAAT 
+55 Human 
5’ Target 1 or 2 Reverse ACTTCAGCCTCCAGCACTGT 
3’ Target 1 or 2 Reverse CCACTGGAGTGGAACCAAGT 
+58 Human 
5’ Target 1 or 2 Forward GGGATCAGAGGTGAACAGGA 
3’ Target 1 or 2 Forward TGGACTTTGCACTGGAATCA 
+58 Human 
5’ Target 1 or 2 Reverse TTGTTTACAGAGGGGCAACC 
3’ Target 1 or 2 Reverse GGGGAAGGGGTATTGAATTG 
+62 Mouse 
5’ Target 1 or 2 Forward AACAGACCCATGTGCTAGGC 
3’ Target 1 or 2 Forward GAACCTGGGAGGCAGAAGAT 
+62 Mouse 
5’ Target 1 or 2 Reverse TGTGTGGACTGCCTTTTCTG 
3’ Target 1 or 2 Reverse TGTGGAGCTCTGGAATGATG 
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Supplemental Table 3.4: Oligonucleotides for mouse +62 deletion analysis 
Region Species CRISPR Pair Orientation Sequence 
+62 Mouse 
Screen 0484 Forward GGTAGTGTGGGGGTGGAGT 
Screen 0475 Reverse TCAGCCTGTTCCCTCAGTG 
+62 Mouse 
Screen 0484 Forward GGTAGTGTGGGGGTGGAGT 
Screen 2456 Reverse TCAGCCTGTTCCCTCAGTG 
+62 Mouse 
Screen 0475 Forward GGTAGTGTGGGGGTGGAGT 
Screen 0490 Reverse TCAGCCTGTTCCCTCAGTG 
+62 Mouse 
Screen 0490 Forward GGTAGTGTGGGGGTGGAGT 
+62 3’ Target Reverse AGATGGTCCTCTGCATCCAC 
+62 Mouse 
Screen 0490 Forward GGTAGTGTGGGGGTGGAGT 
+62 Target 1 Reverse TCAGCCTGTTCCCTCAGTG 
+62 Mouse 
+62 5’ Target Forward TACTTGGTGGCTTTCCCAAC 
Screen 0475 Reverse TCAGCCTGTTCCCTCAGTG 
+62 Mouse 
+62 Target 2 Forward ATGCTTGGTTGTCGCCTTAT 
Screen 0475 Reverse CACTCAAGGAATGCAAGCAA 
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Supplemental Table 3.5: RT qPCR oligonucleotides 
Gene Species Orientation Sequence 
GAPDH Human Forward ACCCAGAAGACTGTGGATGG 
Reverse TTCAGCTCAGGGATGACCTT 
HBB Human 
Forward CTGAGGAGAAGTCTGCCGTTA 
Reverse AGCATCAGGAGTGGACAGAT 
HBG Human Forward TGGATGATCTCAAGGGCAC 
Reverse TCAGTGGTATCTGGAGGACA 
HBE Human 
Forward GCAAGAAGGTGCTGACTTCC 
Reverse ACCATCACGTTACCCAGGAG 
HBD Human 
Forward GAGGAGAAGACTGCTGTCAATG 
Reverse AGGGTAGACCACCAGTAATCTG 
BCL11A Human Forward AACCCCAGCACTTAAGCAAA 
Reverse GGAGGTCATGATCCCCTTCT 
Gapdh Mouse Forward TGGTGAAGGTCGGTGTGAAC 
Reverse CCATGTAGTTGAGGTCAATGAAGG 
β-Major Mouse Forward TTTAACGATGGCCTGAATCACTT 
Reverse CAGCACAATCACGATCATATTGC 
Hbb-εy Mouse Forward TGGCCTGTGGAGTAAGGTCAA 
Reverse GAAGCAGAGGACAAGTTCCCA 
Hbb-
βh1 
Mouse 
Forward TGGACAACCTCAAGGAGACC 
Reverse ACCTCTGGGGTGAATTCCTT 
Bcl11a Mouse 
Forward AACCCCAGCACTTAAGCAAA 
Reverse ACAGGTGAGAAGGTCGTGGT 
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CHAPTER 4 SUPPLEMENTAL MATERIAL 
 
Supplemental Figure 4.1: Degree of saturation for 8 PAM sequences by chromosome. Distances between 
adjacent genomic cleavages to assess PAM availability and distribution by chromosome. For each box-and-whisker 
plot, the three lines of box represent the 25th, 50th and 75th percentile. The upper and lower whiskers represent the 
99th and 1st percentile, respectively. Outliers, defined as above the 99th percentile or below the 1st percentile are 
plotted as individual points. Lower whiskers are omitted if the 1st percentile is 0. 
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Supplemental Figure 4.2: Degree of saturation for 8 PAM sequences by chromosome. 
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Supplemental Figure 4.3: Degree of saturation for 8 PAM sequences in DHS regions for 9 ENCODE cell lines. 
Distances between adjacent genomic cleavages to assess PAM availability and distribution within DHS regions. For 
each box-and-whisker plot, the three lines of box represent the 25th, 50th and 75th percentile. The upper and lower 
whiskers represent the 99th and 1st percentile, respectively. Outliers, defined as above the 99th percentile or below the 
1st percentile are plotted as individual points. Lower whiskers are omitted if the 1st percentile is 0. 
  
115 
 
 
Supplementary Figure 4.4: Degree of saturation for 8 PAM sequences in enhancer regions for 9 ENCODE cell 
lines. Distances between adjacent genomic cleavages to assess PAM availability and distribution within enhancer 
regions. For each box-and-whisker plot, the three lines of box represent the 25th, 50th and 75th percentile. The upper 
and lower whiskers represent the 99th and 1st percentile, respectively. Outliers, defined as above the 99th percentile or 
below the 1st percentile are plotted as individual points. Lower whiskers are omitted if the 1st percentile is 0. 
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Supplemental Figure 4.5: Degree of saturation for 8 PAM sequences in repressed regions for 9 ENCODE cell 
lines. Distances between adjacent genomic cleavages to assess PAM availability and distribution within repressed 
regions. For each box-and-whisker plot, the three lines of box represent the 25th, 50th and 75th percentile. The upper 
and lower whiskers represent the 99th and 1st percentile, respectively. Outliers, defined as above the 99th percentile or 
below the 1st percentile are plotted as individual points. Lower whiskers are omitted if the 1st percentile is 0. 
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Supplemental Figure 4.6: Degree of saturation for 8 PAM sequences in RefSeq genes annotations. Distances 
between adjacent genomic cleavages to assess PAM availability and distribution within RefSeq gene annotated 
regions. For each box-and-whisker plot, the three lines of box represent the 25th, 50th and 75th percentile. The upper 
and lower whiskers represent the 99th and 1st percentile, respectively. Outliers, defined as above the 99th percentile or 
below the 1st percentile are plotted as individual points. Lower whiskers are omitted if the 1st percentile is 0. 
  
118 
 
 
Supplemental Figure 4.7: Degree of saturation for 8 PAM sequences in (a) DHS, (b) enhancer, and (c) 
repressed regions for 9 ENCODE cell lines as well as (d) RefSeq gene annotations.  
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Supplemental Figure 4.8: Representative output figures from DNA Striker analysis using haplotype data, 
whole genome sequencing (WGS), and a custom list of variants for chr6:135282411-135282852 (hg19). a, 
Representative plot displaying location of non-variant sgRNA (black), haplotype variants (pink), and haplotype-
associated sgRNA with a guide frequency ≥1% frequency (blue). The double strand break density is estimated using 
the KS density function (black line). b, Representative plot displaying location of non-variant sgRNA (black), WGS 
variants (pink), and WGS-associated sgRNA (blue). The double strand break density is estimated using the KS 
density function (black line). c, Representative plot displaying location of non-variant sgRNA (black), custom list of 
common variants (pink), and variant-associated sgRNA (blue). The double strand break density is estimated using 
the KS density function (black line). The custom list of variants represents all SNPs in the region with a minor allele 
frequency of ≥1%. d, Representative plot quantifying degree of saturation through determining gaps between 
adjacent genomic cleavages. The 50th percentile (pink) and 90th percentile (red) are indicated by vertical lines.  
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Supplemental Figure 4.9: Combining multiple nucleases reduces gap distance between adjacent cleavages. 
a, NGG-restricted sgRNA library includes a gap between adjacent genomic cleavages of 115 bp in HBS1L-MYB DHS 
(chr6:135513195-135513596, hg19) with 50th and 90th percentile gap distances of 5 bp and 27 bp, respectively. The 
combination of NGG- and NGA-restricted sgRNA reduces the maximum gap to 17 bp with 50th and 90th percentile 
gap distances of 3 bp and 11 bp, respectively. b, NGA-restricted sgRNA library includes a gap between adjacent 
genomic cleavages of 82 bp in HBS1L-MYB DHS (chr6:135351870-135352271, hg19) with 50th and 90th percentile 
gap distances of 8 bp and 18 bp, respectively. The combination of NGG- and NGA-restricted sgRNA reduces 
maximum gap to 23 bp with 50th and 90th percentile gap distances of 5 bp and 15 bp, respectively.  
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Supplemental Figure 4.10: NGG and NGA pooled saturating mutagenesis screen of the HBS1L-MYB 
intergenic region. a, Altered sgRNA or PAM-creation sgRNA in the HBS1L-MYB intergenic region as a result of 
variants from the 1,000 Genomes Project sorted by frequency. The cutoff for inclusion in the library was a frequency 
of 1%. b, Representation of both NGG (n = 2,585) and NGA (n = 2,957) sgRNA within the plasmid pool by deep 
sequencing. The median was 187 normalized reads and the 10th and 90th percentiles (indicated by the vertical dotted 
lines) ranged from 25 to 1,009 normalized reads for NGG sgRNA. The median was 162 normalized reads and the 
10th and 90th percentiles (indicated by the vertical dotted lines) ranged from 21 to 896 normalized reads for NGA 
sgRNA.  
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Supplemental Figure 4.11: HUDEP-2 karyotype. 
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